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Abstract 
Background:   MRI of the prostate is used to detect and localise prostate cancer and diffusion-
weighted imaging (DWI) is a routine sequence. The purpose of the study was to determine the 
diagnostic accuracy of high b-value DWI through meta-analyses. Additionally, the aim was to 
determine the diagnostic accuracy of a novel combined small field-of-view (FOV) and high b-value 
DWI sequence for detecting and localising prostate cancer. 
Material and Methods: Meta-analyses of diagnostic test accuracy of high b-value DWI, and T2WI 
and DWI combined, were performed conforming to the PRISMA statement. A prospective 
observational diagnostic test accuracy study of 40 patients who underwent 3T MRI with small- 
(sDWI) and conventional (cDWI) FOV and subsequent radical prostatectomy were included. Two 
blinded readers assessed the lesion and sectoral-based accuracy of both sequences using radical 
prostatectomy (RP) specimens as reference standard. Apparent Diffusion Coefficient (ADC) of 
benign and malignant tissue was assessed.  
Results:  The sensitivity, specificity and area-under-curve (AUC) of the high b-value DWI, and T2WI 
and DWI meta-analyses were 0.59, 0.92, and 0.92; and 0.68, 0.84 and 0.83, respectively. There 
were 83 prostate cancers detected in the RP specimens and half of prostate sectors contained 
tumour. Sensitivity of cDWI alone was significantly higher than sDWI (0.62 vs 0.45, p=<0.001), but 
specificity was lower (0.88 vs 0.92, p=<0.001). The AUC was not significantly different (0.76 vs 
0.73, p=0.164). The interobserver reliability of cDWI was substantial (κ = 0.63) and sDWI was 
moderate (κ = 0.59). The median mean ADC of tumours was significantly lower than non-tumour 
tissue for both sequences (p=<0.001). The ADC of tumour was significantly lower with sDWI (960 x 
10-6 mm2/sec vs 766 x 10-6 mm2/sec, p=<0.001). 
Conclusion: Conventional DWI outperformed small-FOV DWI imaging at lesion detection, but 
there may be clinical benefit for small-FOV at excluding tumour, particularly in a pre-biopsy 
population. 
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Chapter 1 Introduction 
The prostate gland 
Anatomy of the prostate gland 
The prostate is an inverted cone shape with its base lying cranially and apex caudally. It lies 
posterior to the pubic symphysis, anterior to the rectum and proximal anus, and its base lies 
against the neck of the bladder. The prostatic urethra passes through the gland, as do the 
ejaculatory ducts. It lies in the subperitoneal compartment between the peritoneal cavity and 
pelvic diaphragm.  
In the adult male, without significant hyperplasia, it weighs approximately 20-30g. It is the largest 
accessory gland in the body and secretes a fluid which forms part of the seminal fluid. It is also a 
composite gland and is composed of three glandular components: the peripheral zone (PZ), 
central zone (CZ), and transitional zone (TZ). It has a stromal component known as the anterior 
fibromuscular stroma (AFMS). The gland can also be divided into regions anatomically delineated 
by dividing the gland in thirds in the height dimension. These are known as apex, mid-gland, 
which contains the verumontanum in the mid-prostatic urethra, and base (from caudal to 
craniad).  
The PZ is the largest of the zones, comprising 70% of the glandular tissue, wraps around the 
posterolateral aspect of the gland, and contains the distal prostatic urethra. It is present in the 
apex, mid-gland and base of the prostate and is almost a complete ring, prevented from being so 
by the AFMS [1,2] (Figure 1-1).  
The CZ is comprised of a pair of conical structures with the apex in the mid-gland at the 
verumontanum and extends superolaterally to the prostate base adjacent to the seminal vesicles. 
They contain the ejaculatory ducts and in total account for 25% of the glandular tissue [3]. 
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The TZ is the smallest of the glandular components in a normal prostate, comprising of 5% of 
normal glandular tissue, is present in the base and midgland, and is a pair of globular structures. 
This zone typically enlarges in older men due to benign prostatic hyperplasia (BPH).  
The AFMS is comprised of smooth muscle and fibrous tissue and lies on the anterior surface of the 
prostate in the midline and extends from base to apex. 
The prostate is not surrounded by a true capsule, but is covered incompletely by two layers; an 
inner layer of smooth muscle and an outer layer of collagen [4]. The degree of coverage is variable 
[5],  but is deficient anteriorly at the AFMS, at the extreme apex anteriorly, and at the base [6,7]. 
Although, not technically a true capsule and inseparable from the prostate at surgery it is 
common to use the term capsule when reporting magnetic resonance imaging (MRI) of the 
prostate. Detection of extension of tumour beyond the capsule is of prognostic importance and 
can alter management of prostate cancer. 
The seminal vesicles are a pair of grape-like structures which lie between bladder and rectum and 
extend superolaterally from the prostate base. The base of the seminal vesicle is at its caudal 
aspect lateral to the vas deferens. The duct of the seminal vesicle joins with the vas deferens to 
form the ejaculatory duct which pass through the CZ to the verumontanum and prostatic urethra. 
The size and appearance of the seminal vesicles can be variable and depends on age and sexual 
activity [8]. 
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Figure 1-1. Diagram of the prostate demonstrating the different glandular and stromal compartments, 
and the urethra, ejaculatory ducts and seminal vesicles. 
An understanding of the prostatic zonal anatomy is important when interpreting and reporting 
MRI. Increasingly clinicians require the information on the location of tumour within the gland to 
guide biopsy and target in focal therapies.  
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Prostate cancer histology and grading 
Epidemiology of prostate cancer 
Prostate cancer is the most common cancer in men, making up 26% of cancers in men in England 
and Wales in 2010 [9]. There was a rapid rise in incidence between 1998 and 2001 which was 
thought to be due to the increased use of the Prostatic Specific Antigen (PSA) blood test. In 2014 
there were 46,490 new cases of prostate cancer in the UK and over the last decade the incidence 
rate has increased by 6% [10]. The number of new diagnoses in England and Wales is highest in 
those aged between 65-79 years, but the greatest increase in new diagnoses has been in the 45-
59 year age group.  
Prostate cancer is the 2nd highest cancer killer in men after lung cancer [11]. In 2010 the age 
standardized mortality rate for prostate cancer was 23.8 per 100,000 [9]. There were 11,287 
deaths from prostate cancer in the UK in 2014, but the mortality rate has been in decline since 
2001 [12]. This can be attributed to the increase in the use of PSA test which lead to increased 
cases diagnosed and also survival through lead time bias [13]. 
With the prevalence high and incidence rising the investigation and management of prostate 
cancer is a large expense. The spectrum of disease burden for patients is wide, from those with 
aggressive disease requiring active treatment to those with indolent disease which will never 
cause morbidity or mortality. With more men being diagnosed with prostate cancer it is important 
to have diagnostic tools which can easily and reliably risk stratify patients.  
There are three well established risk factors for developing prostate cancer: increasing age, 
ethnicity, and hereditary factors. Only 1% of prostate cancers are found in those less than 50 
years, approximately one-third are diagnosed over the age of 70 years and the remainder 
between these age groups [14]. This is partly due to the increased use of PSA testing in the 50 - 
80-year group, with decreased use of the test in those greater than 80 years because there are 
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decreased benefits in screening asymptomatic men at this age. In the UK black men are three 
times more likely to be diagnosed with prostate cancer than white men, a difference which is 
greater amongst younger men [15]. In addition, this study found that men of African and 
Carribean origin had similar risks indicating a possible common genetic aetiology.  
Approximately 1 in 4 prostate cancers occur in family clusters and about 1 in 10 are hereditary. 
Men with a first degree relative with the disease have a 2-3 fold increase in developing prostate 
cancer compared to those without [16]. There have been over 100 gene mutations associated 
with increased familial risk, including BRCA 1 and BRCA 2, with mutations in these genes 
associated with more aggressive disease and poorer outcomes [17,18].  
Androgens play an important role in the growth of normal prostate and in prostate cancer, 
however, it’s effect at the initial development of prostate cancer is unclear as men on androgen 
replacement therapy are not at increased risk. Furthermore, drugs which inhibit the androgen 
receptors have been investigated as a potential means of preventing prostate cancer, but thus far 
they have only been proven to decrease the incidence of low grade cancers and potentially 
increase the incidence of higher grade disease [19].  
Prostate cancer histology 
Cancer of the prostate is most typically usual-acinar adenocarcinoma with multiple but infrequent 
variant forms of acinar and non-acinar subtypes outlined by the WHO. The non-acinar variants or 
types account for 5–10% of prostate cancers, of which there are 7, with ductal adenocarcinoma 
the most common, accounting for 3% of prostate cancers [20]. More recently several further 
cancer subtypes have been described due to their specific clinico-pathological features [21]. 
Intraductal adenocarcinoma of the prostate is an aggressive subtype and is associated with a 
higher grade, larger tumours and higher probability of extracapsular extension and seminal vesicle 
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invasion [22]. The individual sub-types of prostate cancer are important prognostically, but are of 
less importance radiologically. 
Prostate cancer grading 
Gleason Grade 
The principle features of Donald Gleason’s five grades of prostate cancer, outlined first in 1966 
[23], has stood the test of time and is still used today due to its reliability and simplicity. Gleason 
Grade 1 is considered the most differentiated and grade 5 the least. It is an important factor in 
determining treatment, predicting biochemical failure and the likelihood of nodal and distant 
metastasis after therapy, and providing prognostic and mortality information [24]. Each tumour 
focus is provided a Gleason Score, which is usually sum of the most and second most prevalent 
Gleason Grade patterns and ranges from 2-10 [25].  
The 2005 ISUP modified Gleason grading system 
In 2005 the International Society of Urological Pathologists (ISUP) consensus on prostate cancer 
grading made some changes to the Gleason grading system which have been universally used 
since and have had a significant impact on prostate cancer investigation and management [26]. 
For example, they decided that prostate cancer with grade of 2 or less and a score of less than 6 
should not be reported with Gleason Grade starting at 3 and Gleason Score at 6. Those tumours 
with a secondary pattern which is higher grade than the primary pattern should always be 
reported, whilst tumours with a secondary pattern of lower grade than the primary should only 
be reported if the secondary pattern is present in over 5% of the tumour focus. In addition, the 
consensus decided to change the way tertiary patterns are decided on biopsy specimens. When a 
high-grade tertiary pattern (such as grade 4 or 5) is identified the primary pattern and the high-
grade tertiary pattern should be used to make the Gleason score.  
  Introduction 
 
22 
The results of the changes at the ISUP consensus meeting was an increase in a significant 
percentage of previously Gleason Score 6 tumours being re-assigned a score of 7 due to tertiary 
pattern 4 areas. Multiple studies have assessed the changes with an increase in Gleason Score 7 
disease between 13-42% and decrease in Gleason Score 6 tumours between 19–26% [27,28]. The 
result has been a more homogenous group of Gleason Score 6 patients with a uniformly excellent 
prognosis. Eggener et al. demonstrated that only 0.03% of patients with organ-confined Gleason 
Score 6 disease following prostatectomy died of prostate cancer using the modified scoring 
system [29]. The difficulty comes in confidently predicting such a favourable prognosis following a 
Gleason Score 6 on biopsy. Pierorazio et al. demonstrated almost one third of Gleason Score 6 
tumours diagnosed on biopsy were upgraded to a score of 7 or more following radical 
prostatectomy [30]. However, when assessing the 5 year biochemical recurrence free survival of 
patients with a score of 6 on biopsy was 94.7% compared to 82.7% for those with a score of 7 
suggesting a significant prognostic value in diagnosing Gleason score 6 on biopsy. 
The influence of the modified Gleason scoring system has resulted in improved concordance 
between biopsy specimens and radical prostatectomy specimens by approximately 15% [27,31]. 
Biopsy undergrading is the most common cause of discordance between results of biopsy and 
radical prostatectomy specimens.  
Gleason Grade Group 
More recently there has been a move to change the Gleason Grading system further. It was 
thought that patients who have Gleason Score 6 disease, the most pathologically insignificant 
grade of prostate cancer, may not find this nomenclature useful as they may see themselves as 
being 6 out of 10 on the aggressiveness scale. Pierorazio et al. proposed that different Gleason 
scores be assigned into different Gleason Grade Groups [30]. 
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This group demonstrated that the grade grouping system accurately predicts prognosis in a group 
of over 7,000 men who have undergone radical prostatectomy in both the analysis of the Gleason 
Grade Group of original biopsy results and radical prostatectomy specimens. To date no 
diagnostic test accuracy study of MRI in prostate cancer has used the Grade Group system.  
Pathologically significant and insignificant prostate cancer 
The most common used criteria for insignificant prostate cancer in radical prostatectomy 
specimens is 1) Gleason score of no more than 6 with no tertiary pattern 4 or 5, 2) organ confined 
disease, 3) tumour volume less than 0.5 cm3 [32]. The use of such criteria has become 
commonplace as patients with insignificant disease have an extremely low risk of progression to 
clinical significance in the absence of treatment. 
It is important for urologists to have a definition of insignificant disease on biopsy specimens as 
identification of men with insignificant disease earlier in the diagnostic pathway reduces the risk 
of overtreatment. The Epstein criteria for insignificant disease on biopsy follows the principles of 
insignificance on prostatectomy: no Gleason Grade 4 or 5; less than 3 cores from a sextant biopsy 
containing cancer; no core with more than 50% tumour involvement [33]. Unfortunately, the 
criteria for insignificance on biopsy does not as confidently predict silent disease as the biopsy 
does not reliably exclude spread, tumour size and grade. Combining the biopsy results with other 
parameters such as digital rectal examination (DRE) findings, serum PSA result and other PSA 
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parameters provides the urologist with more confidence in starting the patient on active 
surveillance (AS) or surgical or oncological therapy [34]. 
Prostate cancer risk 
The definition of insignificant and significant prostate cancer is a histological criterion and 
confined by the limitation of the sampling method. The clinical team, lead by urologists, use other 
parameters to guide treatment. As well as age and comorbidities patients are risk stratified into 
high, intermediate and low risk based on the stage of tumour (combined DRE and imaging 
findings), Gleason Score and PSA results as outlined by D’Amico et al. [24] (Table 1-1).  
Table 1-1. D'Amico prostate cancer risk groups. 
Risk Parameters 
Low Stage T1-T2a and GS ≤ 6 and PSA <10 ng/ml 
Intermediate Stage T2b and/or GS 7 and/or PSA 10-20ng/ml 
High Stage ≥ T2c and/or GS 8-10 and/or PSA >20ng/ml 
Multifocality and index lesion 
Prostate cancer is a multifocal disease with more than one cancer focus in over three quarters of 
radical prostatectomy specimens [35–37]. Wise et al’s study of 559 radical prostatectomy 
specimens found an average of 2.9 separate lesions in each specimen, but 60% of the secondary 
cancers were less than 0.5cm3 [36]. Not only is prostate cancer multifocal but the foci themselves 
are typically different grades. Arora et al. demonstrated that the same primary and secondary 
Gleason grade in each lesion in multifocal disease occurred in only 9% of prostatectomy 
specimens [35]. This lack of homogeneity between tumour foci grades appears to be due to 
differences between the foci at a molecular and a genetic level. The TMPRSS2 gene undergoes re-
arrangement in the majority of prostate tumours, and Mehra et al. demonstrated there is a 
different gene arrangement status and class between different tumour foci in multifocal disease, 
suggesting each focus arises from a different, independent clonal origin [38]. Multiple other 
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separate gene mutations have been discovered which contribute to the development of prostate 
cancer and a recent study by Boutros et al. found very little shared copy number aberrations and 
shared nucleotide variants between cancer foci which all points to the existence of multiclonal 
disease [39–41]. This not only explains the heterogeneity between the aggressiveness of tumour 
foci within the same gland, but also explains the heterogeneity in the responses of different 
patients to treatments. This angle of research opens up the potential development of targeted 
treatments. Diagnosis of prostate cancer may in the future not just be driven by the Gleason 
Grade, but also by the specific genetic mutations of the tumour so that personalised treatment 
can be given. 
The index lesion is often defined as the tumour nodule, in the setting of multifocal disease, which 
is the largest in volume [35,36,42], but the latest ISUP guidelines recommend the index lesion 
should be defined according to the following priority: extra-prostatic extension, then Gleason 
score, then tumour volume [43]. The largest tumour volume also tends to have the most 
aggressive staging parameters (such as extracapsular spread, seminal vesicle invasion and 
neurovascular spread) and also the highest Gleason Score in 89% of cases [44].  
Prostate cancer staging 
Prostate cancer can be staged clinically, radiologically and pathologically. MRI is the preferred 
imaging choice for accurate local staging and assessment of pelvic lymph nodes and bony 
structures. Ultimately, the gold standard for local staging is by histopathological assessment of 
the radical prostatectomy specimen, but only some patients have a radical prostatectomy and 
they tend to be younger and have a higher-grade disease. Pelvic lymphadenectomy is sometimes 
performed at radical prostatectomy providing assessment of the local nodal status. Metastatic 
lymphadenopathy and visceral metastatic disease can be assessed with computed tomography. 
Finally, assessment of bone spread with a nuclear medicine technique, known as bone 
  Introduction 
 
26 
scintigraphy (bone scan), which is sensitive for the presence of bone metastases. The indications 
for some of these imaging tests will be covered later. 
The American Joint Committee on Cancer (AJCC) cancer staging manual 7th Edition (2009) uses the 
TNM classification for tumour stage [45]. The ‘T’ represents the local staging of the ‘Tumour’, the 
‘N’ represents the ‘Nodal’ status, and the ‘M’ represents the assessment for ‘Metastasis’. Table 
1-2 demonstrates the different TNM components for prostate cancer staging. 
Table 1-2. AJCC Prostate cancer TNM staging. 
T Local Tumour Description 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically inapparent tumour neither palpable or visible on imaging 
T1a Clinically inapparent tumour in less than 5% of tissue resected 
T1b Clinically inapparent tumour in more than 5% of tissue resected 
T1c Tumour identified on needle biopsy 
T2 Tumour confined within the prostate 
T2a Tumour involves one half of one lobe or less 
T2b Tumour involves more than half of one lobe, but not both lobes 
T2c Tumour involves both lobes 
T3 Tumour extends beyond the capsule 
T3a Extracapsular extension (uni or bi-lateral) 
T3b Tumour invades seminal vesicle(s) 
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles 
N Regional nodal status 
NX Regional nodes were not assessed 
N0 No regional nodes involved 
N1 Metastasis in regional lymph nodes 
M Distant metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) with or without bony metastasis 
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Biochemical and pathological investigation of prostate cancer 
Prostate Specific antigen 
Prostate-specific antigen (PSA) is the most commonly used biomarker in cancer diagnostics. A 
biomarker is defined by the National Institute for Health as a trait that is objectively measured 
and evaluated as an indicator of biological processes, pathological processes, or pharmaceutical 
response to a therapeutic intervention [46]. Cancer biomarkers are either produced by the 
tumour or by the body in response to a tumour. PSA is a serine protease and has been used in the 
investigation for prostate cancer since the 1980’s. Biologically, PSA is responsible for semen 
liquefaction and is released into the seminal plasma [47]. Its release into the bloodstream is rare 
in healthy men. Only when there is a breakdown in the basement membrane of the epithelial cells 
do the serum levels of PSA significantly rise. 
Serum PSA can be raised in multiple benign conditions of the prostate, such as benign prostatic 
hyperplasia (BPH) and prostatitis, following trauma (including from DRE), as well as in prostate 
cancer. In general, further investigation for prostate cancer is not initiated until the serum PSA 
level reaches 4mg/ml. However, practice does vary in different institutions as prostate cancer is 
possible with serum PSA measurements below 4mg/ml and therefore the serum level reflects a 
continuum with increasing risk of significant prostate cancer with increasing PSA levels [48]. 
Serum PSA level correlates with both index and total tumour volume [49,50]. Sensitivity and 
specificity depend on which cut-off is used. Holstrom et al. case-control longitudinal study 
demonstrated that at PSA levels of 1, 4 and 10ng/ml the sensitivity was 96%, 44% and 15% and 
the specificity was 44%, 92% and 99% respectively [51]. It is also used in the setting of those with 
a negative biopsy following initial PSA measurement rises in serum PSA measurement can prompt 
earlier re-biopsy or imaging of the prostate. 
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Screening men for prostate cancer using PSA levels has been the source of much debate. The 
largest randomized screening trial of PSA levels, the European Randomized Study of Screening for 
Prostate Cancer (ESPRC) using a cut-off of 3ng/ml to prompt prostate biopsy has shown that there 
is a significant relative risk reduction of 0.80 in the screening arm versus the control for prostate 
cancer mortality [52]. The disadvantages of population PSA screening are in the significant 
numbers of false positives and therefore low positive predictive value at PSA levels where 
tumours are more likely to be lower stage and curable. This leads to many unnecessary biopsies, 
overdiagnosis of many insignificant prostate cancers, and the morbidity associated with the 
unnecessary biopsies and treatment. The ESPRC trial estimated that the rate of overdiagnosis was 
approximately 50% [53]. Recommendations for PSA screening by various institutes and bodies 
vary around the world. For example the United States Preventative Services Task Force are 
against screening and the European Association of Urology advise a baseline PSA at 40–45 years 
[54,55]. 
Biopsy 
Pathological specimens of the prostate can be acquired via three different mechanisms: 
incidentally at trans-urethral resection of the prostate (TURP), trans-perineal (TP) approach, or via 
trans-rectal (TRUS) approach which is the most common. Until recently TRUS was most frequently 
performed in patients with clinical suspicion (DRE and PSA level findings) of prostate cancer then 
followed by MRI if prostate cancer was detected or the patient had an increased risk of prostate 
cancer. More recently, there has been a shift in practice to perform MRI before biopsy, which is 
the order in which other cancers are more commonly diagnosed. This negates the effects of 
haemorrhage following that biopsy has on interpretation of the MRI. Currently at the Norfolk and 
Norwich University Hospital (NNUH) TRUS is performed before MRI. 
Currently, the most commonly used TRUS approach is the systematic biopsy in which the user 
takes 6 biopsy specimens blindly from each side of the gland. It is generally untargeted and a 
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suspicious lesion is not searched for and sampled. Rather, areas of the prostate are focused on 
and systematically sampled, usually two from the apex, midgland and base. Care is made to not 
biopsy in the midline to avoid damaging the urethra. The technique is limited to sampling the 
posterior aspect of the gland missing much of the anterior gland. In general, less than 1% of the 
gland is sampled at systematic TRUS biopsy [56]. 
A study of initial and repeat prostate biopsies demonstrated that prostate cancer was found in 
34% of initial biopsies and the rate fell thereafter with 25% on second, 24% on third and 21% on 
4th or greater [57]. A recent multi-centre paired-cohort study with saturation TP biopsy as a 
reference standard investigating over 500 men with suspected prostate cancer demonstrated that 
TRUS biopsy has a sensitivity of 60% for clinically significant prostate cancer indicating that 4 out 
of 10 significant tumours are missed with TRUS [58]. This in part is due to misses of the biopsy 
needle of posterior (accessible) tumours, and due to a significant number of tumours 
(approximately 10%) residing in the anterior gland and likely being inaccessible via TRUS [59]. 
TRUS prostate biopsy is not without complications. The most common complications are 
haematuria and pain, but these are usually mild and self-limiting. Infection is possible following 
the biopsy, however, this is usually limited to a urinary tract infection treatable with antibiotics 
and occurs in 2-6% of cases [60]. A study of over 75000 prostate biopsies in the UK  found that 
between 2 and 6% of cases were admitted to hospital with complications due to infection [61]. 
Infection following TRUS biopsy is more common than following TP biopsy, however the incidence 
of minor and major complication in both groups are similar [62].  
TP biopsy can be performed under general or local anaesthetic and is performed by placing a 
template over the perineum and biopsies taken systematically of the prostate at 5mm intervals. 
Its advantages over TRUS biopsy is that it can biopsy the entire gland. More recently TRUS and TP 
biopsy have become targeted by fusing MRI and US images to guide biopsy. The use of image-
guided biopsy techniques is beyond the scope of this thesis. 
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With the shift in practice moving to a biopsy following MRI it is important that MRI is reliably able 
to identify clinically significant prostate cancers and exclude patients with no or insignificant 
cancer. Thus, reducing the number of inappropriate TRUS biopsies. Additionally, an accurate and 
reliable MRI study can also identify identifying patients who would require a TP biopsy rather than 
TRUS as those with anterior tumours can have a proceed straight to TP biopsy which 
systematically samples the entire gland. 
Treatment of localized prostate cancer 
Active surveillance 
Approximately 60% of elderly men have prostate cancer on autopsy [63]. The real challenge of 
treatment of prostate cancer is deciding who and when to treat and to avoid over-treatment, 
which is an issue in the era of PSA measurement. Active surveillance aims to correctly time 
treatment rather than provide delayed palliative treatment. The intent is curative treatment, but 
to minimise treatment-related toxicity without compromising survival and patients should have a 
life expectancy over 10 years  
Active surveillance should be offered to patients within the low-risk group, but they should also 
have a choice to have radical treatment. There are different criteria used to define low risk, but 
the European Urology Society suggests that patients who have clinically stage T1 or T2 disease, 
PSA < 10ng/ml, Gleason score ≤ 6, ≤ 2 positive cores and a minimal core biopsy involvement of 
less than 50%. Radical treatment and active surveillance should be discussed with the patient and 
if it is decided upon they should be followed up with DRE, repeat biopsies and PSA measurement 
[64].   
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Radical prostatectomy 
Radical prostatectomy is a surgical procedure in which the prostate is removed as well as adjacent 
fat, the seminal vesicles and the ampulla of the vas deferens. It can be done via a retropubic or 
perineal approach, as well as open and laparoscopically, and can be robot-assisted. Incontinence 
(approximately 20%) and erectile dysfunction (approximately 70%) are known complications of 
the procedure, particularly in the first year [65]. Patients with a life expectancy greater than 10 
years can be offered radical prostatectomy with any non-metastatic stage of prostate cancer, but 
those with locally advanced (T3b/4) or N1 patients should be in highly selective cases. Pelvic 
lymphadenectomy is an option in intermediate risk cases with a greater than 5% risk of lymph 
nodes spread and in high risk cases [64]. 
Focal therapies 
High-frequency Ultrasound (HIFU) and cryotherapy are newly available treatments for the 
treatment of locally staged and small volume prostate cancer. Currently the European Urology 
Guidelines are that these therapies should not be used outside the trial setting. If these therapies 
become common place there will be an increased requirement for MRI to aid selection of 
appropriate patients as smaller tumours suitable for this therapy will need to be visualised and 
localised within the gland.  
External beam radiotherapy 
External beam radiotherapy (EBRT) is a form of radical treatment used to treat men with localized 
prostate cancer and can be used in men with locally advanced disease. It can be used in men who 
do not have a history of previous pelvic radiotherapy or inflammatory bowel disease. The use of 
adjuvant hormonal therapies is advocated in intermediate and high risk groups, but the dose of 
EBRT does not differ dependent on the risk group. Whole pelvic radiotherapy is supported in 
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those with pelvic nodal disease as well as the long-term use of hormonal therapies, but is not 
suggested in those with N0 disease [64].  
Brachytherapy 
Low-dose brachytherapy is a viable treatment option for those with a stage of T≤2a, Gleason 
Score ≤6 with less than 50% cores involved, Gleason score 3+4=7 with less than 33% of cores 
involved, a PSA of less than 10ng/ml, a prostate volume of less than 50cm3, and an International 
Prostatic Symptom Score of less than 13 [66]. Radioactive seeds are inserted into the prostate via 
a trans-perineal approach under ultrasound or MRI guidance. Efficacy of treatment is dependent 
on adequate coverage of the prostate. 
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Multiparametric MRI 
Prostate MRI protocols consist of T1 and T2 pulse sequences, combined with functional imaging 
sequences such as DWI, dynamic contrast-enhanced MRI (DCE) and magnetic resonance 
spectroscopic imaging. The combination of functional and the traditional anatomically-based 
pulse sequences is known as multiparametric MRI (mpMRI). The current recommendations 
outlined in the Prostate Imaging – Reporting and Data System version 2 (PI-RADS version 2) [67], 
the most comprehensive and widely accepted guidelines for prostate MRI, suggest the use of T1, 
T2, DWI and DCE, but spectroscopy is not part of routine use and there has been a reduction in 
the volume of research into this technique in prostate cancer. In addition, the use of DCE in 
prostate cancer is currently controversial and it’s value in mpMRI was reduced in the PI-RADS 
version 2 with its use recommended only for the peripheral zone when the DWI findings are 
indeterminate. Currently at NNUH spectroscopy and DCE are not part of the routine prostate MRI 
protocol. 
T1-weighted imaging 
The T1 weighted (T1WI) sequence is a low spatial resolution, large field of view (FOV) sequence 
performed in the axial plane which covers the entire pelvis from the iliac crests to perineum. The 
prostate gland on T1WI is homogeneously low intensity with little anatomical detail of the 
internal architecture of the prostate and no differentiation between peripheral and transitional 
zones (Figure 1-2). Its strengths are in the assessment of nodal disease in the pelvis, for the 
presence of bone metastases, and also for haemorrhage within the gland which manifests itself as 
hyperintensity on T1 weighted images.  
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Figure 1-2. T1WI of the prostate demonstrating the homogenous low signal of the gland and lack of 
differentiation of PZ and TZ. 
Haemorrhage occurs within the prostate following a biopsy of the gland. This can result in an area 
of hypointensity on T2-weighted imaging (T2WI) thus mimicking tumour, increasing the risk of 
false positives, and limiting the interpretation of the MRI. Following biopsy haemorrhage can 
spread throughout the ductal system and involve a greater volume of prostate than expected 
based on the location of the biopsy cores. As most biopsies are performed via a trans-rectal 
approach the majority of the haemorrhage is located in the peripheral zone and seminal vesicles.  
The duration of delay from biopsy to MRI is controversial. The current recommendation is for a 
delay of 6 weeks [67,68], however, this is often considered too long when cancer treatment 
targets need to be met and can add to patient anxiety. The volume of haemorrhage within the 
gland determined subjectively on T1WI is inversely proportional to time from biopsy [69–71], 
however, it is its effects on accuracy which are often the reasons cited for reducing the delay to 
MRI following biopsy. Rosenkrantz et al. (2012) qualitative assessment of accuracy of multiple 
sequences at detecting prostate cancer found a trend towards reduced sensitivity of T2WI, but 
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DWI and DCE accuracy parameters were maintained and furthermore, there was no significant 
effect on accuracy of delays following biopsy [72]. A further study by Rosenkrantz et al. (2010) 
assessing the quantitative parameters of regions of haemorrhage on tumours and normal tissue, 
found that although the ADC value of tumour increased if affected by haemorrhage there was still 
a significant difference in ADC value of tumour compared to normal tissue [73].  
Currently at the NNUH the compromise between pressure to meet cancer treatment targets and 
allowing the haemorrhage to reduce following biopsy is the imposition of a 28 day delay from the 
day of biopsy to MRI. In keeping with PI-RADS version 2 guidelines T1WI of the pelvis are used to 
assess for post-biopsy haemorrhage [67].  
T2-weighted imaging 
Protons within water molecules within the body align when they are in a magnetic field in a 
process known as longitudinal magnetisation. When a radiofrequency pulse is applied to the 
protons they fall out of alignment in a process known as transverse magnetisation. When the 
pulse ends the transverse magnetisation decreases and disappears. This occurs because the 
protons interact with adjacent protons, exchange energy and result in a loss of phase coherence 
across a population of protons in a process known as T2 relaxation. The interaction of the protons 
and exchange of energy is different for protons within different tissues.  
The T2 value for different tissues is the time for transverse magnetisation to decay approximately 
37% of its initial value. Protons within free water such as in fluid or glandular tissue has less 
interaction and exchange of energy and therefore has much slower relaxation time, but water 
within less water-based tissues (tumour, muscle, fibrous tissue) have more interactions and 
shorter T2 values. 
The time to echo (TE) is the time interval between the 90o radiofrequency pulse and the point 
where signal is recorded from the imaged field. Given tissues have different T2 values and signal 
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obtained from different tissues will vary depending on the TE, the TE can therefore be changed to 
optimise the signal intensities and thus contrast between tissues. Often with a greater TE there is 
a greater contrast between tissues but this comes at the expense of continually dropping signal to 
noise ratio (SNR) from the entire image making it potentially non-diagnostic.  
The T2 sequences used come into two categories; spin and gradient echo sequences, and the 
former can be conventional or fast spin echo sequences. The fast spin echo sequence is typically 
used in prostate imaging with the advantage of this technique being its speed of acquisition, but 
can come at the expense of reduced signal. As mentioned the TE is chosen to optimise contrast 
between tissues and in the prostate it is important to delineate between peripheral and transition 
zone as well as between normal prostate tissue and tumour. For MRI of the prostate The T2 
values of prostate cancer, transition zone and peripheral zone have been calculated at 1.5T as 82, 
88 and 122ms [74] with the TE of the fast spin echo sequence set usually between 100 and 130ms 
to maximise tissue contrast. 
The T2WI sequence is the imaging mainstay of any MR prostate protocol. Current 
recommendations are for high resolution T2WI images in three orthogonal planes (axial, coronal 
and sagittal) with 3mm slices and no gap between slices [67]. Currently, the three-plane high 
resolution T2WI sequences in the NNUH MRI prostate protocol are performed at 3.6mm with no 
gap. 
The advantage of the T2WI sequence is the high level of anatomical detail of the prostate and 
surrounding structures combined with the ability to distinguish prostate cancer from normal 
prostate tissue. 
McNeal’s anatomical divisions of the prostate are well demonstrated in the axial plane (Figure 
1-3). The peripheral zone is demonstrated as a homogenous hyperintense crescent of tissue 
extending from base to apex. The anterior fibromuscular stroma is a hypontense band which 
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extends down the anterior aspect of the prostate and is in continuity with the detrusor muscle of 
the bladder. The transitional zone, which is a small proportion of the gland in younger men, 
becomes an increasing fraction of the gland with advancing years due to the development of 
benign prostatic hyperplasia (BPH). BPH arises in the transitional zone and can extrude into the 
peripheral zone. It is usually seen as hyperintense cystic nodules, but stromal nodules are low 
signal and both nodule types can exhibit mixed signal intensities. The central zone resides at the 
base of the gland and is seen as a dumbbell-shaped area of low signal housing the ejaculatory 
ducts. The ejaculatory ducts extend caudally from the base of the seminal vesicles. The seminal 
vesicle are paired lobular areas of hyperintensity on T2WI extending craniad from the base of the 
gland. The prostatic capsule is separated from adjacent structures by a thin low signal rim and if 
tumour is seen to extend beyond, this then changes the staging from T2 to T3 disease.  
Pathology within the prostate appears as low signal in comparison to normal glandular tissue. In 
the peripheral zone, tumours are appreciated as a round or ill-defined area of low signal, but has 
a significant amount of overlap with other conditions and states such as scars, prostatitis, 
haemorrhage, and atrophy [75]. The detection of cancer within the transitional zone is a greater 
challenge as there is a greater overlap of the appearances of tumour and the transitional zone, 
particularly in the presence of BPH. Lesions are typically homogeneously hypointense, 
uncircumbscribed, with a lentiform or spiculate shape [67]. 
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Figure 1-3. T2WI of a normal prostate demonstrating the anatomical divisions of the prostate and seminal 
vesicles. A - Axial slice through the base of the gland. B - Axial through the mid-gland. C - Axial through 
the apex. D - Coronal slice. 
Diffusion-weighted imaging 
Conventional MRI is based on the 1H signal from water (1H2O) which has the advantage of large 
volumes throughout the body providing sufficient signal to form an image. Contrast in 
conventional imaging is based on how the physical properties of water 1H behave in different 
tissues and chemical environments [76]. For example, in the brain the T2 relaxation time for 
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cerebrospinal fluid is large providing an abundance of signal, which is in comparison to brain 
parenchyma which has a shorter relaxation time and displaying less signal thus providing an 
inherent contrast between the two tissues.  
Diffusion-weighted imaging (DWI) also uses the 1H from water to provide signal, but instead of 
using how water behaves in different environments it works on the principle of water movement. 
In the body water molecules move randomly in a pattern known as Brownian motion. DWI studies 
the movement and displacement of water during the gap between two diffusion-sensitising 
gradients. Water movement between the gradients leads to attenuation of signal between the 
gradients. Therefore, in tissues where movement of water is ‘free’, such as within fluid filled 
structures like the urinary bladder, there is a greater loss of signal. In comparison, tissues with 
increased cellularity and intact cell membranes create greater impedance to water movement 
and thus restricted diffusion (Figure 1-4). Tumour tissue in general has higher cellularity and 
greater intact cell membranes [77] and therefore greater restricted diffusion. 
 
Figure 1-4. Diffusion of water molecules. A - Highly cellular environment in which the diffusion of water is 
restricted due to impedence by the extracellular space and cell membranes. B - Free movement of water 
in large extracellular space or due to faulty cell membranes. 
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It is important to note that the MRI signal in DWI is sensitive to the diffusion of water in the 
extracellular and intracellular space, and also the intravascular space. Water molecules within the 
intravascular space tend to move further than those in the intra and extra-cellular spaces and the 
contribution of the intravascular water movement to DWI signal varies between tissues. This 
variation also occurs in tumours, in which the intravascular water diffusion of highly vascular 
tumours can contribute significantly to the DWI signal [78].  
The principles of DWI were initially described by Stejskal and Tanner [79] who designed an 
experiment that detected and quantified the diffusion of water molecules in vivo. It was used on a 
standard T2WI sequence in which an identical pair of diffusion-sensitising gradients were applied 
to the tissue around a 180o radiofrequency refocusing pulse. Figure 1-5 demonstrates the 
difference in diffusion of static and moving water molecules during the image acquisition and how 
they result in different signal output. Static molecules acquire phase information from the initial 
diffusion-sensitising gradient and when the information is rephased during second diffusion-
sensitising gradient there will be minimal reduction in the measured signal intensity. Conversely 
when the second diffusion-sensitising gradient is applied to tissues with mobile water molecules 
there is no reversal of the phase shift and less rephasing of water molecules leading to a reduced 
signal. Therefore, the attenuation of signal is proportional to the degree of water movement.  
 
Figure 1-5. Water diffusion metrics demonstrating the attenuation signal in different tissues between the 
diffusion sensitising gradients with static molecules, such as in tumour, maintaining signal and free-
moving molecules, such as the bladder, losing signal. 
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The sensitivity of the water molecules to the DWI sequence depends on the amplitude of the 
diffusion-sensitising gradient, the time between the gradients and the duration of the diffusion-
sensitising gradient. The ‘b-value’ is a measure of the magnitude of the diffusion weighting 
provided by the diffusion gradients, usually the gradient amplitude rather than the duration of 
and interval between gradients, and is expressed in sec/mm2. Diffusion gradients can be applied 
to any type of sequence, however, currently they are applied to echo-planar imaging (EPI) 
sequences as they are fast and solve many of the problems of motion artefacts.  
 The apparent-diffusion coefficient (ADC) is the measure of the diffusion. It is calculated 
mathematically from at least two b-value images, often more. The signal attenuation, a marker of 
diffusion, of each voxel is plotted against b-value with the slope of the line representing the ADC 
and measured in mm2/sec. Each unit of ADC equates to a signal intensity and therefore, the ADC 
values can be used to create an ADC map, a set of images which is a visual representation of the 
‘true’ diffusion of the scanned area in which each voxel holds information on the amount of 
restricted diffusion within. On the ADC map an area of restricted diffusion will be demonstrated 
as low signal and correspond to high signal on the DWI images. By drawing a region of interest on 
the ADC map the ADC value of the included area can be calculated, thus providing a quantifiable 
measurement of diffusion.  
In clinical practice, when running DWI sequences on an area of the body the DWI images, 
including all b-values, are present to visually and qualitatively assess, as is the ADC map. With the 
ADC map also providing means of quantifiably measuring diffusion. 
Many parameters of the DWI sequences can be altered to optimise the images. An issue with DWI 
is that it is prone to low signal. This is in part is due to signal decay due to T2 effect in the 
sequence. Signal continues to fall as the b-value is increased because the sequence time increases 
as the parameters of the diffusion-weighted gradients change to increase the b-value. Therefore, 
other mechanisms need to be in place to increase the gradient strength whilst reducing the 
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acquisition time. EPI sequences are used as they generally lower the acquisition time whilst 
maintaining SNR.  
DWI in prostate MRI 
Of the three functional sequences in mpMRI of the prostate, DWI is used most frequently and 
relied most heavily on in current reporting guidelines [67]. Its appeal in prostate cancer detection 
is the increased cellular density of tumour compared to normal prostate tissue leading to an 
inherent contrast between tumour and non-tumour tissue, the lack of need for exogenous 
contrast agents, and relatively quick acquisition makes it a routine part of the mpMRI protocol. In 
addition, it has potential uses as a non-invasive biomarker of tumour aggressiveness [80]. 
One of major technical factors to be researched within DWI of the prostate is the choice of b-
values to use. The advantages of using higher b values are an increased tumour to non-tumour 
contrast made achievable by greater suppression of signal of normal prostate tissue and 
theoretically improved tumour detection. However, this is traded against reduced signal to noise 
ratio (SNR), and increased susceptibility and motion artefacts [81]. Therefore, at higher field 
strengths the benefits of greater SNR permit possible use of higher b values. 
The issue with lower b-values is that the displayed signal intensity echoes the effects of tissue 
diffusion and the T2 weighting in the image rather than just the amount of restricted diffusion. 
Normal prostate tissue can exhibit high signal on T2WI reflecting its high glandular components, 
thus lacking contrast with tumour which will be high signal due to the restricted diffusion. This 
obscuration of tumours can be seen even with b-values up to 1000 sec/mm2 with a study 
demonstrating that over half of tumours were not visible at b1000a sec/mm2 using a 1.5T MRI 
despite the reader being provided with a histopathology tumour map to aid localisation [82]. 
                                                             
a It is common practice to refer to the b-value used as b1000 sec/mm2, for example, rather than stating ‘a b-
value of 1000 sec/mm2. 
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Rosenkrantz et al. [81] separately assessed b-value images and ADC maps created using both 
b1000 and b2000 sec/mm2 images at 3T with radical prostatectomy correlation and demonstrated 
that using a b-value of 2000 sec/mm2 compared with a b-value of 1000 sec/mm2 resulted in 
significantly improved tumour sensitivity and higher tumour-to-peripheral zone (PZ) contrast on 
the DWI images, but these benefits were not observed in ADC maps created with maximum b-
values of 2000 sec/mm2 compared to 1000 sec/mm2. Ueno et al. [83] also reported significant 
benefits in specificity, accuracy, and positive and negative predictive values with b-values of 2000 
sec/mm2 compared to b1000 sec/mm2 for detection of prostate cancer in the PZ, but was unable 
to demonstrate these findings for tumours of the transitional zone (TZ). Tumour detection has 
also been shown to be better at b2000 sec/mm2 by other studies at 3T [84,85], and also at 1.5T 
[86]. 
A few studies have compared more than b1000 and b2000 sec/mm2 sequences. Metens et al. [87] 
reported that tumour contrast to noise ratio and image quality were improved in b1500 sec/mm2 
images compared to b-values of 1000 and 2000 sec/mm2 in both central gland and PZ tumours. 
These results were also supported by Wang et al. [88] who found significantly higher SNRs at 
b1500 than 1000 and 2000 sec/mm2. Contrast between normal tissue and tumour was best at 
b1500 and significantly greater at b2000 and b1500 than with b1000 sec/mm2. When these b-
values were used to create individual ADC maps and the ADC values of lesions were used to 
distinguish the likelihood of tumour by assessing the area under the curve (AUC) of the receiver 
operating characteristic (ROC) curve the ADC map created from b1500 data was significantly 
higher, indicating greater accuracy, than a ADC map from b2000 for both PZ and TZ, and ADC map 
from b1000 sec/mm2 for the TZ. However, the ADC map from the b1000 data outperformed the 
map from b2000 sec/mm2 in both zones of the prostate.  
Wetter et al. [89] also analysed multiple b values and concluded that the signal intensity of 
tumour and normal tissue decline with increasing b value but the decline is more pronounced in 
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normal tissue. The contrast ratio at b1500 and b2000 sec/mm2 were significantly better than at 
b1000 and b800 sec/mm2 but there was no significant difference between b1500 and b2000 
sec/mm2.  
When ADC maps, created using different b-values, were assessed in isolation, Wetter et al. [89] 
concluded that the contrast ratios of tumour using ADC maps from multiple b-values (800, 1000, 
1500, and 2000 sec/mm2) were not significantly different. The reduced usefulness of the ADC 
maps derived from ultra high b values is suggested by Tamada et al. [84] with further studies 
demonstrating improved diagnostic performance of ADC maps derived from b1000 compared to 
b2000 sec/mm2 [90,91]. Conversely, using quantitative analysis, ADC maps obtained with a b-
value of 2000 sec/mm2 were superior to that obtained with a b-value of 1000 sec/mm2 for PZ 
tumours but less so for TZ cancers [92]. 
Traditionally, the lower b-value used to create the ADC map was 0 sec/mm2. This has been 
replaced by a low b-value between 50 and 200 sec/mm2 as this reduces the effects of the early 
capillary component on the measured diffusion signal. This was based on work by Le Bihan et al. 
[93] in which two compartments (tissue and capillary) rather than one in each tissue are 
recognised. In this model, there is pseudo-diffusion in the capillary compartment due to the rapid 
movement of water molecules. The effects of this are reduced by using a higher minimum b-value 
and then fitting the mono-exponential decay curve to calculate the ADC value of tissue. Thörmer 
et al. [94] performed a study assessing the effects of using different b- values to create different 
ADC maps, examined the ADC values of tumour and normal tissue, and compared lesion 
conspicuity of different ADC maps. When ADC maps of 0,800 sec/mm2 were compared to those 
using 50,800 sec/mm2 the ADC values of tumour did not change significantly, but lesion 
conspicuity was improved with the latter. The ADC maps on the MRI protocols at NNUH are all 
creating with a non-zero b-value, specifically 100 sec/mm2. 
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The diagnostic accuracy of DWI and the methodology of diagnostic test accuracy studies of 
prostate MRI are examined in the systematic reviews and meta-analyses in Chapter 2 (Page 55) 
and Chapter 3 (Page 82). 
Multiple studies have proven the ADC value of tumour is significantly lower than that of benign 
tissue [80,90,95–98]. However, amongst these studies the ADC values of tumours are variable, as 
is the degree of overlap with normal tissue. For example, the mean ADC values of tumour in Kim 
et al. (2010) [90] was 820 x10-6 mm2/sec compared to Kim et al. (2007) [99] who found the mean 
tumour ADC to be 1,300 x10-6 mm2/sec. The variation is dependent on multiple factors, most 
notably the choice of b-values used. Several studies have shown that the ADC value of tumours 
decreases with increasing b-values [83,89,94]. Given the large discrepancy in ADC measurements 
of tumours the current recommendations for the assessment of tumour with ADC maps is in the 
visual assessment of tumour with DWI images and ADC map rather than by measuring ADC values 
[67]. 
The evidence suggests that b-values of over 1000 sec/mm2 should be used to detect tumour, 
particularly at 3T, but when it comes to creating ADC maps the use of b-values of 1000 
outperform ADC maps created with a b-value of 2000 sec/mm2 , however, the use of ADC maps 
with b1500 sec/mm2 data may be of benefit. This is reflected in the PI-RADS version 2 
recommendations which advocate using a high b-value of 1400 sec/mm2 or more, but the highest 
b-value used to create the map should be 1000 sec/mm2 [67]. The issue with much of the higher 
b-value studies thus far has been the lack of diagnostic accuracy studies rather than the use of, for 
example, lesion conspicuity, contrast ratios and SNR of lesions, as used in many of the studies 
above. Furthermore, the meta-analyses of diagnostic test accuracy of DWI alone [100] and DWI 
and T2WI [101] have not attempted to extract the b-values chosen in the included studies and 
compare if possible the pooled findings of different groups. Performing this extraction and 
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analysis in a meta-analysis would provide stronger evidence as to the practical and clinical 
benefits of using higher b-values. 
With increasing Gleason Grade there is an increase in cellular density within the tumour with a 
resulting decrease in the free movement of water and more restricted diffusion. This results in a 
decrease in ADC value with increasing Gleason grade, a correlation which has been described in 
multiple studies [102–106]. The correlation coefficients of mean ADC to Gleason grade for these 
studies range from weak (ρ = -0.31) to moderate (ρ = -0.66) with a considerable overlap of ADC 
values with different Gleason grades.  
The b-values chosen to make the ADC map has an influence on the ability to distinguish different 
grades of prostate cancer. Peng’s [107] study of 11 different ADC maps created with using 
different combinations of b-values found the lowest correlation (ρ = -0.30) with an ADC derived 
from b1500,2000 sec/mm2 and a highest correlation (ρ = -0.68) from b0,1500 sec/mm2. However, 
there were wide confidence intervals in this study and overlap in correlation coefficients between 
b-values typically used in routine clinical work. Other studies directly comparing ADC maps from 
very high b-values with lower b-values have found no significant difference between them. 
Kitajima et al. [92] reported that the correlation of ADC value and tumour aggressiveness 
(Gleason score) was fair (ρ = -0.33) and Tamada et al. [84] demonstrated no significant difference 
in detecting high or intermediate risk lesion with b0,2000 sec/mm2 vs b0,1000 sec/mm2 ADC 
maps, however, there was a trend towards that conclusion.  
The studies described above have described and focused on mean tumour ADC value, however, 
others have used different ADC metrics other than the mean to determine whether there is a 
stronger correlation. Wu et al. [108] found a stronger correlation using the minimum ADC value 
rather than the mean. Donati et al. [103] establish the 10th percentile ADC value to have the 
strongest correlation (ρ = -0.36) with the mean and median ADC value having coefficients of -0.31 
and -.0.30 respectively.  
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Tumour ADC values have potential to help discriminate tumours of different grades as more 
aggressive tumours have a lower ADC value than lower grade tumours. However, like the use of 
tumour ADC for discriminating tumour from non-tumour tissue the use of ADC values clinically to 
determine the grade of disease is not used in routine clinical practice. The underlying principles 
behind the correlation are sound and it is important when investigating novel DWI techniques 
that this correlation is assessed and compared against conventional DWI and the literature. 
Novel DWI techniques 
As well as increasing the highest b-value other techniques have been created to improve the 
accuracy and reliability of DWI imaging of the prostate. Most of these techniques have revolved 
around improving the spatial resolution of the scan. Medved et al. [109] found by reducing the 
slice thickness and improving the in-plane resolution there was a significant improvement in 
qualitative measures of image quality, lesion conspicuity, and internal architecture definition. In 
addition, they found the ADC values of tumours with the higher resolution DWI sequence to be 
higher than for the standard DWI sequence, however, the ADC maps for each sequence were 
calculated using a different number and choice of b-values, which is known to have a significant 
effect on ADC value [107].  
Another technique recently employed is to reduce the field-of-view of the image. Traditionally, 
DWI imaging of the prostate has been limited to the imaging of the whole pelvis, in which the 
prostate occupies only a small volume of the whole imaged pelvis. Within a larger field of view 
there are magnetic field inhomogeneities, and distortions due to susceptibility artefact, which are 
increased at 3T, all of which decrease image quality. The small cross-sectional size of the prostate 
within the larger field of view limits the spatial resolution. By reducing the field of view the aim is 
to reduce the off-resonance induced artefacts by reducing the read-out duration.  
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This is achieved by using a 2D spatially selective radiofrequency excitation pulse, followed by a 
180o refocusing pulse which selects only a selected area for imaging. The result is a reduction in 
the echo-train-length which minimises distortion caused by susceptibility artefact and also 
reduced the number of k-space lines in the phase encoding direction which enables higher 
resolution [110,111].  
The prostate is a challenging organ to image with DWI as the bladder anteriorly and the gas 
containing rectum posteriorly means the imaging is prone to susceptibility artefact and geometric 
distortion. Reducing the field of view theoretically has the potential to improve both. 
Furthermore, larger slice thickness and field-of-view also have reduced spatial resolution which 
can result in the missing of smaller tumours. Ultimately, the aim of small field-of-view DWI is to 
improve the detection and localization of prostate cancer, with the improved spatial resolution 
also permitting better tumour delineation and therefore more accurate staging. With any new 
DWI sequence the ADC value of tumours and normal prostate tissue must be determined and the 
correlation of tumour ADC and tumour grade performed to assess the potential for the sequence 
to non-invasively assess tumour aggressiveness. 
Reducing the field-of-view has been demonstrated to be advantageous in the clinical setting in 
the spinal cord [112], pancreas [113] and breast [114]. Within the prostate variations of reduced 
field-of-view DWI imaging has been used by multiple groups [110,115–118]. There is consistency 
amongst the results of the reduced field-of-view studies of the prostate in that there is 
improvement in the qualitative measures of image quality and distortion, with some groups 
demonstrating a reduction in quantitative measures of distortion [110,119]. When ADC was 
measured in normal and tumour tissue there is variation in ADC values found between the large 
and reduced FOV techniques with some finding that values are higher with reduced FOV 
[116,117], some lower [118] and some found no significant difference between techniques [119]. 
Brendle et al. [119] and Feng et al. [115] are the only groups to assess for prostate cancer, with 
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the former the only to test for diagnostic accuracy, and both groups use biopsy specimens as a 
reference standard for all or some of the included patients. Brendle et al. [119] did not 
demonstrate a significant difference in sensitivity, specificity or AUC between the reduced and 
large FOV technique, but it is unclear if they tested for multifocality and only used 15 patients. 
Field-of-view optimized and constrained undistorted single-shot (FOCUS) is a commercially 
available small FOV DWI sequence created by General Electric. Feng et al. [115] used the 
sequence in their assessment of prostate cancer concluding the small FOV technique to have 
improved image quality, and reduced distortion, blurring and artefact with higher ADC values of 
tumour when compared to the conventional large FOV technique. They used b-values of 0 and 
800 sec/mm2 to qualitatively assess the image quality and to create the ADC maps. The limitations 
were that they only assessed the index lesion, used biopsy specimens as the reference standard 
and had a small number of patients. 
Molecular imaging of prostate cancer 
Molecular imaging of prostate cancer is an emerging field that aims to provide further non-
invasive information about tumour biology, behaviour and diversity not just in the prostate, but 
across the whole body. There are a variety of methods of assessing prostate cancer at a molecular 
level and they assess cell metabolism, membrane proteins, and hormone receptors. Most 
techniques have concentrated on the combination of one these techniques with anatomical 
imaging such as CT. Most notably the combination of radiolabelled choline, a nutrient essential 
for the synthesis of cell membranes during cell growth, and radiolablled prostate specific 
membrane antigen, a membrane glycoprotein found at 100-1000 times higher proportions in 
prostate cancer, with CT [120]. These are examples of molecular imaging of cell metabolism and 
membrane receptors, respectively, and choline PET is available in some centres within the NHS.  
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The limitation of using the above techniques is the poor spatial resolution locally within the 
prostate, so the detection of smaller lesions and local staging is poor. MRI spectroscopy is a 
technique which measures the levels of metabolites, which are altered in prostate cancer, thus 
becoming a biomarker for malignancy. In normal prostate citrate levels are high and choline low, 
whilst in prostate cancer the reverse is observed. Creatine is another metabolite measures, and 
although the levels between tumour and normal tissue are similar, the choline and creatine-to 
citrate ratios are normally observed. MRI spectroscopy is technically challenging, performed in 
few centres, and achieving the imaging acquisition and interpretation quickly enough to be used 
routinely is not possible. For these reasons spectropscopy is not routinely used in prostate MRI.  
MRI can also be fused with PET and can be used locally to detect and stage prostate cancer. 
Gallium labelled prostate-specific membrane antigen PET/MRI has been investigated and a recent 
study has shown it to have improved accuracy at prostate cancer detection compared to PET 
alone and also mpMRI [121]. The combination of molecular imaging with MRI is promising, but is 
currently a long way from being available routinely with its use limited to trials.  
Diagnostic test accuracy studies 
To optimise clinical practice, it is important for radiologists and other members of the clinical 
team to understand the strengths and weaknesses of the tests they request, report and base 
clinical decisions on. Awareness of the accuracy and reliability of these diagnostic tests is vital for 
safe management of patients. Diagnostic test accuracy studies are performed to assess the ability 
of a test to correctly identify a patient with a disease and also exclude disease from patients 
without a condition, however, they are prone to particular biases, and the studies with particular 
shortcomings can lead to the overestimation of accuracy of tests [122,123].  
The Standards for Reporting of Diagnostic Accuracy Studies (STARD) statement was published in 
2003 to provide guidance on the reporting of diagnostic accuracy studies to improve transparency 
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and comprehensiveness [124]. Since its creation there has been an increase in the reporting of 
the 25 items which were deemed the minimum set of essential items to be included in a 
publication of a diagnostic test accuracy study. Although, there are still deficiencies in certain 
aspects, in particular the reporting of inclusion criteria, blinding and confidence intervals [125]. 
There is, however, higher reporting of the items in accuracy studies of radiological tests in 
comparison to laboratory tests [125].  
In 2015, there was an update to the STARD reporting item list, resulting in 30 essential items to 
report in diagnostic test accuracy studies [126]. The new list now includes, for example, the 
requirement to describe the study hypotheses to keep the focus of the results narrow and avoid 
generous interpretation of the results. In addition, prospective studies should be considered as 
trials and registered on a clinical trials registry to allow identification of the study’s existence and 
prevent selective reporting.  
It is the intention with the FODIPb study to recognise and report the 30 items, in particular, the 
reporting of biases and limitations with the aim of answering the clinical questions outlined in the 
methods and materials (Page 109) and avoid making over-reaching generalisations when 
discussing the results and comparing to the current literature. 
Choice of reference standard and correlation with MRI  
Diagnostic test accuracy studies of MRI in the detection of prostate cancer are varied and attempt 
to answer many clinical questions. The focus of the accuracy studies can be on the detection and 
localisation of prostate cancer within the gland, or the presence and extent of extracapsular 
extension or seminal vesicle invasion.  
                                                             
b FODIP refers to the name of diagnostic test accuracy study of this thesis. 
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The choice of reference standard and patient group has a significant impact on the type of study. 
Using biopsy samples as a reference standard allows investigation of a pre-treatment population 
including men potentially with no prostate cancer. However, the limitations of using TRUS biopsy 
specimens is the significant number of false negative studies due to the small volume of tissue in 
the biopsy sample compared to total prostate volume and the non-targeted approach [56]. 
Ahmed’s [58] multicentre paired validating confirmatory study assessing the diagnostic accuracy 
of mpMRI versus TRUS biopsy in patients with a clinical suspicion of possible prostate cancer and 
using systematic high volume transperineal core biopsy specimens of the entire gland found the 
sensitivity of TRUS to be 48% for clinically significant prostate cancer.  
The use of transperineal biopsies as in the above study could be considered the best way to 
sample the prostate in a clinical and research environment as the entire gland is sampled, 
clinically significant tumours are less likely to be missed and tumours can be localised to certain 
aspects of the gland. However, the limitations are an inability to accurately measure tumour 
dimensions, the procedure usually involves general anaesthetic, requires considerable resource, 
and has significant morbidity, particularly given a reasonable proportion of patients will not have 
any or at most clinically insignificant prostate cancer. 
The use of radical prostatectomy specimens as the reference standard has benefits and 
weaknesses. The radical prostatectomy specimen can be sampled in a variety of ways, but the 
most common and recommended method, is by whole mount section of the entire gland which 
provides axial slices through the prostate, except the extreme apex, which are close in alignment 
to MRI [127]. This potentially allows for the closer correlation of MRI and prostatectomy 
specimens; including lesion localisation within the gland using landmarks both visible in pathology 
specimen and on MRI such as urethra [95]; lesion size and shape; delineation and increased 
confidence in the presence of multiple tumours; and assessment of spread beyond the capsule or 
into the seminal vesicles. The use of radical prostatectomy specimens does introduce selection 
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bias to diagnostic test accuracy studies as the patients who have this surgery tend to be younger 
and fitter, and their disease is more likely to be of higher grade and therefore more likely to be 
visible at MRI. In addition, the correlation is not exact as slice thicknesses and locations may not 
match and they may not both be in the same plane. Finally, after assessment of MRI and radical 
prostatectomy, preferably independent of each other and blinded to all clinical details, the 
correlation must be performed by a person(s) which introduces human error into the 
determination of the accuracy of the MRI sequence. 
STARD’s most recent iteration [126] introduced definitions of “Key STARD terminology”. The 
guidelines differentiate between ‘Clinical Reference Standard’, which is the best available method 
for establishing the presence and absence of the target condition, and ‘Gold-standard’, which is 
an error free reference standard. The use of radical prostatectomy specimens as the reference 
standard introduces many biases and limitations, and although the alternatives allow the 
assessment of a population with and without prostate cancer, the ability to correlate better with 
axial MRI slices and consistently assess for all tumours makes radical prostatectomy specimens 
the best clinical reference standard for diagnostic test accuracy studies of MRI sequences. 
The PROMIS study and comparison to FODIP 
One of the most influential pieces of research affecting the management of patients with 
suspected prostate cancer was the PROMIS study [58]. As mentioned, this was a prospective 
multicentre paired validating confirmatory study assessing men with suspected prostate cancer.  
In this study 576 men with suspected prostate cancer underwent a prostate MRI before a TRUS 
biopsy. This was followed by a non-targeted systematic transperineal biopsy, which was used the 
reference standard. The important aspect of the prostate MRI was that it was unaffected by 
haemorrhage (as it was done by before biopsies); was on a 1.5T magnet (to make the study 
relatable as all institutions will have a 1.5T magnet, and not necessarily a 3T magnet); the protocol 
used DCE in addition to DWI and T2WI; the MRI readers received training prior to participating; 
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and then had clinical details (such as PSA and DRE ) available. They assessed diagnostic accuracy 
of the MRI and TRUS biopsy against the TP biopsy as reference standard, using different 
thresholds for a positive sample based on percentage of the biopsy core involved and Gleason 
grade of tumour. 
The results showed that MRI was significantly more sensitive, but less specific than TRUS biopsy 
for all definitions of prostate cancer, however, most importantly the negative predictive value of 
MRI was significantly greater than TRUS. The advantage of a high negative predictive value for 
MRI is that if you can confidently exclude patients with significant prostate cancer you can 
prevent the man going on for an unnecessary TRUS biopsy, whilst still having the high sensitivity 
required to diagnose a significant number of prostate cancers. The results of the study are 
significant in that it is the most robust piece of evidence that there is a benefit in switching the 
investigative pathway of men with suspected prostate cancer from TRUS biopsy then MRI if 
positive to MRI then TRUS or TP biopsy. 
There are very few similarities between the FODIP and PROMIS studies. FODIP is a diagnostic 
accuracy study of a specific DWI sequence on a 3T magnet with blinded readers, comparing their 
reads against blinded reads of radical prostatectomy specimens by histopathologists. It is 
therefore difficult to directly compare the results of both studies, however, the significance of the 
PROMIS study’s results and the shift to pre-biopsy MRI does prompt a change in how the results 
of the FODIP study are considered, particularly how the DWI sequences will fit into a pre-biopsy 
setting as this is how almost all investigate suspected prostate cancer now. 
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Chapter 2 Meta-analysis: Accuracy of high b-value DWI 
Background 
The standards outlined in the PRISMA statement [128] provide a framework for conducting a 
systematic review and meta-analysis. The reporting standards and checklist are not exclusive to 
reviews of diagnostic accuracy, but are also relevant to cost-effectiveness, interventions and 
therapeutics, policy making and prognostic questions. Parameters described in the checklist 
include systematic review registration and publication of review protocol, eligibility criteria, study 
search and selection, data collection, risk of bias, presentation and synthesis of results, limitations 
and conclusions.  
Systematic reviews and meta-analyses of diagnostic test accuracy are important for clinicians. 
They offer an evidence-based display and summary of a potentially large body of evidence whilst 
minimizing bias and improving the reliability of conclusions [129]. They can provide summaries of 
sensitivity, specificity, positive and negative predictive values, odds ratios and summary receiver 
operating characteristic curves [130]. Crucially, they can help decide whether results are 
inconsistent or can be generalized. 
The diagnostic accuracy of mpMRI and DWI for the detection of prostate cancer is well-
established, with multiple meta-analyses reporting their diagnostic performance [100,101,131]. 
Current guidelines for the use of DWI in prostate MRI emphasise the use of b-values greater than 
1000 sec/mm2 [67], but none of the published meta-analyses have attempted to extract 
information on the ideal b-value.  
Accuracy of DWI in prostate cancer can be performed in different ways, namely a qualitative, 
visual assessment for tumour using either or both DWI and ADC map images, or using a 
quantitative, ROI based method of assessment for tumour using cut-offs of ADC values.  
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Visual assessment of the diagnostic performance of prostate MRI can be achieved through 
different methodologies. The most common approaches are a lesion-based and a sector-based 
accuracy assessment.  
Lesion-based analysis 
The lesion-based analysis is perhaps considered the more clinically appropriate where readers 
identify lesions within the prostate and are asked to localise them to a part of the prostate. 
Readers are either required to identify just the index lesion or can assess for multiple lesions. The 
definition of the index lesion often varies, but is usually the largest tumour and highest Gleason 
score on pathological specimens, usually prostatectomy [132]. Readers can be assessed 
‘stringently’ or ‘approximately’. A ‘stringent’ approach requires the reader to correctly identify the 
tumour in the exact location within the prostate that it is identified on histopathology. For the 
‘approximate’ approach, if the radiologist correctly identifies the lesion near the exact location it 
is considered a true positive assessment. Both approaches have merit. The ‘stringent’ accuracy 
may be of increased importance when the results are used for targeted biopsy or focal therapies, 
however, the ‘approximate’ approach reflects the limitations of correlating histopathology and 
radiology.  
Turkbey et al. [133] described a ‘stringent’ and ‘approximate’ approach, with the latter 
considering positive radiologic-pathologic correlation if the tumour was localised to a 
neighbouring sector. Rosenkrantz et al. [134] modified Turkbey’s [133] ‘approximate’ lesion 
localisation method by suggesting positive radiologic-pathologic correlation was present when a 
lesion in the neighbouring zone was chosen as long as the correct side of the gland (right or left) 
and zone (peripheral or transitional) was selected.  
The lesion-based analysis has been used to test the accuracy of multiple different imaging 
techniques in prostate cancer detection [81,134–137], however, the limitation is that areas 
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without prostate cancer are not assessed thus preventing the ‘True Negatives’ being identified 
and preventing the completion of the 2x2 contingency table. This limits the analysis of the 
diagnostic performance of the technique to sensitivity and positive predictive value and 
preventing the assessment of specificity and negative predictive value. Therefore, precluding the 
use of these studies in a diagnostic test accuracy meta-analysis as a complete 2 x 2 contingency 
table is an eligibility requirement. 
Sector-based analysis 
The sectoral based analysis allows ‘True Negatives’ to be assessed and the completion of the 2 x 2 
contingency table. This facilitates other diagnostic performance parameters, such as area under 
the receiver operating characteristic curve and accuracy, to be calculated.  
For this methodology, the prostate is divided into a specific number of sectors. Radiologists then 
decide if each sector has or does not have tumour present or provides a probability, usually a 
Likert score, of likelihood of tumour presence in each sector. The pathologists then assess the 
prostatectomy or biopsy specimen and map the tumour out on a similar reporting template to the 
radiologist. The different cut-offs available when using a Likert scale allows the interplay between 
sensitivity and specificity to be gleaned thus allowing the ROC curve to be created and AUC 
calculated. Determining the absence of tumour is an important finding when reading prostate 
MRI. A drawback to this method is that the analysis is at the mercy of the limitations in the 
radiologic-pathologic correlation and thus follows the ‘stringent’ criteria outlined in the lesion-
based analysis above. This could falsely lower the calculated diagnostic performance of the 
sequence.  
There is a variation in the literature as to how many sectors the prostate is divided into. Most 
biopsy papers limit the number of sectors to between 6 and 8, but when the reference standard is 
a prostatectomy specimen the prostate is divided into 8 sectors [138–141] or 12 sectors 
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[104,142]. In both approaches the peripheral zone is divided into left and right in the gland base, 
mid-gland and apex. The difference is in the division of the transitional zone, in which the 8 sector 
approach divides the whole transitional zone into left and right, but the 12 sector approach 
considers the 3 different levels like in the peripheral zone. The 12 sector approach equalises the 
importance of identifying tumour in all three levels of the prostate as well as in the peripheral or 
transitional zone.  
A balance must be struck between dividing the prostate into enough regions to allow a fair 
assessment of tumour localisation, but have too many and the assessment is falsely low as the 
challenge of identifying the sector becomes greater than the identifying the tumour. 
High b-value meta-analysis 
The aim of this systematic review and meta-analysis was to determine the diagnostic performance 
of high b-value DWI at detecting prostate cancer. In addition, it was important to recognise 
whether there were any differences in the qualitative and quantitative assessment of DWI 
accuracy. A subgroup analysis of different study characteristics could highlight whether any 
parameters of study design, MRI protocolling or method of assessing for tumour affect the 
accuracy of high b-value DWI. 
The meta-analysis also provided an up-to-date measure of the accuracy of high b-value DWI and 
allowed comparison with the diagnostic performance of the DWI sequences used in the FODIP 
study as well as permiting a comparison with other published meta-analyses. Additionally, it had 
the potential to provide information on common sources of bias and limitations in similar 
accuracy studies which possibly could then be minimised within the FODIP study methodology.  
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Material and Methods 
This meta-analysis was reported using the preferred reporting items for systematic reviews and 
meta-analyses outlined in the PRISMA statement [128]. The review was registered prior to 
commencing on PROSPERO, an international database of prospectively registered systematic 
reviews in health care.  The PROSPERO reference number is CRD42015027644 and the protocol is 
found at http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015027644. The 
status of the meta-analysis was kept up-to-date throughout. 
Search strategy 
A comprehensive systematic literature search was independently performed by two reviewers 
(KG, TSy) to identify studies investigating the diagnostic accuracy or performance of high b-value 
DWI for detecting prostate cancer. A MEDLINE search is presented in Table 2-1. In addition, 
searches were conducted of EMBASE, and the grey literature/trial registry databases: WHO 
International Clinical Trials Registry Platform and OpenGrey. Studies were not limited by country 
of origin, but were limited to those published in English. All searches were from database 
inception to 1st January 2016.  
Table 2-1. MEDLINE search strategy 
 Search Number of studies 
1 "prostatic neoplasms/diagnosis"[MeSH Terms] 54849 
2 “diffusion magnetic resonance imaging” [MeSH Terms] 13053 
3 1 AND 2 402 
4 Limit 3 to Humans 398 
5 Limit 4 to English 372 
6 Limit 5 to Abstracts 351 
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Eligibility criteria 
Retrospective and prospective studies were included if they reported detection of prostate cancer 
in a pre-treatment population using high b-value DWI of the prostate. Only primary research 
articles, available as full-text, were accepted; however, review articles were checked for 
additional primary references. High b-value was defined as a bmax ≥ 1000 sec/mm2. 
Histopathological results as a reference standard (biopsy or radical prostatectomy), and sufficient 
data to calculate true positive (TP), false positive (FP), false negative (FN), and true negative (TN) 
data were required. A minimum of 10 patients was also required. If multiple b-values were used, 
including b < 1000 sec/mm2, the study was only eligible if data with b ≥ 1000 sec/mm2 could be 
extracted. Studies using high b-value DWI in combination with other diagnostic sequences to 
detect cancer were excluded. 
Study identification 
Titles and abstracts from the search results, and the full-text papers for all studies which met or 
potentially met the eligibility criteria, were independently reviewed by two reviewers (Keith 
Godley (KG), Tom Syer (TSy)). Each reviewer performed the study search independently with the 
pre-determined eligibility criteria as guidance. An abstract or title which potentially met eligibility 
criteria resulted in the assessment of the full text. At this point both reviewers discussed their 
eligible papers. Those studies which met the eligibility criteria on full review were included in the 
final analysis. Disagreements on inclusion suitability were resolved by consensus between the two 
reviewers (KG, TSy). 
Data extraction 
Both reviewers then independently extracted the data on a pre-defined template, including: 
publication year, country of origin, sample size, description of study population (age), study 
design (prospective, retrospective, or unknown), patient enrolment (consecutive or not), inclusion 
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and exclusion criteria, reasons for exclusions from analysis, and number of experts who assessed 
and interpreted MRI results. Data were recorded on: blinding of MRI measurements to clinical, 
biochemical or histopathological results; methods used to determine diagnosis; types of coils; and 
b-values used. For each study, the number of true-positive, false-positive, true-negative, and 
false-negative findings for high b-value DWI in diagnosing prostate cancer was recorded. 
Disagreements in data extraction findings were resolved through discussion or through 
adjudication with a third reviewer (Toby Smith (TSm)). In some instances, not all the data for the 2 
x 2 contingency table was published, however, if the missing data could be calculated from other 
data, for example, positive predictive value or specificity results, then the study was included. No 
attempts were made to contact authors to ask for missing data. 
Quality Assessment 
Two reviewers (KG, TSy) independently assessed each included paper’s quality using QUADAS-2 
(Quality Assessment of Diagnostic Accuracy Studies) [122]. QUADAS-2 is a publically available 
resource designed to provide a standardised quality assessment of different parameters of 
diagnostic test accuracy studies and a modified version has been endorsed by the Cochrane 
Collaboration and advised for use in any diagnostic test accuracy Cochrane reviews. The results of 
each reviewer’s QUADAS assessment were discussed by the two reviewers and disagreements 
were resolved through discussion or through adjudication with a third reviewer (TSm). 
Statistical analysis 
Study heterogeneity was assessed through examination of the data extract table. On review of 
the principle characteristics of the included studies, such as patient population, study 
methodology, imaging protocol, and reference standard used were broadly homogenous, 
meaning a meta-analysis was appropriate. 
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Specificity and sensitivity of each study was calculated using 2×2 contingency tables. Pooled 
sensitivity, specificity and positive and negative likelihood ratios with 95% CIs were calculated. 
Finally, the specificity and sensitivity were used to calculate a summary receiver operating 
characteristic (sROC) curve and the area under the curve (AUC). This was performed using the 
Moses-Littenberg method which has been used extensively in diagnostic test accuracy meta-
analyses [143].  
Statistical heterogeneity between the included studies was assessed using the Cochran’s Q test, 
Q, and the inconsistency, !" [144]. When p = < 0.10 and !" = > 50%, unexplained statistical 
heterogeneity was evident and diagnostic performance analyses were performed using a random-
effects model. These parameters are performed using the below software and they are of 
increased benefit in the assessment of statistical heterogeneity in therapeutic and intervention 
meta-analyses, but as they are designed to assess heterogeneity around a single outcome variable 
they are less benefit in diagnostic test meta-analyses as they do not allow for the influence of 
threshold effect [145]. Statistical heterogeneity is almost always expected in diagnostic test 
accuracy meta-analyses and random-effects model of assessment of diagnostic performance is 
performed as a default. 
Threshold effect is an important concept when reviewing the results of a diagnostic test accuracy 
meta-analysis. Different studies assessing for the same condition can use a different 
threshold/cut-off for a positive test. The accuracy of the study therefore depends on the choice of 
threshold and changing the threshold can increase sensitivity and reduce specificity, or vice versa. 
Differences in threshold used between studies can result in differences in their summary data, a 
concept known as threshold effect. 
Threshold effect can be assessed visually and statistically. To do so visually this needs to be done 
with both the sensitivity and specificity data of all studies present simeoultaneously. This is 
performed using a Receiver Operating Characteristic (ROC) curve where sensitivity is plotted 
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against (1-specificity) and all the studies are included. If threshold effect is observed the studies 
will all be grouped in a ‘shoulder-arm’ shape. Quantitatively assessing the correlation between 
sensitivity and (1-specificity) using a Spearman correlation coefficient of the logit of sensitivity and 
the logit of (1-specificity) allows statistical assessment of threshold effect , with a strong 
correlation (p = <0.05) indicating the heterogeneity between studies could be explained by 
threshold effect [145].  
Threshold effect was not found to be factor in the heterogeneity between studies and therefore a 
meta-regression and subgroup analysis were performed to explore other sources of heterogeneity 
to determine how they influence diagnostic performance. Meta-regression of pre-determined co-
variates, such as reference standard and threshold method, was computed using a generalisation 
of the Littenberg and Moses model allowing weighting for random effects and by the inverse of 
variance or sample size [143,146].  
All statistical computations were performed using Meta-DiSc (version 1.4, Javier Zamora) and 
Review Manager (version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2014). The statistical analysis and creation of tables and figures was performed by 
KG.  
Results 
Search results 
A summary of the search strategy results is presented in Figure 2.1. In total, 351 studies were 
identified from the search results, of which 61 were deemed potentially eligible. After full-text 
review, 10 studies met the final eligibility criteria and were included in the analysis 
[90,91,141,142,147–152]. 
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Characteristics of included studies 
The principle characteristics of the included studies are displayed in Table 2-2, with imaging and 
study methods listed in Table 2-3. From the 10 included studies, 522 patients were analysed, with 
mean (range) age = 64 (43–87) years. The mean and median PSA was 19 and 9.3 ng/mL, 
respectively.  
 
Figure 2-1. Flow diagram of study identification and exclusion. 
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Table 2-2. Principle characteristics of included studies. 
Study Year Country Number. of 
patients 
Mean Age 
(range) 
Mean PSA 
(range) 
Design 
Chen [147] 2008 China 42 63 (4582) 52.5 (4.7–147) Retro 
Girometti 
[148] 
2012 Italy 26 64*(51–74) 6.0*(2.5–10) Pro 
Isebaert [141] 2013 Belgium 75 66*(49–74) 10.4 (1.5–70.9) Pro 
Kim [90] 2000 South Korea 48 66 (45–80) 7.2*(2.3–23.2) Retro 
Koo [91] 2013 South Korea 80 66 (45–81) 7.2 (1.2–57) Retro 
Kumar [149] 2007 India 23 64.5 11*(0.5–1000) Pro 
Lim [142] 2009 South Korea 52 65 (48–76) 66 (45–80) Retro 
Peng [152] 2013 USA 48 61.5 (44–73) 15.6 (0.8–256) Retro 
Rosenkrantz 
[150] 
2015 USA 58 63 8.2 Retro 
Vilanova [151] 2011 Spain 70 63.5 (43–87) 7.4*(4–17.2) Retro 
PSA – Prostate specific antigen (ng/mL), * Median, Pro – prospective, Retro – retrospective 
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Table 2-3. Imaging and methodological characteristics of the included studies. 
Study Field Strength Coil b-values (sec/mm
2) TE (ms) Spasm Reference Standard Blinded 
Threshold 
method 
Chen 1.5T A 0 & 1000 94 U Bx (sextant) Y ADC  
Girometti 3T A 0, 800 & 1200 60 Y Bx (octant) U ADC  
Isebaert 1.5T A 0, 50, 100, 500, 750 & 1000 79 U RP (octant) Y Visual 
Kim 3T A 0 & 1000; 0 & 2000 83-95 Y RP (14 sectors) Y Visual 
Koo 3T A 0 & 300; 0 & 700; 0 & 1000; 0 & 2000 75-76 Y RP (10 sectors) Y Visual 
Kumar 1.5T B 0, 250, 500, 750 & 1000 96 U Bx (whole gland) Y ADC   
Lim 3T A 0 & 1000 117 Y Bx (12 sectors) Y Visual 
Peng 1.5T B 0, 50, 200, 1500 & 2000; 0 & 1000* 71-85 Y RP N ADC  
Rosenkrantz 3T A 50 & 1000 86 U RP (4 sectors) Y ADC  
Vilanova 1.5T B 0 & 1000 94 U C (octant) Y ADC  
Coil A – without endorectal coil, Coil B – with endorectal coil; TE – Echo time; RP – radical prostatectomy, Bx – biopsy, C – both RP and 
Bx included; Y – yes, U – unclear; Spasm – Anti-spasmodics; ADC – Apparent diffusion coefficient 
* 29 patients were imaged with b-values of 0,50, 200, 1500 and 2000; 24 patients were imaged with b-values of 0 and 1000. 
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Three studies were prospective and seven retrospective. Field strengths of 1.5T 
[141,147,149,151,152] and 3T [90,91,142,148,150] were each used in five studies. Radical 
prostatectomy specimens were used as the reference standard in six studies 
[90,91,141,142,150,152], biopsy specimens in three [147–149] and one study used a combination 
[151]. The MRI reader was blinded in eight studies [90,91,141,142,147,149–151], blinding was not 
known in one, and one was not blinded [152]. Anti-spasmodic agents, either glucagon or hyoscine 
butylbromide, were used in five studies [90,91,142,148,152] and their use unknown in the 
remainder. Five studies [90,91,142,148,152] used b-values of greater than 1000 sec/mm2.  
Several methods were used to detect prostate cancer: region-of-interest (ROI) based  ADC 
quantification was used in six studies [147–152]; and visual assessment of lesions was performed 
in four studies [90,91,141,142]. A more detailed description of the ADC quantification and visual 
assessment threshold methodology is found in Table 2-4 and Table 2-5, respectively. 
All ten studies used the monoexponential function to create ADC maps and estimate ADC. In 3 
studies [90,91,150], extracted data were split into subsets. Kim et al. [90] and Koo et al. [91] 
generated multiple ADC maps: b = (0, 1000), and (0, 2000) sec/mm2 for the former, and b = (0, 
300), (0, 700), (0, 1000), and (0, 2000) s/mm2 for the latter. Rosenkrantz et al. [150] split data into 
peripheral and transitional zone results. The other studies generated only one set of ADC maps 
from their DWI data, performing monoexponential fitting to all acquired b-values 
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Table 2-4. Description of threshold method used for included studies using ADC measurements 
Study Description of threshold method used 
Chen ROI measurement of visually low signal area and ‘normal' tissue creating a 5-point scale from the quintiles of the ADC 
measurements.  
Girometti ADC cut-off value of 0.9 x 10-3 mm2/sec.  
Kumar  Mean ADC for all the peripheral zone and central gland. Gland assessed as a whole.  
Peng 10th percentile ADC measurements of non-blinded assessment of the ADC map.  
Rosenkrantz Normalised ADC measurement of lowest signal area in PZ and TZ of both lobes.  
Vilanova ROI measurement of octants with 5-point scale using ADC cut-offs.  
      
 
 Table 2-5. Description of threshold method used for included studies using visual assessment of tumour. 
Study Description of threshold method used 
Isebaert Visual assessment of DWI and ADC map. Binary cut-off.  
Kim Visual assessment of ADC maps. Binary cut-off.  
Koo Visual assessment of DWI and ADC. Likert scale.  
Lim Visual assessment of ADC map. Likert scale.  
  Meta-analysis: Accuracy of high b-value DWI 
 
69 
Quality assessment 
Study quality assessment is presented in Table 2-6. Figure 2-2 demonstrates the QUADAS-2 
graphical summary of the studies indicating the proportion of high, low, or unclear risk in each 
domain. A high risk of bias was demonstrated in the patient selection domain, but overall the 
quality of the studies included was considered ‘good’. 
Table 2-6. Quality assessment of the included studies. 
 Risk of bias Applicability concerns 
Patient 
Selection 
Index 
test(s) 
Reference 
Test 
Flow & 
Timing 
Patient 
Selection 
Index 
test(s) 
Reference 
Test 
Chen + + - + + + + 
Girometti - + - - - + + 
Isebaert - + + U + + + 
Kim - + + + - + + 
Koo - + + + - + + 
Kumar + + - + + + + 
Lim - + + + + + + 
Peng - - + U - + + 
Rosenkrantz - + + U + + + 
Vilanova + + - + + + + 
+ Low risk, – High risk, U Unclear risk 
 
 
Figure 2-2. QUADAS-2 results summarising the proportion of low, high and unclear risk of bias and 
applicability concerns
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Diagnostic performance 
The results from the individual studies are presented in Table 2-7. The pooled sensitivity and 
specificity of high b-value DWI MRI in detecting prostate cancer was 0.59 (95% CI, 0.57–0.61; 
Figure 2-3) and 0.92 (95% CI, 0.91–0.92; Figure 2-4), respectively. Sensitivity and specificity 
heterogeneity tests gave Q = 435.05 (p  0.001), !"  = 97.2% and Q = 89 (p  0.001), !"   = 86.5% 
respectively, indicating significant statistical heterogeneity between studies. 
Table 2-7. Diagnostic performance of eligible studies and subsets. 
Study TP FP FN TN Sens Spec Notes 
Chen 42 37 9 164 0.82 0.82  
Girometti 4 14 8 182 0.33 0.93  
Isebaert 359 44 617 732 0.37 0.94  
Kim 158 49 22 443 0.88 0.92 b=1000 
 128 40 52 452 0.71 0.92 b=2000 
Koo 174 38 31 557 0.85 0.94 b=1000 
 152 22 53 573 0.74 0.96 b=2000 
Kumar 17 10 6 27 0.63 0.82  
Lim 171 57 56 340 0.75 0.86  
Peng 49 6 12 37 0.86 0.80  
Rosenkrantz 15 13 24 64 0.39 0.83 TZ 
 42 2 42 30 0.50 0.94 PZ 
Vilanova 37 8 14 81 0.73 0.91  
TP – true positives, FP – false positives, FN – false negatives, TN – true negatives, Sens – sensitivity, 
Spec – specificity, TZ – transitional zone, PZ – peripheral zone 
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The pooled positive and negative likelihood ratios for high b-value DWI MRI in detecting prostate 
cancer were 6.64 (95% CI, 4.9–9.0; Figure 2-5) and 0.33 (95% CI, 0.2–0.5;Figure 2-6), respectively. 
Positive and negative likelihood ratio heterogeneity tests gave Q = 82.50 (p  0.001), !"   = 85.5% 
and Q = 517.45 (p  0.001), !"   = 97.7%, respectively, indicating significant statistical 
heterogeneity between studies. 
Figure 2-7 shows the sROC curve of the 10 studies, where AUC = 0.92, indicating ‘good’ diagnostic 
accuracy [153]. 
 
Figure 2-3. Forest plot of sensitivity with pooled sensitivity, Q statistic of the chi-squared, and I-squared 
results. 
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Figure 2-4. Forest plot of specificity with pooled specificity, Q statistic of the chi-squared, and I-squared 
results. 
 
Figure 2-5. Forest plot of positive likelihood ratio with pooled positive likelihood ratio, Q statistic of the 
chi-squared, and I-squared results. 
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Figure 2-6. Forest plot of negative likelihood ratio with pooled negative likelihood ratio, Q statistic of the 
chi-squared, and I-squared results. 
 
Figure 2-7. The summary Receiver Operating Characteristic (sROC) curve for high b-value DWI in detecting 
prostate cancer.  
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Meta-regression analysis 
The ROC curve did not demonstrate a ‘shoulder-arm’ shape (Figure 2-8) and the Spearman 
Correlation Coefficient between the logit of sensitivity and the logit of (1-specificity) was 0.286 
(p=0.344), confirming that the threshold effect is not responsible for the variation in accuracy 
between studies.  
 
Figure 2-8. Sensitivity and 1-specificity plotted in Receiver Operating Characteristic curve for individual 
studies and subsets. 
Subgroup analysis 
Subgroup analysis was based on different study characteristics and perceived sources of bias and 
applicability uncovered in the QUADAS assessment. Studies at 3T with and without an endorectal 
coil demonstrated the highest pooled sensitivity of 0.76 (95% CI, 0.71–0.80) and 0.74 (95% CI, 
0.71–0.79) respectively. When assessing protocols with a maximum b-value > 1000 sec/mm2, the 
pooled specificity and AUC of the sROC were greater: 0.94 (95% CI: 0.93–0.95) and 0.98, 
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respectively. A statistically significant improvement was seen using assessment of tumour 
presence as a visual threshold versus quantitative ROI measurements (p = 0.03). The diagnostic 
performance of the subgroup analysis and p-values of the above-mentioned factors and others 
are demonstrated in Table 2-8. 
 
Table 2-8. Results of the subgroup analysis. 
Study characteristics No Pooled sensitivity  
(95% CI) 
Pooled specificity  
(95% CI) 
AUC p-value* 
Total 13 0.59 (0.57–0.61) 0.92 (0.91–0.92) 0.92  
b-value (sec/mm2)     0.31 
      1000 9 0.55 (0.53–0.58) 0.90 (0.89–0.92) 0.91  
       >1000 3 0.72 (0.67–0.76) 0.94 (0.93–0.95) 0.98  
Field strength     0.20 
       1.5T 6 0.49 (0.46–0.51) 0.90 (0.88–0.91) 0.89  
       3T 7 0.74 (0.71–0.79) 0.93 (0.92–0.94) 0.96  
Coil     0.32 
      With endorectal 4 0.76 (0.71–0.80) 0.86 (0.83–0.89) 0.84  
      Without endorectal 9 0.56 (0.53–0.58) 0.93 (0.92–0.93) 0.94  
Reference standard     0.16 
       Biopsy 3 0.73 (0.63–0.82) 0.86 (0.82–0.89) 0.86  
       Prostatectomy 9 0.56 (0.56–0.60) 0.92 (0.91–0.93) 0.94  
Threshold method     0.03 
      ADC 7 0.64 (0.59–0.69) 0.87 (0.84–0.89) 0.88  
      Visual 6 0.58 (0.55–0.60) 0.93 (0.92–0.93) 0.95  
Patient selection bias     0.29 
      High risk 10 0.58 (0.56–0.60) 0.92 (0.91–0.93) 0.94  
      Low risk 3 0.77 (0.68–0.84) 0.83 (0.79–0.87) 0.86  
AUC – Area under the curve. *p-value – comparison of diagnostic odds ratio of subgroups 
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Discussion 
This analysis indicates that high b-value imaging is a good diagnostic tool for detecting prostate 
cancer. The results of the threshold method subgroup analysis imply that there is a benefit in 
using a higher maximum b-value in a clinical setting. The lesser value of quantitative ADC 
thresholding as a tool for detecting tumour is in line with PI-RADS version 2 recommendations 
(standardized reporting standards for prostate MRI) [67]. The evidence on which this analysis was 
made was graded as ‘good’ using the QUADAS-2 tool, however results should be interpreted with 
caution given the significant statistical heterogeneity in the meta-analysis. 
There have been multiple meta-analyses investigating the diagnostic accuracy of DWI alone or in 
combination with other imaging techniques [100,101,131]. The pooled sensitivity, specificity, and 
AUC of this study were 0.58, 0.92 and 0.92 respectively, which is similar to Jie’s [100] meta-
analysis of DWI alone. This is likely due to overlap of included studies, with nine of the ten 
included studies featured in their meta-analysis. However, in contrast to Jin’s meta-analysis of all 
b-values, the sensitivity was lower in this study (0.58 vs. 0.77), but the pooled specificity and AUC 
were higher (0.92 vs. 0.84 and 0.92 vs. 0.88 respectively) [131]. This suggests high b-value imaging 
may help to rule out significant prostate cancer.  
There was significant statistical heterogeneity between the included studies demonstrated in the 
Inconsistency value and Chi-Squared of the Q statistic results. Heterogeneity between studies is 
also demonstrated in the visual assessment of the sensitivity, specificity, and positive and 
negative likelihood ratio Forest plots, particularly the former. Following assessment of the ROC 
curve and Spearman rank correlation coefficient of the logit of sensitivity versus logit of (1-
specificity) results it was concluded that the heterogeneity could not be explained by threshold 
effect.  
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Heterogeneity in a meta-analysis can come from multiple sources, including both clinical and 
study parameters. Potential clinical parameter diversity between studies includes patient age, 
analysis of patients with and without prostate cancer versus just those with cancer, and patient 
age. Examples of study design variability exist in the method of assessment for tumour, 
prospective versus retrospective analysis, use of coil or antispasmodics, and choice of b-values 
analysed. 
Results of the studies were pooled in a meta-analysis and given the significant statistical 
heterogeneity, a random-effects model was used. Diagnostic results of the individual studies were 
pooled to provide an overall estimate of different diagnostic parameters. This is not 
recommended in the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy as it 
is felt that pooling studies which used different threshold methods creates a notional average 
which is not useful clinically [154]. However, despite this advice it is relatively common practice to 
include pooled results in diagnostic test accuracy meta-analyses [145]. RevMan, the meta-analysis 
software created by Cochrane has many functions including the creation of Forest plots, but it 
does not provide pooled results. On the other hand, MetaDisc does provide pooled results for 
random and fixed effects models [155], but again advises caution in the presence of statistical 
heterogeneity.  
When statistical heterogeneity exists that cannot be explained by threshold effects a subgroup 
analysis can be performed to look for reasons for the heterogeneity of the results. It is important 
to identify subgroups a priori as pooling of these subsets should only be performed if the subsets 
are homogenous. Performing subgroup analysis of low numbers of studies can introduce more 
heterogeneity. In this meta-analysis, the subgroups assessed were chosen prior to analysing the 
data, however, it was unclear at the outset how many studies would be in each subgroup leading 
to some with only 3 studies included. The subgroups’ pooled results should be assessed with even 
more caution. 
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Meta-DiSc provides a measure of difference between covariates within the subgroup analysis. The 
p-value provided is a measure of the strength of difference between the diagnostic odds ratio of 
each subgroup. Diagnostic odds ratio is used as it provides an overall marker of accuracy and 
includes the results of the sensitivity, specificity, and positive and negative likelihood ratios. The 
diagnostic odds ratios of the individual results were not displayed as the result alone have little 
meaning clinically and interpreting accuracy as a ratio of odds is challenging. Therefore, the AUC 
of the sROC was chosen as it is a more well-known indicator of overall accuracy. 
Improved tumour contrast at high b-values comes at the cost of decreased signal-to-noise [156]. 
This can be mitigated through the use of 3T field strength. Most of the diagnostically specific high 
b-value diagnostic accuracy studies use 3T [83,85,88,157]. The subgroup analysis of field strength 
demonstrated a trend towards improved accuracy with 3T. Although, the diagnostic odds ratio of 
the 3T subgroup was not significantly superior to the 1.5T subgroup, the sensitivity and specificity 
were significantly higher (assessed by reviewing the confidence intervals) and the AUC improved. 
The sensitivity results of the 3T subgroup alone are similar and the specificity and accuracy are 
better than those found in Wu’s meta-analysis of accuracy of visual assessment of combined T2WI 
and DWI sequences for prostate cancer detection [101].  
An important subgroup analysis was the comparison of the qualitative and quantitative 
methodologies. They are two very distinct and differing methodologies, both of which have merit. 
The visual assessment of tumour is more clinically applicable as this is what radiologists use in 
their daily practice interpreting prostate MRI. ADC measurement and cut-offs do provide 
diagnostic information, but they are not recommended currently for routine use, particularly as 
the ADC values of tumours vary with field strength, b-value, and other scanning parameters 
[94,107]. A further advantage of performing pooling of the results, on these subgroups, are that 
the studies within each subgroup are more homogenous thus providing more certainty about the 
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accuracy of the pooled results, although, the methods used in the ADC value measurements 
studies were varied. 
About half of the studies qualitatively assessed the ability of blinded readers to visually detect 
prostate cancer either by answering a binary question regarding cancer presence or using a 
probability scale [90,91,141,142]. The remaining studies used ROI-based ADC calculations to 
determine prostate cancer presence or absence, or used a scale of ADC values to predict cancer 
[147–152]. The diagnostic performance of tumour visual assessment on ADC maps was 
significantly better than quantitative ADC methods, with visual assessment giving similar results to 
Wu’s combined T2WI and DWI meta-analysis [101], indicating potential value for high b-value 
imaging clinically.  
The variability amongst the ADC assessment study methodologies was associated with a 
variability in the diagnostic results of the studies resulting in wide confidence intervals. The 
pooled results of this subgroup should be interpreted cautiously as it likely does not reflect the 
usefulness of the technique accurately.  
The homogeneity of the qualitative studies’ methodology is seen in the blinded visual assessment 
of images by readers, as well as in the use of radical prostatectomy specimens as reference 
standard, and finally in the division of the prostate into sectors. By using a sectoral-based 
qualitative accuracy assessment it increases the number of data points significantly, as each 
sector is considered a single data point rather than an individual patient or tumour being 
considered a data point. However, sectoral assessment of the prostate is flawed and not the most 
applicable clinically. As mentioned previously a lesion-based analysis does not provide an ability 
to measure true negatives, but the ability to identify individual lesions and stage them accurately 
is, perhaps, more beneficial to clinicians. 
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A potential explanation for the relatively poor performance of quantitative ADC methods is that 
four of the six studies used biopsy as a reference standard whereas all visual assessment studies 
used radical prostatectomy specimens. TRUS biopsy as a reference standard is limited given its 
poor octant localization, small sampling volume, and substantial number of tumours missed 
[158,159]. There was a trend towards improved diagnostic performance in studies which used 
radical prostatectomy as a reference standard in comparison to biopsy studies, although the 
difference was not statistically significant.  
No other subgroup analyses demonstrated a significant difference between the groups. In some 
subgroups a statistical difference would have been difficult to demonstrate given the small 
numbers of studies. For example, only three studies used biopsy as a reference standard, but 
despite this, this subgroup analysis provided the second strongest statistical source of 
heterogeneity (p = 0.18). The limitations of biopsy as a reference standard are described above, 
but limiting MRI assessment to patients who have had a prostatectomy introduces patient 
selection bias, as patients considered for radical prostatectomy tend to be younger, fitter, and 
have clinically significant tumours, prompting surgery. Radical prostatectomy allows examination 
of the entire gland including the anterior gland (which TRUS cannot) and detects multifocality, 
which is frequent [37,160]. Eight of nine studies in the prostatectomy subgroup assessed for 
multifocal disease, or for tumour in multiple segments of the prostate, and this subgroup’s results 
may be more representative of the diagnostic accuracy of high b-value diffusion. 
There are limitations to the review and meta-analysis. Limitation by language and database may 
have introduced bias. The use of two larger databases, and grey literature, should encompass 
most eligible English language studies.  Publication bias was not assessed. A Deek’s funnel plot is 
considered the most accurate method of assessing accuracy in meta-analyses of diagnostic test 
accuracy, however in the presence of heterogeneity of diagnostic odds ratio results and with a 
small numbers of included studies the test is of low power [161]. Finally, this study was restricted 
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to testing localization of prostate cancer within the gland. This is important in determining the 
accuracy of high b-value diffusion, but not the only useful outcome. Identifying the presence of 
capsular breach, seminal vesicle invasion and pelvic lymphadenopathy are important staging and 
prognostic characteristics not assessed in this meta-analysis. 
In conclusion, these findings should be considered cautiously given the degree of statistical 
heterogeneity. However, this meta-analysis demonstrated that high b-value diffusion is a valuable 
diagnostic tool, with a sensitivity of 59%, specificity of 92% and sROC AUC of 0.92. There was 
better diagnostic performance by visual assessment of high b-value DWI studies compared to ADC 
quantification highlighting the potential value of high b-value DWI clinically, particularly at 3T. The 
methodologies and patient selection employed by the visual assessment studies are similar to the 
methods used in the FODIP study, thus providing a marker of accuracy to compare assessed DWI 
sequences against.  
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Chapter 3 Meta-analysis: Accuracy of DWI and T2WI 
Background 
The results of the previous chapter’s systematic review and meta-analysis provided a rationale for 
using higher b-values and suggest it is a good diagnostic test. Furthermore, it added to the 
evidence that a qualitative assessment of diagnostic performance of DWI for prostate cancer 
detection is advised over a quantitative analysis of ADC. It’s limitations, however, were the small 
number of studies included in the meta-analysis, particularly, if assessing only the visual 
assessment subgroup, which had only four studies. 
The majority of diagnostic test accuracy studies of DWI in prostate MRI include T2WI sequences in 
their assessment for tumour. This realisation became apparent to the two reviewers during the 
study identification step of the high b-value meta-analysis and that, although, the meta-analysis 
could provide useful information it would not provide much valuable information on comparisons 
of b-values.  
Although, the T2WI sequence is an important sequence in the MRI prostate protocol and part of 
many diagnostic accuracy studies research protocols it is rarely the focus of the study. Despite the 
technical parameters of the T2WI sequence usually being described in a study it rarely features as 
a point of discussion or as an explanation for a study’s results. The T2WI sequence is included in 
these studies as it is an imaging mainstay in the prostate MRI protocol; it’s benefits, particularly in 
the transitional zone, cemented in reporting guidelines [67,68]; and, perhaps because it usually is 
part of research protocols, new studies include it when designing their study to facilitate 
comparison with the wider literature. 
A diagnostic test accuracy meta-analysis of T2WI and DWI sequences for detecting prostate 
cancer has been performed [101]. This study provided an understanding of the clinical benefit as 
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it included only studies visually assessing for tumour. The study was published in 2012 and 
included only 10 primary studies. In addition, they assessed b-value subgroups, comparing b-
values of less than 1000 sec/mm2 with those 1000 sec/mm2 and greater, but found no significant 
difference in pooled sensitivity and specificity. Like most studies, although including T2WI 
sequences in their analysis, Wu’s meta-analysis did not comment or assess the technical 
parameters of this sequence. Finally, a potential limitation of this study was it did not perform a 
QUADAS-2 assessment and did not comment on their adherence to the PRISMA statement.  
Repeating the T2WI and DWI diagnostic test accuracy meta-analysis was considered to be 
beneficial. Firstly, it had been 5 years since this meta-analysis meaning more studies could now be 
included, which had the potential to provide a more confident understanding of the diagnostic 
performance. In addition, a subgroup analysis including more studies increases the surety of any 
potential significant differences between groups. The subgroup analysis possibly could identify 
the ideal b-value so that it could be implemented when choosing b-values for the FODIP study 
DWI sequences. Finally, the FODIP study planned to also assess the accuracy of DWI and T2WI 
together and therefore, this meta-analysis of studies that visually assessed for tumour would 
provide a reliable benchmark to compare the diagnostic performance of the radiologists in the 
FODIP study against.  
Materials and methods 
As in the previous meta-analysis it was registered prospectively with PROSPERO International 
prospective register of systematic reviews, reference number: 42016036196 [162], and was 
carried out in accordance to the Preferred reporting items for systematic reviews and meta-
analysis (PRISMA) guidance [128]. 
A systematic review of the literature was independently undertaken by two reviewers (KG and 
TSy) to identify studies which investigated the diagnostic accuracy of DWI and T2WI MRI in the 
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detection of prostate cancer. Searches were performed using MEDLINE and EMBASE electronic 
databases as well as OpenSIGLE to explore sources of unpublished grey literature. The Science 
Citation Index was used to identify articles which cite those identified with the original search 
terms. Once eligible studies were found their reference lists were manually searched for further 
potential papers. The search strategy for MEDLINE including Boolean operators and MeSH terms 
is presented in Table 3-1, the same search strategy was used for each database with alterations to 
suit. All studies were included up to the date of the search; 1st September 2017.  
Table 3-1. MEDLINE search terms and strategy. 
1 Exp Prostate* Neoplasm*/ 
2 Prostat* cancer*.mp. 
3 Prostat* carcinoma*.mp. 
4 Or/1-3 
5 Exp Diffusion magnetic resonance/ 
6 DW magnetic resonance imaging.mp. 
7 DWI.mp. 
8 DW-MRI.mp. 
9 Or/5-6 
10 4 and 9 
11 10 limit to Human studies 
12 11 limit to English Language 
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Eligibility 
The eligibility criteria for the studies included within the systematic review were  
• Both DWI and T2WI MRI used in combination for the visual assessment of prostate 
cancer.  
• Assessment of the pre-treatment patient population  
• Histopathological reference standard, be that biopsy or radical prostatectomy.  
• Sufficient information to produce a 2x2 contingency table (true positives, false 
positives, false negatives and true negatives) to calculate sensitivity and specificity.  
• Published in English 
•  Assess more than 10 individual patients.  
Studies would be excluded if they did not satisfy the inclusion criteria above or they used a 
different combination of imaging sequences from DWI and T2WI so that individual data for the 
desired combination could not be extracted. They would also be excluded if an ADC cut-off was 
used to discriminate malignant from benign tissue as opposed to visual assessment by 
radiologists. Studies were not excluded by country of origin, age of patients or study design. 
Study identification 
Initially papers were reviewed by relevancy of title and then abstract. Residual articles had their 
full text reviewed against the inclusion and exclusion criteria. This was also performed 
independently by the same two reviewers; any disagreement was solved by consensus or a third 
expert reviewer if necessary (TSm).  
Data extraction 
The following data were extracted from each eligible study; year of publication, country of origin, 
patient group, number of patients, average age and prostate specific antigen (PSA), study design 
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(retrospective or prospective) and the histopathological reference standard used. Further 
information on the imaging specifications was also gathered; field strength, coil used, field-of-
view, b-value, and whether they used DWI, ADC maps or both to assess each patient. True 
positives, false positives, false negatives and true negatives were also extracted for pooling 
results, when insufficient data was available reviewers would manually calculate them from other 
reported statistics when possible. All data extraction was independently verified by two reviewers 
(KG, TSy).  
Quality assessment  
The quality of the each included study’s methodology was assessed with the Quality Assessment 
of Diagnostic Accuracy Studies (QUADAS-2) tool [122]. This was also undertaken independently by 
two reviewers (KG, TSy) and disagreement resolved with consensual discussion and consulting a 
third expert reviewer if consensus could not be met (TSm).  
Statistical analysis 
The sensitivity and specificity with 95% Confidence Intervals were calculated for each study using 
the extracted details of the 2x2 contingency tables, and Forest plots produced.  
Initially heterogeneity of studies was examined visually using the data extraction tables, followed 
by statistical analysis using the inconsistency value (I²) and Q statistics of the Chi-squared value. 
An I² >50% and p-value<0.10 respectively would indicate significant statistical heterogeneity and a 
random-effects model would be applied to data pooling. Pooled results for sensitivity, specificity, 
positive and negative likelihood ratios with 95% Confidence Intervals and a sROC curve was also 
presented.  
To explore predictable sources of heterogeneity between included studies, the sensitivity and 1-
specificity was plotted on an ROC plane to visually assess the presence or absence of a ‘shoulder 
arm’ shape, which would indicate a threshold effect. This was also tested statistically with the 
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spearman correlation coefficient of the logit of sensitivity and logit of (1-specificity) with a p-value 
<0.05 suggesting a threshold effect. Subgroup analysis was performed for; b-values (<1,000, 1,000 
and >1,000), field strength (1.5T and 3T), coil type (endo-rectal and body), method of assessment 
(DWI, ADC or both), reference standard (Biopsy and radical prostatectomy), tumour zone 
(Peripheral or transitional zone) and study design (retrospective and prospective). Pooled 
sensitivities, specificities, positive and negative likelihood ratios and meta-regression of diagnostic 
odds ratio with p-values was performed for these sub-groups. All statistical analysis was 
conducted on Meta-DiSc (version 1.4, Javier Zamora). The choices of statistical tests used are 
identical to those outlined in Chapter 2 (Page 61).  
Results 
Search results 
With the presented search strategy 2,825 citations were discovered, after duplicates were 
removed there was 1,880 unique articles. 33 studies were included in the final analysis after 
reviewing against the eligibility criteria. The PRISMA flowchart of the search results is presented in 
Figure 3-1. 
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Figure 3-1. PRISMA Flow Diagram. 
Quality assessment 
The full results of the QUADAS-2 appraisal is presented in Figure 3-2. The strengths across the 
included studies were that a majority used consecutive patient selection with appropriate 
inclusion and exclusion criteria, however, two studies [163,164] limited their investigation to 
transitional zone tumours and another [165] to patients with ‘low risk’ cancer. Therefore, a sub-
group analysis was deemed particularly important to assess the differences between peripheral 
and transitional zone tumours. Another strength was that all index tests used were applicable to 
clinical practice with no peculiar imaging methods outside of the norm. All but one study imaged 
patients after a positive biopsy while patients in Tanimoto et al. had a pre-biopsy MRI [166]. A 
number of studies did not state the timings between biopsy and MRI [139,141,167,168], which 
could have implications if the timing was long enough to cause a disparity between the images 
and histopathology correlation, or too short resulting in an increased incidence of post-biopsy 
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haemorrhage potentially affecting image interpretation. Kitajima et al. [138] and Morgan et al. 
[169] reported delays between biopsy and imaging much less than the recommended 6 weeks 
[68]. 
 
Figure 3-2. QUADAS-2 results summarising the proportion of low, high and unclear risk of bias and 
applicability concerns. 
The predominant weakness of included studies was the applicability of the patient groups 
selected by the studies, as they were often limited to those who underwent radical 
prostatectomy, who in general would be younger with a narrower range of tumour staging. This is 
acceptable to obtain a reference test with low bias.  
Study characteristics 
The data extracted for study characteristics are described in Table 3-2 – Table 3-4. There were 
2,949 patients across the 33 studies. The mean age and PSA was 65.1 (range=41-86) years and 9.0 
(range=0.4-130) ng/mL respectively. A majority of studies (n=20) used a retrospective study 
design as opposed to prospective (n=13). Most of the studies (n=19) used 3T field strength, 
thirteen used 1.5 T, and one used both 1.5 and 3T. The highest b-value used by a study ranged 
from 600 – 2000 sec/mm2. The majority of studies (n=18) used a maximum b-value of 1,000 
sec/mm2, and all studies using b-values over 1,000 used 2,000 sec/mm2. Nine studies used DWI 
images alone for diagnosis, while seven used ADC maps only, and seventeen using both. Most 
(n=20) used radical prostatectomy as reference standard. Seven used TRUS biopsy, two used MRI 
guided biopsy, and one used trans-perineal biopsy and another used a mixture of TRUS biopsy 
and radical prostatectomies. 
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Table 3-2. Principle characteristics of included studies. 
Study Year Country No. of 
patients 
Mean Age 
(range) 
Mean PSA 
(Range) 
Design 
Agha [170] 2015 Egypt 20 n/a n/a Pro 
Bains [171] 2014 Switzerland 111 64*(43-82) n/a (0.7-112.2) Pro 
Baur [172] 2016 Germany 44 66 (46-81) 12.3 (5.2-70) Pro 
Brendle [119] 2016 Germany 15 66 (52-76) 11.8 (3.3-65.4) Pro 
Costa [173] 2016 USA 49 63 (49-79) 11.2 (2.5-48.5) Pro 
Haider [140] 2007 Canada 49 61*(46-75) 5.4* (0.9-26) Pro 
Hoeks [163] 2013 Netherlands 28 n/a (45-73) n/a (1.9-44) Retro 
Isebaert [141]  2013 Belgium 75 66*(49-64) 10.4 (1.5-70.9) Pro 
Iwazawa [174] 2011 Japan 178 69 (41-86) n/a Retro 
Jung [164]  2013 South Korea 156 59*(42-75) 4.9 (0.4-93.7) Retro 
Katahira [86]  2011 Japan 201 69 (43-80) 13.2 (2.6-114) Retro 
Kim [165]  2014 South Korea 100 63* (51-76) 6.5* (2.2-9.5) Retro 
Kitajima [138]  2010 Japan 53 69* (56-84) 11.1*(4.2-112) Retro 
Kuhl [175] 2017 Germany 542 64.8 (42-80) 8.5 (3.2-67.5) Pro 
Lim [142] 2009 South Korea 52 65 (48-76) 10.5 (1.2-79.6) Retro 
Loggitsi [176] 2017 Greece 26 63.7 (48-73) 8.1 (2-21.9) Pro 
Morgan [169] 2007 United Kingdom 54 68 (52-80) 10 (n/a) Pro 
Ohgiya [85] 2012 Japan 73 70 (n/a) 11.7* (n/a) Retro 
Petrillo [167] 2014 Italy 136 66 (n/a) 6.8 (n/a) Pro 
Rosenkrantz 2011[177] 2011 USA 42 62 (47-76) 6.2 (1.3-32.5) Retro 
Rosenkrantz 2015[178] 2015 USA 106 62 (56-81) 6.9 (n/a) Retro 
Shimofusa [179] 2005 Japan 37 71 (54-82) 21.8 (4.5-130) Retro 
Shinmoto [180] 2015 Japan 87 n/a (51-75) n/a (2.8-35.2) Retro 
Stanzione [181] 2016 Italy 82 65 (n/a) 8.8 (n/a) Pro 
Tanimoto [166] 2007 Japan 83 67 (53-87) 19.4 (n/a) Pro 
Thestrup [182] 2016 Denmark 204 64.1 (45-75) 14 (2.2-120) Retro 
Ueno 2013 [83] 2013 Japan 73 67 (50-77) 9.51 (2.9-49) Retro 
Ueno 2013[168] 2013 Japan 80 67 (50-77) 9.51 (2.9-49) Retro 
Ueno 2015[139] 2015 Japan 31 65 (51-81) 8.6 (4.7-16.5) Retro 
Vargas [104] 2011 USA 51 56* (46-74) 5.3 (0.4-62.2) Retro 
Yoshimitsu [183] 2008 Japan 37 66 (56-75) 11.9 (0.7–54.8) Retro 
Yoshizako [184] 2008 Japan 23 65* (52-76) n/a Retro 
*Median, n/a - not available, PSA - Prostate specific antigen (ng/mL), Pro – prospective, Retro – retrospective 
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Table 3-3. Imaging and methodological characteristic of included studies. 
Study Field Strength ERC FOV (cm) b-value (sec/mm
2) Reference AS Method 
Agha  3T N 30x30 0, 1000 Bx U Both 
Bains  3T N n/a 0, 500, 1000 RP Y Both 
Baur  3T Both 20×20 0, 100, 500, 1000 MR N Both 
Brendle  3T N 27.6×28 50, 800 RP U Both 
Costa  3T Both 16×16 0-2000 Mix U Both 
Doo  3T N 28x28 0, 1000 RP U ADC 
Haider  1.5T Y 14x14 0, 600 RP U ADC 
Hoeks  3T Y 20.4x20.4 0, 50, 500, 800 RP U Both 
Isebaert  1.5T N 30.9x38 0,50,100,500,1000 RP U DWI 
Iwazawa  1.5T N 30x30 0, 1000 Bx U DWI 
Jung  1.5T/ 3T Y 12x12/14x14 0, 1000 RP U ADC 
Katahira  1.5T N 35x35 0,1000, 2000 RP U DWI 
Kim  3T N 34x16.8 0, 100, 1000 RP Y Both 
Kitajima  3T N 35x25 0, 1000 TP N Both 
Kuhl 3T N 21×21 0, 800, 1000, 1400 MR U Both 
Lim  1.5T Y 22x22 0, 1000 RP Y ADC 
Loggitsi 1.5T N 10×10 0, 250, 500, 750, 1000 RP U Both 
Morgan  1.5T Y 20x20 0, 300, 500, 800 Bx* Y ADC 
Ohgiya  3T N 35x35 0,500,1000,2000 Bx U DWI 
Petrillo 1.5T Y 13.6x16 0,50,100,150, 300,600, 800 Bx N Both 
Rosenkrantz 
2011  1.5T N 30x24.4 0, 500, 1000 RP U DWI 
Rosenkrantz 
2015  3T N 
20x20/ 
28x22 50,1000,2000 RP U Both 
Shimofusa  1.5T N 20x20 0, 1000 Mix U DWI 
Shinmoto  3T N 24x24 0, 1000 RP Y ADC 
Stanzione 3T N 20×20 0, 400, 2000 Bx U Both 
Tanimoto  1.5T N 36x36 0, 1000 Bx U Both 
Thestrup 3T U 19×19 0, 100, 800, 2000 Mix Y Both 
Ueno 2013 3T N 45x45 0, 1000, 2000 RP Y DWI 
Ueno 2013 3T N n/a 0, 1000, 2000 RP Y DWI 
Ueno 2015 3T N 45x36 0, 2000 RP Y DWI 
Vargas  3T Y 14x14 0, 700/ 0, 1000 RP U ADC 
Yoshimitsu  1.5T N 24x24 0, 500, 1000 RP U Both 
Yoshizako  1.5T N 42x21 0, 1000 RP Y Both 
T - tesla, ERC – endo-rectal coil, Y – Yes, N – No, FOV - field-of-view, Bx – biopsy, * trans-perineal 
biopsy, RP - radical prostatectomy, Mix - mixture of Bx and RP, AS - antispasmodic, U – unclear 
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Table 3-4. Diagnostic Performance of included studies. 
Study TP FP FN TN Sens Spec Notes 
Agha  10 1 5 4 0.67 0.80  
Bains  73 7 7 24 0.91 0.77  
Baur  14 11 0 18 0.97 0.62 Body coil 
 10 7 1 21 0.91 0.75 Endo coil 
Brendle  17 2 12 149 0.59 0.99  
Costa 20 19 06 73 0.44 0.79 Body coil 
 76 51 22 145 0.78 0.74 Endo- coil 
Doo  113 21 58 216 0.66 0.91  
Haider  120 39 29 204 0.81 0.84  
Hoeks  65 39 47 101 0.58 0.72 TZ 
Isebaert  444 79 546 731 0.45 0.90  
Iwazawa  238 223 80 883 0.75 0.80  
Jung  91 62 84 699 0.52 0.92 TZ 
Kitajima  971 559 616 2669 0.61 0.83 b=1000 
 1162 332 425 2896 0.73 0.90 b=2000 
Kim  17 7 22 72 0.44 0.91  
Kitajima  75 19 24 306 0.76 0.94  
Kuhl 138 49 9 346 0.94 0.88  
Lim  199 49 28 348 0.88 0.88  
Loggitsi  43 33 62 330 0.41 0.91  
Morgan  64 56 78 126 0.45 0.69  
Ohgiya  25 5 30 13 0.45 0.72 b=500 
 43 4 12 14 0.78 0.78 b=1000 
 42 2 13 16 0.76 0.89 b=2000 
Petrillo  18 48 7 63 0.72 0.57  
Rosenkrantz 2011  61 29 59 103 0.51 0.78  
Rosenkrantz 2015  34 13 28 561 0.55 0.98 b=1000 
 46 10 16 564 0.74 0.98 b=2000 
Shimofusa  96 11 15 56 0.86 0.84  
Shinmoto  93 12 58 185 0.62 0.94  
Stanzione  29 1 5 52 0.85 0.98  
Tanimoto  37 6 7 33 0.84 0.85  
Thestrup  65 116 3 20 0.96 0.15  
Ueno 2013 258 87 83 156 0.76 0.64 b=1000 
 276 79 65 164 0.81 0.68 b=2000 
Ueno 2013 270 119 57 194 0.83 0.62 b=1000 
 275 105 52 208 0.84 0.66 b=2000 
 272 95 55 218 0.83 0.70 b=c2000 
Ueno 2015  101 63 20 64 0.83 0.50 b=2000 
 86 51 35 76 0.71 0.60 b=c2000 
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Vargas  65 10 42 157 0.61 0.94  
Yoshimitsu  105 29 42 46 0.71 0.61  
Yoshizako 21 2 5 14 0.81 0.88 TZ 
(TP - true positive, TN - true negative, FN - false negative, FP - false positive, sens – sensitivity, spec – specificity, b - b-
value, c – computed, PZ - peripheral zone, TZ - transitional zone) 
Meta-analysis 
The visual assessment of the data extraction tables was deemed homogeneous enough to 
undertake a meta-analysis with pooling. The pooled sensitivity, specificity, positive and negative 
likelihood ratio, AUC and diagnostic odds ratio with the Inconsistency values are present in Table 
3-5, and Figure 3-3 – 3.6. The pooled sensitivity and specificity of all included studies was 0.69 
(95% CI, 0.68–0.69) and 0.84 (95% CI, 0.83–0.85), respectively. While the pooled diagnostic odds 
ratio (DOR) was 12.27 (95% CI 9.60–15.68).  The sROC (Figure 3-7) gave an AUC of 0.839, 
indicating good diagnostic accuracy [153]. 
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Table 3-5. Sub-group analysis and meta-regression. 
Group  
(number of studies) Sensitivity (95% CI) Specificity (95% CI) DOR p-value*
 
Total (n=40) 0.69 (0.68–0.69) 0.84 (0.83–0.85) 12.27 (9.60–15.68)  
b-value (sec/mm2)    0.068 
      <1,000 (n=8) 0.60 (0.56–0.64) 0.80 (0.78–0.83) 8.02 (3.18–20.26)  
      1,000 (n=26) 0.64 (0.62–0.65) 0.85 (0.84–0.85) 12.56 (9.56–16.50) 
      >1,000 (n=15) 0.78 (0.76–0.79) 0.83 (0.82–0.84) 14.32 (9.06–22.65) 
Field Strength    0.418 
      1.5T (n=18) 0.64 (0.63–0.65) 0.85 (0.84–0.86) 10.68 (7.34–15.55)  
      3T (n=18) 0.81 (0.79–0.82) 0.81 (0.79–0.82) 13.77 (9.54–19.88) 
Coil    0.462 
      Body (n=38) 0.68 (0.67–0.69) 0.85 (0.84–0.85) 13.06 (10.05–16.97)  
      Endo-rectal (n=10) 0.68 (0.65–0.69) 0.84 (0.84–0.82) 10.40 (4.87–22.24) 
Tumour zone    0.239 
      PZ (n=6) 0.71 (0.70–0.73) 0.84 (0.82–0.85) 12.64 (7.13–22.41)  
      TZ (n=11) 0.66 (0.64–0.68) 0.88 (0.87–0.88) 13.46 (8.08–22.44) 
Assessment method    0.070 
      DWI (n=21) 0.68 (0.67–0.69) 0.82 (0.81–0.83) 8.91 (6.80–11.68)  
      ADC map (n=8) 0.66 (0.64–0.69) 0.89 (0.87–0.90) 15.44 (6.80–35.05) 
      Both (n=20) 0.72 (0.70–0.75) 0.86 (0.85–0.87) 18.58 (9.77–35.30) 
Design    0.918 
      Prospective (n=16) 0.59 (0.56–0.61) 0.81 (0.80–0.83) 11.93 (6.61–21.54)  
      Retrospective (n=33) 0.71 (0.70–0.72) 0.84 (0.84–0.85) 12.56 (9.57–16.49) 
Reference standard    0.420 
      RP (n=31) 0.67 (0.66–0.68) 0.85 (0.85–0.86) 12.09 (9.24–15.81)  
      Biopsy (n=14) 0.73 (0.70–0.76) 0.81 (0.80–0.83) 15.83 (7.27–34.44) 
* Comparison between the diagnostic odd ratio of subgroups, RP – radical prostatectomy 
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Figure 3-3. Forest plot of sensitivity for detecting prostate cancer including 95% CI, I² value and Q statistic. 
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Figure 3-4. Forest plot of specificity for detecting prostate cancer including 95% CI, I² value and Q statistic. 
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Figure 3-5. Forest plot of positive likelihood ratio for detecting prostate cancer including 95% CI, I² value 
and Q statistic. 
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Figure 3-6. Forest plot of negative likelihood ratio for detecting prostate cancer including 95% CI, I² value 
and Q statistic. 
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Figure 3-7. Summary receiver operating characteristic (SROC) curve for the detection of prostate cancer. 
 
The I² value and Chi-square Q was 94.6% and 882.53 (p<0.001), respectively, for sensitivity and 
96.7% and 1446.59 (p<0.001) for specificity indicating a significant level of statistical 
heterogeneity. The ROC plane (Figure 3-8) did not show a ‘shoulder-arm’ shape and the spearman 
rank correlation coefficient of the logit of sensitivity against logit of (1-specificity) was 0.335 
(p=0.018), indicating there could be heterogeneity due to a threshold effect.  
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Figure 3-8. Sensitivity and 1-specificity plotted in Receiver Operating Characteristic curve for individual 
studies and subsets. 
Sub-group analysis 
The highest DORs were when using ADC maps alone or with DWI for tumour assessment and for 
b-values greater than 1,000 sec/mm2. There was a significantly higher sensitivity achieved when 
using b-values greater than 1,000 sec/mm2, a 3T field strength, assessing peripheral zone 
tumours, studies with a retrospective design, and those using biopsy as a reference standard (by 
assessing confidence intervals). Specificity improved significantly with a 1.5 T field strength, 
assessing transitional zone tumours, using ADC maps alone and with DWI, and those studies using 
radical prostatectomy as the reference standard. The complete sub group analysis is shown in 
Table 3-5. 
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Discussion 
The findings from this systematic review and meta-analysis demonstrate that the diagnostic 
accuracy of diffusion and T2 weighted imaging of prostate cancer is good, when using a visual 
assessment [153]. The greatest diagnostic accuracy can be achieved with b-values over 1,000 
sec/mm2 and when assessing lesions with ADC alone and with DWI images. The interplay between 
sensitivity and specificity can be significantly altered by the choice of field strength and whether 
tumours originate from the peripheral or transitional zone. The overall strength of the evidence, 
on which this analysis was based, was graded as good using the QUADAS-2 critical appraisal tool 
[122]. There was a high degree of unknown statistical heterogeneity so care should be taken 
when interpreting these results and even though the meta-analysis cannot specify an optimal 
imaging protocol it does highlight important factors to be considered. 
The pooled results match that of Wu and Tan’s diagnostic test accuracy meta-analyses of T2WI 
and DWI, this is likely to be because of the large overlap of included studies [101,185]. Compared 
to Jie et al., who analysed DWI use alone, there is a higher sensitivity but lower specificity [100]. In 
comparison to the high b-value DWI meta-analysis in the previous chapter the use of T2WI and 
DWI combined resulted in significantly greater sensitivity, but inferior specificity and AUC when 
compared to the use of high b-value alone. The results of the subgroup analysis of peripheral zone 
tumours alone are similar to the high b-value meta-analysis’ pooled results (page 75). This 
suggests that the addition of T₂-weighted imaging may improve the sensitivity for diagnosing 
transitional zone tumours, although Jie et al. did not present a subgroup for TZ tumours and it 
was not possible to extract comparative TZ data in the high b-value meta-analysis. This finding 
supports the present consensus that T2WI should be the predominant imaging technique and 
DWI a secondary sequence for diagnosing transitional zone tumours [67]. 
When comparing the visual assessment subgroup of high b-value DWI in the previous chapter’s 
meta-analysis (sensitivity – 0.58, specificity – 0.93, AUC – 0.95) with the total pooled results and 
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matching b-value subgroups (≥1000 sec/mm2) within this meta-analysis, the sensitivity is 
significantly worse when visually assessing high b-value images alone, but the specificity and AUC 
are significantly improved.  
There is a significant increase in sensitivity using a b-value greater than 1,000 sec/mm2 in both 
meta-analyses and improved specificity with a b-value of 1000 sec/mm2 and greater when visually 
assessing with T2WI and DWI. The improved contrast possible with higher b-values by further 
suppression of normal prostate tissue would explain the increase in sensitivity. By making 
tumours more visually apparent and the suppression of normal prostate signal results in greater 
reader confidence in deciding there is no tumour in a region of the prostate.  
Two of the studies [139,168] also used visual assessment of computed high b-value DWI images, 
which in both showed a decrease in sensitivity and increased specificity compared to the natural 
b-value equivalent. There has been limited research directly comparing the diagnostic accuracy of 
computed b-values but it shows promise with improved distortion, ghosting and tumour 
conspicuity [136,186]. 
A further limitation of the b>1000 subgroup is the small number of included studies. Only 6 were 
identified, three of which are by the same group [83,168,187] and in at least two of those the 
same patient cohort was used. This leaves only three studies which reduces the strength of 
evidence of the subgroup. Furthermore, all studies in this subgroups, except Kuhl’s study [175], 
used a b-values of 2,000 sec/mm2. Wang et al. and Metens et al. found greatest contrast and 
image quality using b-values of 1,500 compared to either 1,000 or 2,000 sec/mm2, however there 
is no apparent data on the diagnostic accuracy of b1,500 sec/mm2 DWI [105,107].  
As well as maximum b-value, the minimum number of b-values used to calculate ADC maps has 
shown to significantly alter ADC values, but there is little evidence about their impact on 
diagnostic accuracy with visual assessment [88,107]. All but one of the included studies in this 
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analysis used b=0 as the minimum b-value but the number of b-values ranged from two to seven. 
Thörmer et al. found an improved qualitative image score using just two b-values and a minimum 
of 50 as opposed to 0 [105], but they tested only a limited number of combinations with a 
maximum b-value of just 800. Further work directly comparing high b-value ADC maps with 
different minimum and number of intermediary b-values for visual diagnostic performance would 
help further optimise mpMRI.  
There was an insignificant difference in DOR between 1.5T and 3T studies (p=0.825), but there 
was a significantly higher sensitivity and lower specificity with 3T studies (comparison of 
confidence intervals). Higher field strengths have the advantage of increased signal-to-noise ratio 
which gives the potential for better spatial and temporal resolution. Theoretically, the higher field 
strength may increase the frequency of susceptibility artefact and signal heterogeneity, but there 
is conflicting evidence to the advantage of 3T over 1.5 T [156].  
For some of the studies it was possible to separate the results for peripheral and transition zones. 
There was a significantly higher sensitivity for the peripheral zone but higher specificity for the 
transition zone. Transition zone tumours are often of a lower grade than those found in the 
peripheral zone so may be less apparent on imaging [188,189]. There is also some difficulty in 
differentiating malignant from benign nodules common in the transitional zone, particularly with 
DWI. Benign nodules are often heterogeneous and can demonstrate restricted diffusion. 
Peripheral zone tissue is usually more homogeneous and higher signal than tumour on T2WI. This 
could explain the difference in sensitivity between the peripheral and transitional zones. One 
would expect the greater overlap between imaging features of benign and malignant transitional 
zone lesions would result in greater false positives, thus reducing specificity. In addition, the 
relative rarity of TZ tumours may explain the drop in sensitivity however the overall DOR was not 
significantly different. It may be that different imaging parameters are needed for optimal 
diagnosis of peripheral or transitional zone disease. Given the different challenges of diagnosing 
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tumours in different regions of the prostate and the different accuracy and strengths of T2WI and 
DWI, it is important when assessing the diagnostic accuracy of prostate sequences the whole 
gland and also different zone are assessed. Furthermore, when assessing the contrast ratio of 
tumours to normal tissue they should be assessed relative to the signal in the normal tissue of the 
same prostate region. 
The results showed a significant increase in both sensitivity and specificity when using ADC maps 
alone or with DWI images for diagnostic assessment, as opposed to purely DWI. There are many 
advantages to using ADC maps which might explain this change. ADC maps give a more accurate 
measure of tissue diffusion and are particularly useful in differentiating areas which have high 
signal on DWI images due to T₂ shine through and thus mimic tumour, such as post-biopsy 
haemorrhage, and therefore can improve specificity by reducing the overcalling of these lesions.  
The retrospective studies investigated men with previously confirmed prostate cancer and 
therefore the readers knew there was cancer present in each prostate. This may cause the 
readers to be more liberal with diagnosing suspicious lesions in borderline cases where there 
were no other lesions in the gland. This would help explain the significantly higher sensitivity. 
Using radical prostatectomy as the reference standard allows the assessment of individual 
tumours within the gland, facilitates assessment of more than one tumour lesion, and is a more 
accurate method of defining tumour. In comparison, TRUS biopsy is ‘blind’ and only samples a 
small area of the prostate, with a false negative rate of over 30% [190]. This would lead to 
increased false positives on imaging, decreasing the specificity as was seen in the sub-group 
analysis.  
In comparison to the previous chapter’s QUADAS 2 assessment (Page 69) the reviewers of the 
included studies changed how they interpreted the limitations of using patients who have had a 
radical prostatectomy. In the high b-value DWI meta-analysis the risk of bias was high in the 
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patient selection parameter. However, in this meta-analysis the high risk of bias shifted to high 
applicability concerns in the patient selection parameter (Page 88). 
To conduct the ideal blinded study there should be assessment of the diagnostic performance of 
an imaging sequence against a reference standard in a population with and without the disease. 
This is not possible if the reference standard involves removing the prostate as in patients who 
have a had a radical prostatectomy. Initially, it was believed that this study design limitation 
introduced a high risk of bias because according the guidelines on performing the QUADAS-2 
assessment there were “inappropriate exclusions” in patient selection. However, on further 
reflection these studies did not have inappropriate exclusions, but rather the patients “included in 
the study differ, compared to those targeted by the review question” [122] thus making the 
patient selection less applicable.  
Arguments could be made that using only patients who have had a radical prostatectomy 
undermines the applicability of the diagnostic results or introduces significant bias into the study, 
or both. It is perhaps more important to note that many studies used radical prostatectomy 
specimens and highlight the strengths and weaknesses of this. This is because it allows 
assessment of the whole gland and for multiple tumours, and it provides a means of more 
accurately comparing visual assessment of tumour radiologically and histopathologically as both 
are ‘sliced’ in or close to the axial plane. The fact that all the patients have cancer, tend to be 
younger, and have higher grade disease, could influence the reading of the MRI by the radiologists 
and give a falsely high assessment of the diagnostic performance. 
This systematic review has a few limitations. Like the previous chapter’s review the search was 
limited by a finite number of databases, however, those chosen contain a large amount of the 
relevant journals and by exploring the grey literature and hand searching references the search 
strategy was of sufficient sensitivity. Secondly the search was limited to the English language, a 
majority of articles are published in English but there may be data in another language that were 
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not include in this meta-analysis. Again publication bias was not assessed for reasons stated in the 
statistical analysis section, however the degree to which publication bias impacts diagnostic tests 
is unknown [191]. The exact T2WI parameters for the included studies were not assessed which 
could explain some of the heterogeneity seen. Reader experience is another factor which was not 
assessed as it was often poorly reported and in different formats such as years practicing, years 
reporting prostate mpMRI, or number of prostate mpMRIs. It is recognised that reader experience 
is important in interpreting mpMRI and should be considered when implementing prostate 
imaging [192,193]. Although diagnostic accuracy is important for the prostate cancer assessment 
there are other aims of mpMRI which have not been assessed in this meta-analysis. For example, 
assessment of extracapsular extension, seminal vesicle or lymph node involvement as well as its 
ability to quantify tumour size and volume. These findings are all used for proper staging of 
disease and need to be considered when deciding optimal imaging sequences. Finally, accuracy is 
but one measure of the usefulness of a diagnostic test. A test should also be consistent and 
therefore interobserver reliability assessments should be performed when studying a novel 
diagnostic technique. 
In conclusion, the advantage of this meta-analysis over the previous is the greater number of 
included studies. The primary aim of many of the included studies was to specifically assess DWI 
sequences and techniques, but also included T2WI. This is closer to typical clinical assessment for 
tumour on prostate MRI, particularly using a visual assessment for tumour. The diagnostic 
accuracy of diffusion-weighted and T₂-weighted imaging for prostate cancer detection is good. 
There is improved diagnostic accuracy using b values of 1,000 sec/mm2 and greater, but the 
results of the b>1000 subgroup should be interpreted cautiously given the small number of 
included studies. Indeed, all the pooling results should be carefully scrutinized as there was a high 
degree of statistical heterogeneity between the included studies, however, the quality of included 
studies was considered good by QUADAS-2 assessment. 
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Summary of meta-analyses and aims of FODIP study 
The literature and results of the two meta-analyses performed in Chapters 2 (Page 55) and 3 
(Page 82) suggest a role for higher b-values, particularly at 3T, a recommendation which is echoed 
in the latest PI-RADS version 2 guideline for imaging and reporting prostate MRI [67]. This 
iteration of the guidelines suggests using a maximum b-value of 1400-2000 sec/mm2 if the MRI 
technology, such as the scanner, software and manufacturer, permits a high enough SNR. The 
lowest b-value should not be 0 sec/mm2 but rather 50–200 sec/mm2 to negate the pseudo-
perfusional effects as described in the introduction.  
The results of the meta-analyses, and review of the literature and current guidelines resulted in 
the implementation of a non-zero low b-value, namely 100 sec/mm2, and the use of two high b-
values, 1000 sec/mm2 and 1500 sec/mm2, for the DWI sequences in the FODIP study. 
Small FOV techniques demonstrate promise, however, there is currently no study of the 
diagnostic accuracy and quantitative diagnostic parameters of small FOV DWI techniques with 
radical prostatectomy specimen as the reference standard. Furthermore, with the literature and 
guidelines promoting the use of high b-values, no research group has studied a DWI sequence 
which combines the use of high b-value and small FOV techniques.  
Proceeding with the FODIP study the results of the meta-analyses justified the plan for a 
prospectively designed observational diagnostic test accuracy study. Patient selection is important 
and although there is bias in using patients who have had a radical prostatectomy, the advantages 
of better radiologic-pathologic correlation outweigh these. Additionally, by using experienced 
readers (radiologists and histopathologists) blinded to clinical details the diagnostic performance 
of a novel small field-of-view DWI sequence could be assessed, whilst also comparing it to a more 
conventional larger field-of-view sequence and also the results of these meta-analyses. The 
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results also rationalise the use of b-values greater than 1000 sec/mm2, the assessment of DWI 
alone and in combination with T2WI, and the use of DWI and ADC maps in combination. 
The aim of the FODIP study is to determine the diagnostic accuracy and reliability of a small FOV 
sequence (FOCUS), performed at the b-values described above, and compare the performance to 
a conventional DWI sequence with matching b-values. 
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Chapter 4 Materials and Methods 
Summary 
This was a prospectively designed observational study of the diagnostic accuracy and reliability of 
two diffusion-weighted sequences at detecting prostate cancer. The sequences compared were a 
conventional large FOV EPI DWI sequence in which the whole pelvis is imaged and a smaller FOV 
EPI DWI sequence in which the imaging field-of-view is confined to the prostate and immediate 
adjacent tissue. Henceforth the sequences will be known as cDWI (conventional DWIc) and sDWI 
(small field-of-view DWI). The cDWI and sDWI sequences had other technical parameters 
matched, such as b-values used and slice thickness. The MRI were read by two radiologists 
blinded to clinical, biochemical and histopathological details. The accuracy was determined with 
respect to radical prostatectomy specimens, which was reviewed by two pathologists, with all 
lesions measuring 5mm or greater in maximum axial diameter assessed. 
Research questions 
1. What was the diagnostic accuracy of sDWI and cDWI sequences at detecting and locating 
prostate cancer alone and in combination with T2WI sequence?  
2. What was the inter-observer reliability of the cDWI and sDWI sequences alone and in 
combination with T2WI sequence? 
3. Did the ADC values of tumours differ between the cDWI and sDWI ADC maps? Was there 
a correlation between ADC value and Gleason Score and Gleason Grade Group? 
4. What were the quantitative characteristics of tumours on sDWI and cDWI sequences, 
namely signal-to-noise ratio (SNR), contrast ratio (CR) and contrast-to-noise ratio (CNR).  
                                                             
c The use of ‘conventional’ does not represent a specific type of DWI sequence which is available and widely 
used, but refers to a more typical EPI DWI sequence. ‘Conventional’ is used rather than ‘large FOV’ to avoid 
the emphasis on the difference between the FOV. 
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Routine clinical care of patients with prostate cancer at NNUH 
Clinical pathway 
Patients who are suspected of having prostate cancer are usually assessed with clinical 
examination, blood tests and prostate biopsy (usually TRUS biopsy). Patients who have a positive 
biopsy and are being considered for radical treatment are offered a MRI. In addition, patients who 
are considered at high risk of having prostate cancer, but have had a negative biopsy are 
recommended to have a MRI to help guide a targeted biopsy.  
In the NNUH there are 4 MRI scanners on which MRI prostate studies are performed. The 3T field 
strength MRI scanner at NNUH has the sDWI sequence. Patients can be scheduled for their 
prostate MRI scan on any of the scanners. The MRI prostate protocol for all patients being 
scanned on the 3T MRI is described below. MRI source data, including scan images, are stored on 
the NNUH NHS picture archiving and communications system (PACS), which is a secure database. 
The delay between biopsy and MRI at NNUH is recommended to be 6 weeks [68]. This is to allow 
the post-biopsy haemorrhage to settle in the gland to allow better assessment of the MRI. The 
NHS mandates a 62 day timeframe for cancer patient management from initial referral to 
treatment. Waiting 42 days in the middle of the pathway for haemorrhage within the prostate 
gland to settle would make the target difficult to achieve. A compromise, agreed between the 
radiology and urology department at NNUH, is to have a 4 week  delay between biopsy and MRI, 
which in general is adhered to. 
After issuing of the MRI report patients are discussed at the weekly uro-oncology meeting at 
NNUH. Based on the results, clinical assessment, MDT consensus, and patient wishes, some 
patients will go on to have radical prostatectomy to treat their prostate cancer.  
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The radical prostatectomy specimens of all patients are analysed with a technique known as 
whole mount step section. Prostates can either be completely or partially sampled after 
prostatectomy. Whole mount section is a recognised method of complete prostate sampling 
[127]. After surgery the prostate is stored overnight in formaldehyde. The seminal vesicles are 
removed and the prostate sliced from base to apex in the axial plane, with the apical slice then 
sliced in a longitudinal manner to assess for tumour in the extreme apex. The sections are stained 
with haematoxylin and eosin and analysed for presence and location of tumour, Gleason score, 
extracapsular extension and seminal vesicle invasion. 
Routine clinical MRI Protocol 
MRI prostate studies performed on a 3T MRI (Discovery MR750w wide bore, GE Healthcare 
Systems, Milwaukee, Wisconsin) at NNUH adhere to the following protocol, which was 
implemented on 1st September 2015.  
• Standard anatomical sequences include axial T1WI and T2WI of the whole pelvis; coronal 
T2WI fat-saturated sequence of the pelvis; high resolution axial, sagittal and coronal T2WI 
sequences of the prostate and seminal vesicles.  
• Axial DWI sequences include cDWI of the whole pelvis, and sDWI (known as FOCUS by 
manufacturer) sequence of the prostate and seminal vesicles. 
• A quadrature body coil for transmission and a 36-channel phased-array receiver coil. No 
endorectal coil is used. 
The order of sequences described above is the order the sequences are performed. 20mg of 
intramuscular hyoscine butylbromide (Buscopan, Boehringer Ingelheim Ltd., Bracknell, United 
Kingdom) is administered following the coronal T2WI fat-saturated sequence. 
Total scan time is approximately 40 minutes.  
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Study procedure 
Recruitment policy 
Recruitment continued until 40 eligible patients completed the study. 
Inclusion criteria 
• Males 
• Aged 18 and over 
• Biopsy proven prostate cancer. 
• No contraindication to MRI scanning. 
• Smokers and non-smokers 
• Patients who had a complete scan on the 3T scan MRI at NNUH and then went on to have 
a radical prostatectomy at the NNUH. 
Exclusion criteria 
• Those regularly taking 5-alpha reductase inhibitors or testosterone replacement 
medicines. 
• Those with significant artefact from surgically implanted metalwork. 
• Those who have had pelvic radiotherapy. 
• Those with a delay of less than 21 days between biopsy and MRI. 
Identification of patients 
There was a retrospective review of patients who have had a MRI at 3T at NNUH from 1st 
September 2015 on Soliton, the Radiology Information System. 
There was a retrospective review of patients who had a radical prostatectomy at NNUH from 1st 
September 2015 using the trust theatre booking system Orsos.  
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Patients who had a MRI prostate examination at 3T and had a radical prostatectomy will be 
considered for the study. Following this there was a review of patient clinic notes and previous 
imaging to determine if they met the other eligibility requirements. 
Patient characteristics 
The patient characteristics data collected included name, patient number, date of birth, age at 
MRI, date of MRI, sequences performed, missing sequences, indication for MRI, PSA result (prior 
to biopsy if possible), biopsy performed, date of biopsy, biopsy type, biopsy positive, time from 
biopsy to MRI, Gleason score from biopsy, side of gland with tumour, date of radical 
prostatectomy, and time from MRI to radical prostatectomy. 
MRI imaging parameters 
Once the required number of eligible patients was reached the MRI data was collected and 
analysed. There was no interference with the routine clinical pathway of the patients eligible for 
the study. 
The sequences relevant to the study of eligible patients’ MRI studies were placed in a unique 
anonymised folder on the local PACS system, a secure database, with only each patients’ unique 
study number displayed (described in the section ‘Patient Confidentiality’). No other identifiable 
information was displayed. This was important ethically as the radiologists who read the MRI for 
the study were not necessarily part of the clinical team involved in the patients’ care when the 
studies were initially read prior to the MDT and therefore would not be allowed access to their 
images and personal data. In addition, if the radiologist was involved in the initial read of the MRI 
as part of patients’ routine clinical care, anonymising patient data and using a study number 
reduced the risk of recall bias.  
The parameters of the sequences relevant to the study are displaced in Table 4-1.  
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Table 4-1. Imaging parameters of sequences relevant to the FODIP study. 
Parameter 
Sequence 
T1WI HiRes T2 PROPELLAR (T2WI) 
Conventional 
DWI (cDWI) 
FOCUS DWI 
(sDWI) 
TR (ms) 450 9307.14 7000 4000 
TE (ms) 12.86 107.07 77 81 
Bandwidth (Hz) 31.25 83.3 250 250 
Echo-train length 3 26 N/A N/A 
Matrix size  320P/512F 320/320 80/92 160/80 
FOV (cm) 34 x 40.7 (38cm) 24 x 28.7 (24cm) 34x40.7 (34cm) 26 x 13 (13cm) 
No. of acquisitions 1 2 1,2,3 (per  b-value) 
8,12,16 (per  
b-value) 
Slice thickness (mm) 6 3.60 3.60 3.60 
Interslice gap (mm) 2 0 0 0 
Parallel imaging 
factor (ARC) 1.77 2 2 N/A 
b-value (sec/mm2) N/A N/A 100, 1000, 1500 100, 1000, 1500 
ADC maps N/A N/A 
1500, 1000, 100 
(confidence level 
0.4) 
1500, 1000, 100 
(confidence level 
0.4) 
Duration (min.sec) 4.00 5.30 6.30 8.00 
TE – Echo time, TR – Time of repetition 
 
MRI assessment 
Two radiologists, Dr Tristan Barrett (Rad1/Reader 1) and Dr Paul Malcolm (Rad2/Reader 2), 
assessed the MRI studies. Both are experienced uro-radiologists with 7 and 15 years of experience 
reading prostate MRI, respectively. The reads of the MRI were performed independently. They 
were blinded to clinical and biochemical information, and MRI and pathology findings. They were 
aware that the patients had prostate cancer and were treated with a radical prostatectomy.  
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Only the relevant sequences for each imaging protocol were available to the reader. The only 
patient identifier was a unique patient code. Each patient had a different unique code displayed 
on each of the MRI assessments. This code only had meaning to KG and not the readers.  
There were 4 different imaging protocols: 
Protocol A T1WI, cDWI (inc. ADC map) 
Protocol B T1WI, T2WI, cDWI (inc. ADC map) 
Protocol C T1WI, sDWI (inc. ADC map) 
Protocol D T1WI, T2WI, sDWI (inc. ADC map) 
 
For protocols A and B the cases were read in chronological order of date of radical prostatectomy. 
For the second read (protocols C and D) the cases were randomised using an online randomiser 
[194], therefore the cDWI and sDWI cases were read in a different order. By randomising the 
order the risk of recall and learning bias during the second read was reduced. Protocols B and D 
were read at the same sitting as A and C, respectively, on a case by case basis rather than after 
reading all 40 cases. For example, after reading case 32A the reader assessed 32B before moving 
to 33A.  
For each protocol read the T1WI sequences were available to assess for post-biopsy 
haemorrhage. Haemorrhage was defined as an area of high signal on the T1WI sequence. 
Presence and location of haemorrhage was documented on the reporting template. Figure 4-1 
illustrates the high signal caused by haemorrhage, usually following TRUS biopsy, within the 
peripheral zone.  
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Figure 4-1. T1 weighted image of the prostate demonstrating post-biopsy haemorrhage in the peripheral 
zone bilaterally (red arrows). 
There was a delay of at least 2 weeks between the read of the cDWI protocols (A and B) and the 
sDWI protocols (C and D) to reduce recall bias. The MRI and histopathology assessment timeline is 
summarised in Figure 4-2.  
 
Figure 4-2. Histopathology and imaging assessment timeline. 
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On T2WI sequences tumours have different appearances depending on whether they are located 
in the peripheral or transitional zone (PZ and TZ) [67]. Within the TZ a homogenous low signal 
mass which destroys normal structures or benign pathology such as hyperplastic nodules in 
benign prostatic hyperplasia, is considered definitely malignant. Within the PZ, lesions which exert 
mass effect, are homogenously low signal, and are irregular in shape with ill-defined borders, are 
considered definitely malignant. An example of prostate cancer in the PZ and TZ on T2WI is 
displayed in Figure 4-3.  
 
Figure 4-3. Example of malignant lesions on T2WI axial images. a) A focus of Gleason Score 3+4=7 
prostate cancer in the left peripheral zone at 5 o'clock. b) A focus of Gleason Score 4+3=7 prostate cancer 
in the transitional zone anteriorly (red arrow). 
On DWI, a lesion demonstrating high signal on the b-value imaging with corresponding low signal 
on the ADC map is considered malignant. An example of prostate cancer on the different DWI 
images and ADC maps is demonstrated in Figure 4-4.  
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Figure 4-4. Example of the same left peripheral zone prostate tumour on different DWI sequences and 
their respective ADC maps. On the DWI images the tumour appears as high signal relative to surrounding 
non-tumour tissue and on ADC maps the tumour is lower signal than non-tumour tissue. The same 
Gleason Score 4+3=7 tumour is demonstrated on a) b1500 cDWI. b)ADC map cDWI. c) b1500 sDWI. d) ADC 
map sDWI. 
Radiologist assessment 
The lesion and sectoral-based accuracy, as described in the introduction to chapter 2 (page 56), 
were assessed for both readers and all protocols.  
The radiologists documented the location of each tumour in terms of right or left hemi-gland; the 
base, mid-gland or apex; and the TZ and PZ. The maximum axial diameter and the width 
perpendicular to the maximum axial diameter on the same image slice were documented. Finally, 
the top and bottom slice the tumour was seen on was noted. A Likert score for the lesion was also 
documented as well as the presence of extension beyond the capsule or seminal vesicle invasion. 
The lesion was also drawn on the prostate reporting diagram Figure 4-5 taking care to 
demonstrate the sectors the lesion involves.  
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The lesions identified by the radiologists were assessed by a ‘stringent’ and ‘clinical’ approach. A 
‘stringent’ assessment required the reader to correctly identify the tumour in the exact location it 
was identified on histopathology. A ‘clinical’ approach considered a lesion to be a true positive if it 
was in a neighbouring sector as long as the correct hemi-gland was selected. The ‘clinical’ 
approach allowed for some leeway, as although a radiologist could have correctly identified the 
tumour the histopathologists determined the tumour to be in a different location, possibly due to 
the limitations in the correlation of MRI and histopathology. Therefore, following this approach 
the localisation of the tumour by the reader was assessed as being ‘close enough’ thus putting 
more emphasis on the detection of the tumour rather than localisation. 
The sectoral accuracy was determined by assessing the tumour reporting diagram (Figure 4-5). A 
12 sector reporting diagram was used with the gland divided into left and right; apex, mid-gland 
and base; and peripheral and transitional zones. For each sector, each reader provided a score of 
1-5 depending on the likelihood of tumour in this region. The Likert scores used in the lesion and 
sectoral assessment were as follows:  
1 - definitely absent  
2 - probably absent 
3 - indeterminate  
4 - probably present  
5 - definitely present 
The reporting instructions for the radiologists are in Appendix 2 (Page 262). 
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Figure 4-5. Prostate reporting diagram divided into 12 sections. 
Radiologist reporting template 
The reporting template is displayed in Figure 4-6. An example of a completed radiologist reporting 
template is demonstrated in Figure 4-7. The completed template is by Rad2 (PNM) demonstrating 
a lesion in the anterior gland which was interpreted to be highly suspicious for prostate cancer. 
The reader thought the tumour extended from apex to base and resided in both sides of the gland 
and in the peripheral and transitional zones. Each of the 12 sectors was scored a 5, as denoted by 
the Likert score column. The striped area indicates there is haemorrhage throughout the right 
peripheral zone.  
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Figure 4-6. Radiology reporting template. 
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Figure 4-7. Completed radiologist template for case 16. 
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Histopathology analysis 
As mentioned above (in the ‘Standard clinical care’ section) all patients who have undergone 
radical prostatectomy had their prostatectomy specimens evaluated with a technique known as 
whole mount step section.  
The radical prostatectomy specimens of eligible patients were re-assessed for this study. Two 
histopathologists (HP1 and HP2) performed this independently. HP1 is an experienced consultant 
uropathologist with 20 years experience, and HP2 is a senior histopathology trainee with a 
particular interest in uropathology. The histopathologists were blinded to the clinical, 
biochemistry and MRI findings. It was not possible to blind the histopathologists to patient name, 
unique hospital number and date of birth. These details are written on sample pots and slides 
making blinding of this information difficult to achieve. Furthermore, blinding could introduce a 
significant risk of error in sample identification and mis-sampling.  
As for the routine clinical histopathology assessment the Gleason score, presence of extracapsular 
extension and seminal vesicle invasion of each lesion were assessed, however, lesions less than 
5mm in maximum axial diameter were excluded. The location of the tumour with reference to the 
12 sectors was documented. 
The histopathology assessment will be reported on a histopathology reporting template (Figure 
4-8) with the patients’ unique study number as the only identifying patient detail. The similarity of 
the radiology and histopathology template will facilitate correlation of the two reports.  
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Figure 4-8. Histopathologist reporting template. 
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No extra tests (stains, genotyping etc) were performed on the specimen and did not prevent 
further clinical examination of the tissue in the future. 
The definitions of the dimensions were: the length was the maximum dimension of the tumour on 
the prostate slide where the tumour was visually the longest; the width was measured 
perpendicular to the length on the same slide; and the height was the estimated height of the 
prostate based on the number of slides the tumour was visualized on considering the estimated 
distance between slides. The estimated slice thickness was calculated by dividing the height of the 
prostate by the number of slices. The height of the gland is documented as part of the initial 
assessment of the prostate following prostatectomy within standard NHS care. The reporting 
instructions for the histopathologists can be found in Appendix 2 (page 268).  
An example of a histopathological assessment of a prostatectomy specimen with a completed 
histopathology template (Figure 4-9) and the photograph of the pathology specimens with the 
tumours outlined (Figure 4-10).
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Figure 4-9. Completed histopathologist template for case 3.
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Figure 4-10. Case 3 histopathology slides. 
Figure 4-9 and Figure 4-10 demonstrate the histopathology assessment and results for their 
analysis of case 3 radical prostatectomy specimen. There were six slices and three eligible 
tumours. Lesion 1, denoted with the T1 label (highlighted by the red “Tumour 1” marker and 
arrow), resides in the left peripheral zone at 5 o’clock and is present in apex, mid-gland and base. 
Lesions 2 and 3 (labelled by the histopathologists as T1WI and T2WI) reside in the right peripheral 
zone. This example case also highlights the potential for mis-registration as on the 4th slice (top 
right in Figure 4-10) the right (R) and left (L) labels were drawn incorrectly (highlighted by the red 
“Mis-registration” marker and arrow). Following discussion between KG and HP2 it was decided 
that the left and right were labelled incorrectly. 
Once the samples have been analysed they were returned to storage, as they would have done 
following the initial routine clinical assessment following prostatectomy. 
 
  
  Materials and Methods 
 
128 
Correlation of MRI and Histopathology 
1. Initial review of pathology results against images 
After the histopathology templates were completed KG reviewed the sectoral maps, drawings of 
tumours and tumour parameters outlined in the histopathology reported template of all cases, 
and compared these against the MRI images. This initial step prior to determining accuracy aimed 
to, firstly, assess any cases with multiple tumours and determine on imaging whether multiple 
tumours could all be part of one tumour. The advantage of the DWI and T2WI sequences was the 
absence of gaps between the images (3.6mm slice thickness and no gap) ensuring the entire 
prostate had been imaged. On the other hand, the pathology assessment is of a micrometre thin 
slice every 4 to 6mm, making the potential for a tumour to extend or stop between slices a 
possibility. Therefore, a case in which there were thought to have been multiple lesions on 
histopathology may actually have been a single lesion as they ‘joined up’ on imaging. Secondly, all 
lesions will be assessed to determine whether they meet eligibility requirements, most 
importantly if they meet size criteria. 
2. Histopathology and radiology consensus of contentious cases and missed 
lesions. 
Thereafter, KG and HP2, in consensus, assessed those contentious cases outlined in the step 
above with the images, pathology slides, and histopathology templates available. If a multifocal 
tumour is decided to represent one lesion then the pathologists amended the tumour dimensions 
and prostate map appropriately to reflect this. 
Another important function of the review of images and histopathology results was to decide the 
location of tumours on imaging that were present on pathology and eligible for inclusion but 
cannot be identified on cDWI and/or sDWI. It was important to perform the qualitative and 
quantitative analysis of all lesions, including the misses, to attempt to determine why these 
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lesions were not seen. Reasons for radiologist missing lesions might include the presence of 
haemorrhage, a small tumour and a low Gleason grade. The histopathology data was then 
entered into a spreadsheet to be analysed. 
3. Sectoral accuracy of MRI interpretation 
From the histopathology tumour maps it was be possible to determine which of the sectors of 
prostate had tumour present. Each sector was given a binary code to represent whether tumour 
was present or not.  
This was then compared (by KG) against each radiologists Likert score for each sector for each of 
the four protocols. From this the 2 x 2 contingency table could be completed for different Likert 
score cut-offs. The definitions of each component of the 2 x 2 contingency table for each sector 
were as follows. 
True positive (TP) Radiologist score was higher than the Likert cut-off and the pathologists deemed tumour was present 
True negative (TN) Radiologist score was less than the cut-off and the pathologists deemed tumour was absent 
False positive (FP) Radiologist score was higher than the cut-off and the pathologists deemed tumour was absent 
False negative (FN) Radiologist score was lower than the cut-off and the pathologist deemed tumour was present 
 
From this the sensitivity, specificity, and positive and negative predictive values were calculated 
using the following formulae. Additionally, the receiver operating characteristic curves (ROC) were 
created and the area under the curve (AUC) calculated.  
!"#$%&%'%&( = TP/(TP + FN) !2"3%4%3%&( = TN/(TN + FP) 56$%&%'"	28"9%3&%'"	':;<" = TP/(TP + FP) =">:&%'"	28"9%3&%'"	':;<" = TN/(TN + FN) 
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4. Lesion accuracy of MRI interpretation 
The lesion accuracy analysis of the histopathology and radiology reports was performed by KG. 
From assessment of the histopathology tumour maps and the radiology tumour maps it was 
possible to determine three components of the 2 x 2 contingency table: true positive, false 
positive, and false negative. Following assessment of the diagnostic accuracy results of the 
sectoral analysis by KG a Likert cut-off of 3 and above for a tumour was considered to represent a 
possible tumour and those with a score of 2 or less disregarded. A justification for this cut-off is 
discussed in Chapter 6 (page 194). A ‘stringent’ and ‘clinical’ lesion accuracy analysis was 
performed.  
A true positive lesion for the ‘stringent’ approach was a radiologist determined lesion with a Likert 
score of 3 or above which was present in the same sector as a lesion on the pathology tumour 
map. In addition, the lesion visually must overlap on the radiologist and pathologist prostate map 
and this is at the discretion of KG. This prevented tumours at different extremes of a sector being 
considered a true positive, for example a 7 o’clock PZ lesion on the radiological map and a 11 
o’clock PZ lesion on the pathological map being considered a correctly identified tumour rather 
than a false positive lesion.  
The ‘clinical’ approach allowed tumours which overlap in appearance, but are up to one sector 
out in height or PZ or TZ, but confined to the correct hemi-gland to be considered a true positive.  
A false negative for both approaches is a tumour seen on the pathology map but not seen by the 
radiologist.  
A false positive is a tumour described by a radiologist but not seen by a pathologist.  
Using the results the sensitivity and positive predictive values of each radiologist for each protocol 
was calculated using the equations demonstrated above.   
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5. Lesion accuracy of index lesions 
The index lesion was defined as per the ISUP guidelines [43] based on the following priority: 
presence of extension beyond the prostate, then tumour grade, then tumour volume. For each 
radiologist and on each protocol whether the index lesion was correctly identified (true positive) 
was determined by KG using the ‘stringent’ and ‘clinical’ definition outlined above. 
6. Quantititative analysis: Contrast-to-noise ratio , Contrast ratio and Signal-to-noise 
ratio 
The anonymised cases were transferred to a PACS known as Horos (version 1.1.7). This PACS 
software allowed a closed polygonal shape to be drawn over any part of the image and also any 
slice. The closed polygonal shape is referred to as a Region-of-Interest (ROI). It also allowed 
splitting of the DWI images into their unique b-values, namely b100, b1000 and b1500. These 
individual b-value images, ADC maps, and T2WI and T1WI images are linked anatomically so 
scrolling on one set of images results in scrolling through the images of the others automatically. 
ROIs drawn on one image can be copied to the exact location on all other sequences. In some 
instances, there were some mis-registration between sequences resulting in the copied ROI not 
residing in the exact anatomical location as the initial ROI. When this occurred a judgement was 
made by KG whether they matched and moved to a more accurate position if required. 
Horos PACS ROI provided multiple data parameters including the mean, maximum, minimum and 
standard deviation of the signal intensity within the ROI. The mean signal intensity on the ADC 
map correlates to the mean ADC of the ROI. In addition, the surface area of the ROI is provided. 
The signal intensity is denoted by the symbol µ. The images of every ROI for all cases were saved. 
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Figure 4-11 demonstrates case 19 lesion 1 on sDWI images and T2WI and T1WI axial sequences. 
Following assessment of the histopathology tumour map a ROI was drawn around, but not 
outside, the margin of the tumour taking care not to extend into non-tumour tissue. The ROI was 
initially drawn on b1500 image as this was the sequence that the tumour was most conspicuous 
and the ROIs were copied to all other b-value images and the ADC map. Data from each ROI 
provided by the imaging software was collected. Haemorrhage was present in the peripheral zone 
as indicated by the high signal on the T1WI sequence (bottom right image), but was not present at 
the location of tumour. 
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Figure 4-11. Left transitional zone prostate cancer with ROI drawn around the lesion on all three b-value images and ADC map. The corresponding T2WI (top right) and 
T1WI weighted slice are also demonstrated. 
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ROIs were drawn in an area of normal prostate peripheral zone and normal prostate transitional 
zone. The location of the normal tissue was decided by KG after scrutinizing the histopathology 
tumour maps and imaging sequences taking care to avoid areas of haemorrhage noted on the 
T1WI sequence as high signal. 
Tumours were identified by KG by consulting the histopathology tumour maps and visualising the 
images. After reviewing the T1WI, if a tumour was present within an area of haemorrhage this 
was recorded. When a histopathologically confirmed tumour was visualised on MRI a ROI was 
drawn around the lesion as seen on the MRI sequence, as opposed to the boundaries defined by 
the histopathology tumour maps and slides. The first sequence the ROIs were drawn was the 
sequence the tumour was most conspicuous to KG. The ROI was then copied to other sequences. 
For tumours which were not identified on MRI by KG the histopathology map and pathology slides 
were consulted to best estimate the location. Using local landmarks, such as the urethra, prostate 
capsule, verumontanum, cysts, calcification and hyperplastic nodules, the ROIs could be more 
accurately sited [98].  
Noise within an image is defined as the standard deviation of the signal within a homogeneous 
tissue within an image. Many studies estimating noise on prostate MRI are calculated by drawing 
an ROI within bone [87] or air outside the body [88]. The reduced field-of-view in the sDWI 
sequence can result in air outwith the patient almost always not visible. Another homogenous 
tissue in the region is muscle and the closest and most reliably imaged is obturator internus [195]. 
A ROI was drawn on either the left or right obturator internus.
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Figure 4-12. sDWI, T2WI and T1WI sequences of case 7. ROI drawn on normal peripheral and transitional zones, and on the left obturator internus muscle. 
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Figure 4-12 demonstrates ROIs which were drawn on normal peripheral and transitional zones 
and obturator internus muscle. After consultation of the histopathology tumour map to 
determine where tumour was not present and assessment of the T1WI sequence to ensure there 
was no haemorrhage, a peripheral and transitional zone target was identified. The delineation 
between the PZ and TZ was best appreciated on T2WI and therefore ROIs were copied from the 
T2WI sequence to ensure they do not extend into the adjacent zone. Once correctly sited they 
were copied from once sequence to the next and data documented. The obturator internus ROI 
would initially be drawn on the T2WI sequence and then copied across.  
Occasionally, as on the tumour ROI drawing process described above, there was image distortion 
between sequences resulting in a ROI drawn on T2WI being copied to a different anatomical 
location on the other sequences. On these occasions the ROI was moved, preserving the shape to 
a more suitable and accurate location. More frequently peripheral and transitional zone, and 
obturator internus ROI’s were drawn on different slices rather than on the same slice as in the 
Figure 4-12. 
Whether the ROI is being drawn on normal tissue, tumour tissue or muscle, the surface area of 
the ROI was made as large as possible without extending beyond the boundaries of the intended 
tissue. 
With the signal intensities and noise calculations from the ROI’s the signal-to-noise ratio (SNR), 
contrast ratio (CR) and contrast-to-noise (CNR) were calculated for each tumour by using the 
equations below. The CNR and CR of tumours was calculated by comparing the contrast between 
tumour and normal tissue within the zone the tumour predominately resided within. CR is 
another measure of tumour contrast which does not account for the effect of the noise and is 
used widely in prostate DWI studies [89,139]. The SNR, CNR and CR were calculated for b1000, 
b1500 and ADC map images using the following equations. 
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!"# = 	 &	'()*(+	,-./01,'0/20+2	234-0'-*/	*5	/*-,3 
6"#(89) =	 &(89)	'()*(+	,-./01	– 	&(89)	'-,,(3	,-./01,'0/20+2	234-0'-*/	*5	/*-,3  
6"#(<9) = 	&(<9)	'()*(+	,-./01	– 	&(<9)	'-,,(3	,-./01,'0/20+2	234-0'-*/	*5	/*-,3  
6#(89) = 	 &(89)	'()*(+	,-./01	– 	&(89)	'-,,(3	,-./01&(89)'()*(+	,-./01 + 	&(89)	'-,,(3	,-./01 
6#(<9) = 	 &(<9)	'()*(+	,-./01	– 	&(<9)	'-,,(3	,-./01&(<9)'()*(+	,-./01 + 	&(<9)	'-,,(3	,-./01 
5. Quantitative analysis – ADC values of tumour 
As mentioned previously the mean signal intensity within a ROI on the ADC map also represents 
the mean ADC of the ROI in mm2/sec. As above, the SNR, CNR and CR of lesions will be calculated 
for the ADC map to provide a measure of lesion conspicuity on the ADC map. The mean and 
minimum ADC value of tumours and normal tissue were recorded. Most studies investigating ADC 
values of prostate cancer use the mean ADC to compare different DWI techniques and measure 
correlation with Gleason Grade. More recently the minimum ADC value within a ROI has been 
proven to also have a correlation with Gleason Grade [119,196].  
In addition, the mean and minimum ADC values of tumour and normal tissue can be used to 
create a ROC curve. As in many of the studies included in the high b-value meta-analysis (Chapter 
2), ADC values can be used to create a ROC curve and determine the AUC and ideal ADC value cut-
off for determining tumour from normal prostate. 
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Statistical Analysis 
Sample size calculation 
Using the ADC of tumour of b-0,1000 and b-0,2000 sec/mm2 ADC maps in Koo’s study [91] 
analysing DWI in prostate cancer with radical prostatectomy specimens as reference standard at 
3T, a calculation was performed to provide a sample representative of the population. Based on a 
power of 0.90, a significance criterion of 0.05, and a total confidence interval for the mean ADC of 
0.1, using the equation outlined by Eng [197], this produced as sample size of n=35. Thirty five 
patients was rounded up to forty (n=40). 
Data analysis 
1. Diagnostic performance of small FOV DWI and conventional DWI 
The sensitivity, specificity, accuracy, and positive and negative predictive values of each readers 
assessment of protocols A-D were calculated. 
Receiver operating characteristics (ROC) curves were created for each protocol and AUC will be 
assessed for each radiologist and protocol. 
A comparison of the equivalent cDWI and sDWI protocol for each reader was performed using the 
McNemar test for sensitivity and specificity with Bonferroni correction applied for multiple 
comparisons, and by the Z-test of proportions for positive and negative predictive values. The 
comparison of the AUC between cDWI and sDWI was performed using DeLong’s test.  
2. Comparison of tumour ADC values on different b-values in the same DWI sequence and 
between sDWI and cDWI datasets. 
A Wilcoxon signed rank and paired t-test were used to compare the ADC values of different b-
values and between different DWI sequences. ADC differences was assessed for all tumours, 
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visible and non-visible lesion subgroups, and lesions within and free of haemorrhage subgroups, 
and this was performed using a Mann-Whitney U test. 
3. Compare the SNR, CR and CNR of tumours on different b-values in the same sequence 
and between sDWI and cDWI datasets.  
A Wilcoxon signed rank and a paired t-test were used to compare the SNR, CR and CNR of 
tumours of different b-values and between the DWI sequences. 
4. Comparison of tumour ADC and non-tumour tissue ADC. 
A Wilcoxon signed-rank and paired t-test were used to compare ADC and signal intensity on 
b1000 and b1500 sequences of malignant lesions and non tumour tissue. 
5. Accuracy of ADC measurement 
Receiver operating characteristic curves were created to determine the AUC and optimal ADC cut-
off value between tumour and non-tumour tissue.  
6. Correlation between tumour ADC and their Gleason score 
The mean and minimum tumour ADC value on cDWI and sDWI was correlated with the Gleason 
score of the tumour using Spearman Rank Correlation Coefficient test. 
7. Inter-observer MRI assessment agreement 
Inter-observer agreement of the Likert scores of the sectors between the two radiologists was 
performed using a weighted kappa statistic. Inter-observer reliability for the peripheral and 
transitional zones was determined.  
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Reliability statistics, McNemar, Z-test of proportions and DeLong’s test will be done on R statistics 
(Rstudio version 1.0.143, psych and pROC packages [198]). All other statistics will be performed 
using SPSS version 23. A p-value of less than 0.05 is considered significant. 
Patient Confidentiality  
Patient data was collected and stored in a password protected file held in the NNUH IT system, a 
secure system. It was only made accessible to KG and TSy. 
MRI images were stored on the NNUH PACS under the patient name. It was transferred to the 
BioImaging server sited in the Department of Nuclear Medicine, NNUH. These were accessed from 
the Image Analysis Laboratory in the NNUH where they were fully anonymised by stripping out all 
patient identifiable data from the DICOM file header and replacing these data with unique study 
identifiers. This was conducted by KG. The radiologists reviewing the sequences were blinded to 
patient identifiers. 
Histopathology and radiology reporting forms were kept in a locked cabinet in the radiology 
department at NNUH and digital copies in a password protected directory in the Trusts IT system. 
Ethical Considerations 
Consent 
Following consultation with Dr Ray Lonsdale, consultant pathologist with a specialist interest in 
ethics, regarding consent, it was decided written consent was not required for this study. This was 
for the following reasons 
• The routine clinical care of the patient was not altered or interfered with. Although 
prospectively designed, the analysis of patients’ images and pathological specimens 
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occurred after they had been diagnosed and treated, and exited the prostate cancer 
clinical pathway.  
• Individuals did not undergo any further investigation or suffer any inconvenience as a 
result of their imaging study being used.  
• The review of the prostatectomy specimens was not to perform further tests on the 
specimen. The same information as for the routine clinical assessment was acquired. 
Instead of a descriptive report (as in routine clinical care) the histopathologists’ 
assessment was reported on a reporting template. 
• Any data stored or published was and will be fully anonymised and only accessible by the 
investigators.  
• Data stored will remain on a secure computer without any patient identifiers. 
Human Tissue Act 
Although, the additional histopathology assessment could not be completely anonymised during 
the assessment of prostatectomy specimens by the histopathologists it was important to ensure 
the study complied with the Human Tissue Act 2004 [199]. Advice was sought from Dr Ray 
Lonsdale, histopathologist, to decide whether the study complied with the act, particularly with 
the below statement 
“the researcher is not in possession, and not likely to come into possession of information that 
identifies the person from whom it has come; and where the material is used for a specific 
research project approved by a recognised research ethics committee.” 
As the histopathologists were part of the direct care team for these patients and their reports of 
their assessment of the prostatectomy specimens was documented on reporting proforma 
without any patient identifiable data, the study complied with the Human Tissue Act. 
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Timeline and correspondence 
The study was submitted via the Integrated Research Application System (IRAS) on 21/12/2015. 
The study was submitted under the name Focused Diffusion-Weighted-Imaging in Prostate Cancer 
under the acronym FODIP.  
The IRAS number was 182283. The study was also accepted onto the NIHR clinical portfolio and 
was given a CPMS ID: 30968. 
18th January 2016 - Favourable opinion of proportionate review at Research and Ethics Committee 
subject to conditions (Appendix 3, page 271) 
The committee asked the research team to clarify why it was not possible to blind histopathology 
to patient identifiers. It was explained that it was possible to blind the histopathologists by using a 
further researcher to obscure the patient identifiers on each pathology specimen slide, however, 
this posed a greater risk to the patient namely from the potential to mix slides from different 
patients. The risk of the pathologists seeing the patient name and hospital number was deemed 
low, particularly as the histopathologists were part of the direct clinical team. 
22nd January 2016 – Favourable opinion of proportionate review at Research and Ethics 
Committee (Appendix 3, page 275) 
13th May 2016 – Notification of non-substantial amendment sent to Health Research Authority 
This was to facilitate the transfer of the completely anonymised study images via Image Exchange 
Portal to Addenbrooke’s Hospital secure PACS system to facilitate the reading of the MRI by Rad1. 
The approval was granted on (Appendix 3, page 277). 
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Risk to patients 
The study team identified level of risks for the study as follows: 
        Risk to Severity Frequency 
Patients 
Mild discomfort (MRI) Rare 
Severe adverse event (MRI) Rare 
Study Low 
Trust Low 
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Chapter 5 Results 
Patient descriptive statistics 
40 patients were included in the study with a mean age of 64 years, a median of 65 years and a 
range of 42 to 72 years. The distribution of ages of patients is demonstrated in Figure 5-1 and 
Shapiro-Wilk test of normality indicated this was not a normal distribution (p=0.003). All 
continuous data within this chapter was tested for normality using the Shapiro-Wilk test and by 
assessing the histogram. If a normal distribution was observed on the histogram and the p-value 
of the Shapiro-Wilk was greater than 0.05 then the mean and standard deviation (SD) are 
described. If the data was not normally distributed (non-bell shaped curve and p = <0.05) the 
median and interquartile ranges (IQR) are described. 
 
Figure 5-1. Distribution of ages of included patients.  
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The median duration of biopsy to MRI was 31 days (IQR, 27–39) and the range was -90 days to 
406 days (Figure 5-2). Five subjects had their MRI before biopsy, which accounts for the negative 
numbers, and the remainder had their biopsy after MRI. The subject who waited 406 days for MRI 
after biopsy had low volume prostate cancer on biopsy and had had a MRI prior to the biopsy, but 
due to rise in PSA they had a repeat MRI and went on to have a radical prostatectomy. 
 
Figure 5-2. Histogram of time from biopsy to MRI. 
The median PSA level before biopsy was 8.6 ng/ml (IQR, 6.6–13.4) and the range 4.6 to 34.2 
ng/ml. Thirty patients had a TRUS biopsy, nine patients had a Trans-Perineal biopsy and one 
patient had tumour identified in the pathological specimen obtained at Trans-Urethral Resection 
of the Prostate. Three subjects had a Gleason Score of 3+3 on biopsy, 25 with 3+4, one with 3+5, 
nine with 4+3, and two with 4+5 disease. Figure 5-3 demonstrates the distribution of Gleason 
Grade groups from the biopsy specimens. The median number of days from MRI to radical 
prostatectomy was 57 days (IQR, 38–75) with a range of 24 to 164 days.  
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Figure 5-3. Biopsy Gleason Grade Group distribution. 
Histopathology descriptive statistics 
Of the 40 histopathology specimens 83 lesions were identified with a maximum axial diameter 
greater than or equal to 5mm. Four separate prostate tumours was the largest number identified 
in a single prostatectomy specimens. Of the 480 prostate sectors (40 patients with 12 sectors per 
patient), tumour was present in 238 (49.6%) sectors. In the peripheral zone 166 (69.7%) of 240 
sectors contained tumour and in the transitional zone 72 sectors (30.3%) contained tumour. 
Post-biopsy haemorrhage, as identified on the T1-weighted images, was present in the location of 
21 tumours. The majority of the tumours identified in the radical prostatectomy specimens were 
Gleason score 3+4=7 and were a Grade Group of 2 (Figure 5-4 and Figure 5-5), but unlike on 
biopsy specimens there were no Gleason Score 3+3=6 (Grade Group 1) tumours. 79 of the 
tumours resided predominately in the peripheral zone and 4 in the transitional zone. 17 tumours 
extended beyond the capsule and three tumours invaded the seminal vesicles. Figure 5-6 
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demonstrates the increasing likelihood of tumour extension beyond the capsule with increasing 
Gleason Grade. 
 
Figure 5-4. Frequencies of tumour Gleason Grade in the included tumours. 
 
 
Figure 5-5. Frequencies of tumour Gleason Grade Group in the included tumours.  
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Figure 5-6. Bar chart demonstrating the number of tumours which extended beyond the prostate capsule 
within different Gleason Grade Groups. 
The intraclass correlation coefficient (ICC) measurements for the maximum axial diameter of 
tumour, and tumour width and height between the two histopathologists were 0.99 (95%CI, 
0.99–1.00), 0.99 (95%CI, 0.98–0.99) and 0.90 (95%CI, 0.84–0.94) respectively (p = <0.001), 
indicating “excellent” inter-rater reliability [200,201]. Due to the excellent agreement in tumour 
size measurements between histopathologists only one (Histopathologist 1) measurement is 
described.  
The median maximum axial diameter was 15 mm (IQR, 11–23 mm) with a range of 5 to 42mm. 
The median tumour width and height was 8mm (IQR, 5–11 mm) and 15 mm (IQR, 10–25 mm). The 
median tumour volume with no correction factor was 1.05cm3 (IQR, 0.32–3.34 cm3).  
The median maximum axial diameter for tumours of Gleason Grade Group 2 to 5 are 15mm (IQR, 
10–23 mm), 18mm (IQR, 8–23 mm), 16mm (IQR, 12.5–26 mm), and 22 (IQR, 14–30 mm), 
respectively (Figure 5-7). There was no correlation between maximum axial diameter and Gleason 
Grade Group as indicated by the Spearman Rank correlation coefficient of 0.058 (p=0.604). The 
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median volume of tumours of Gleason Grade Group tumours 2 to 5 are 0.82cm3 (IQR, 0.28–3.34 
cm3), 1.67cm3 (IQR, 0.26–3.47 cm3), 1.68cm3 (IQR, 0.35–6.16 cm3), 2.14 (IQR, 1.17–3.11 cm3), 
respectively (Figure 5-8). There was no correlation between maximum axial diameter and Gleason 
Grade Group as indicated by the Spearman Rank correlation coefficient of 0.046 (p=0.683).  
 
Figure 5-7. Boxplot of maximum axial diameter of different tumour Gleason Grade Groups. 
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Figure 5-8. Boxplot of tumour volume of different tumour Gleason Grade Groups. 
 
The mean axial diameter of index tumours was 23.0 ± 9.69 mm and the median axial diameter of 
non-index tumours was 12 mm (IQR, 8–17 mm), which was a statistically significant difference 
(p=<0.001, Mann-Whitney U test) (Figure 5-9). The median tumour volume of index tumours was 
3.10 cm3 (IQR, 0.61–5.14 cm3) and non-index tumours was 0.44cm3 (IQR, 0.11–1.17 cm3) which 
was also significantly different (p=<0.001, Mann-Whitney U test) (Figure 5-10). 
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Figure 5-9. Comparison of tumour diameter of index and non-index lesions. 
 
 
Figure 5-10. Comparison of tumour volume of index and non-index lesions. 
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The median maximum axial diameter of tumours confined by the capsule was 13mm (IQR, 10–22 
mm) and mean diameter of tumours which extended beyond the capsule was 25.1 ± 8.69 mm, a 
significant difference (p=0.001, Mann Whitney U test) (Figure 5-11). There was a significance 
difference between the tumour volume of tumours which extended beyond the capsule (median, 
3.10cm3; IQR, 0.61–5.14cm3) and those which did not (median, 0.44cm3; IQR, 0.11–1.17cm3) (p = 
<0.001, Mann Whitney U test) (Figure 5-12). 
 
Figure 5-11. Comparison of tumour diameter of tumours confined to and those which extended beyond 
the capsule. 
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Figure 5-12. Boxplot of tumour volume of tumours whoch extended beyond the capsule and those which 
did not. 
Three tumours invaded the seminal vesicles. The median axial diameter of tumours that did not 
invade the seminal vesicles was 15mm (IQR, 11–23 mm), and the mean dimeter of tumours which 
did invade the seminal vesicles was 20 ± 12.5mm (p = 0.791, Mann-Whitney U) (Figure 5-13). 
There was no significant difference (p=0.635) between the tumour volumes of tumours which did 
and did not invade the seminal vesicles and shown in Figure 5-14. 
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Figure 5-13. Boxplot displaying the difference in maximum axial diameters of tumours which did and did 
not invade the seminal vesicles. 
 
 
Figure 5-14. Boxplot of tumour volume of lesions which did and did not invade the seminal vesicles. 
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Diagnostic performance of DWI sequences: sector-based analysis 
The apex of the prostate was not covered on the sDWI sequence in two cases, as a result the 4 
apical sectors of these cases were omitted from the analysis and thus 476 sectors were analysed 
in the sDWI (protocol C) and sDWI + T2WI (protocol D) reads. The cDWI analysis included 12 
sectors in all 40 cases, with 480 sectors in cDWI (protocol A) and cDWI + T2WI (protocol B) reads.  
Both readers regardless of imaging protocol had more Likert scores of 1 and 5 compared to scores 
of 2 to 4, and reader 2 had few Likert scores of 2 (Table 5-1 and 5.2). Both readers, generally, 
correctly identified when tumour was absent from a sector and when tumour was present with all 
imaging protocols (Figure 5-15 A-D and Figure 5-16 A-D).  
Table 5-1. Reader 1 frequency of Likert scores in different protocols. 
Reader 1 Protocol 
Likert score cDWI (A) cDWI + T2WI (B) sDWI (C) sDWI + T2WI (D) 
Tumour definitely absent (1) 206 214 262 244 
Tumour probably absent (2) 90 87 82 95 
Indeterminate (3) 26 20 22 18 
Tumour probably present (4) 23 27 14 14 
Tumour definitely present (5) 135 132 88 101 
 
 
Table 5-2. Reader 2 frequency of Likert scores in different protocols. 
Reader 2 Protocol 
Likert score cDWI (A) cDWI + T2WI (B) sDWI (C) sDWI + T2WI (D) 
Tumour definitely absent (1) 319 305 333 310 
Tumour probably absent (2) 7 7 8 13 
Indeterminate (3) 18 11 16 4 
Tumour probably present (4) 51 20 20 32 
Tumour definitely present (5) 85 137 95 113 
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Figure 5-15. Bar chart demonstrating the ratio of sectors with tumour present or absent to probability of 
the tumour presence with the conventional DWI sequence. A – Reader 1 Protocol A, B – Reader 1 
Protocol B, C – Reader 2 Protocol A, D - Reader 2 Protocol B. 
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Figure 5-16. Bar chart demonstrating the ratio of sectors with tumour present or absent to probability of 
the tumour presence with the small FOV DWI sequence. A - Reader 1 Protocol A, B - Reader 1 Protocol B, 
C - Reader 2 Protocol A, D - Reader 2 Protocol B. 
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The 2 x 2 contingency table was completed for both readers and all protocols using a Likert score 
3 and greater as positive for tumour and also 4 and greater. A threshold effect was demonstrated 
throughout with less true and false positive results and more true and false negative results with 
the higher Likert cut-off. The diagnostic results of each protocol for both readers are presented in 
Table 5-3 and Table 5-4. 
Table 5-3. Diagnostic performance of reader 1 for each imaging protocol on a per sector basis. 
Reader 1 Likert cut-off 
True 
Positives 
False 
Positives 
True 
Negatives 
False 
Negatives 
cDWI  
(Protocol A) 
3 147 37 205 91 
4 136 22 220 102 
cDWI + T2WI 
(Protocol B) 
3 142 37 205 96 
4 131 28 214 107 
sDWI  
(Protocol C) 
3 105 19 221 127 
4 89 13 227 143 
sDWI + T2WI 
(Protocol D) 
3 115 18 222 117 
4 103 12 228 129 
 
Table 5-4. Diagnostic performance of reader 2 for each imaging protocol on a per sector basis. 
Reader 2 Likert cut-off 
True 
Positives 
False 
Positives 
True 
Negatives 
False 
Negatives 
cDWI  
(Protocol A) 
3 126 28 214 112 
4 123 13 229 115 
cDWI + T2WI 
(Protocol B) 
3 136 32 210 102 
4 133 24 218 105 
sDWI  
(Protocol C) 
3 113 18 222 119 
4 105 10 230 127 
sDWI + T2WI 
(Protocol D) 
3 120 29 211 112 
4 117 28 212 115 
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The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) 
with 95% CI for Likert cut-off’s of 3 and 4 are presented in Table 5-5 and Table 5-6. The statistical 
comparison of the comparable sDWI and cDWI imaging protocols for each of the diagnostic 
parameters is also shown. 
For reader 1 there was a significant improvement in sensitivity of the cDWI sequence over sDWI 
regardless of the presence of the T2WI sequence (Likert 4 cut-off, p = <0.001), and conversely the 
sDWI specificity was significantly better than cDWI (Likert cut-off 3, p = 0.003). Reader 2 found no 
significant difference in sensitivity or specificity between cDWI and sDWI regardless of cut-off or 
protocol. The sDWI sequence sensitivity significantly improved when the T2WI sequence was 
added for reader 1 (Likert 4 cut-off, p = 0.007) and the same was observed with reader 2 for the 
cDWI sequence (Likert cut-off 4, p = <0.001). The specificity was significantly lower for reader 2 
when T2WI was added to either the cDWI (Likert cut-off 4, p = 0.001) and sDWI sequence (Likert 
cut-off 4, p = <0.001). There was little difference between the PPV and NPV for reader 1 and 
reader 2 when sDWI was compared to cDWI. McNemar test was performed to compare the 
sensitivity and specificity results, and a test of proportions was performed for PPV and NPV  
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Table 5-5. Diagnostic performance of reader 1 and comparison of cDWI and sDWI sequences. 
Reader 1 Likert cut-off 
Protocol A 
cDWI 
Protocol C 
sDWI 
Protocol B 
cDWI + T2WI 
Protocol D 
sDWI + T2WI 
A vs C 
(p-value) 
B vs D 
(p-value) 
A vs B 
(p-value) 
C vs D 
(p-value) 
Sensitivity 
3 0.62  (0.55-0.68) 
0.45  
(0.39-0.52) 
0.60  
(0.53-0.66) 
0.50 
(0.43-0.56) <0.001* 0.007 0.499 0.041 
4 0.57 (0.51-0.63) 
0.38 
(0.32-0.45) 
0.55 
(0.48-0.61) 
0.44 
(0.38-0.51) <0.001* 0.005 0.441 0.007 
Specificity 
3 0.85 (0.80-0.89) 
0.92 
(0.88-0.95) 
0.85 
(0.80-0.89) 
0.93 
(0.88-0.95) 0.003* 0.004 1.000 1.000 
4 0.91 (0.87-0.94) 
0.95 
(0.91-0.97) 
0.88 
(0.84-0.92) 
0.95 
(0.91-0.97) 0.096 0.011 0.263 1.000 
PPV 
3 0.80 (0.73-0.85) 
0.85 
(0.77-0.91) 
0.79 
(0.73-0.85) 
0.86 
(0.79-0.92) 0.285 0.102 0.894 0.683 
4 0.86 (0.80-0.91) 
0.87 
(0.79-0.93) 
0.82 
(0.76-0.88) 
0.90 
(0.82-0.94) 0.786 0.097 0.368 0.595 
NPV 
3 0.69 (0.64-0.74) 
0.64 
(0.58-0.69) 
0.68 
(0.63-0.73) 
0.65 
(0.60-0.71) 0.124 0.483 0.762 0.588 
4 0.68 (0.63-0.73) 
0.61 
(0.56-0.66) 
0.67 
(0.61-0.72) 
0.64 
(0.59-0.69) 0.056 0.445 0.654 0.484 
AUC  0.76 (0.72-0.81) 
0.73 
(0.69-0.77) 
0.79 
(0.75-0.83) 
0.79 
(0.75-0.83) 0.164 0.818 0.138 <0.001 
* Denotes the comparison remains significantly different following Bonferroni correction for multiple comparisons. 
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Table 5-6. Diagnostic performance of reader 2 and comparison of cDWI and sDWI sequences. 
Reader 2 Likert cut-off 
Protocol A 
cDWI 
Protocol C 
sDWI 
Protocol B 
cDWI + T2WI 
Protocol D 
sDWI + T2WI 
A vs C 
(p-value) 
B vs D 
(p-value) 
A vs B 
(p-value) 
C vs D 
(p-value) 
Sensitivity 
3 0.53 (0.46-0.60) 
0.49 
(0.42-0.55) 
0.57 
(0.51-0.64) 
0.52  
(0.45-0.58) 0.403 0.170 0.002* 0.189 
4 0.52 (0.45-0.58) 
0.45 
(0.39-0.52) 
0.56 
(0.49-0.62) 
0.50  
(0.44-0.57) 0.143 0.161 0.002* 0.012 
Specificity 
3 0.88 (0.84-0.92) 
0.93 
(0.88-0.95) 
0.87 
(0.82-0.91) 
0.88  
(0.83-0.92) 0.112 0.719 0.388 0.019 
4 0.95 (0.91-0.97) 
0.96 
(0.93-0.98) 
0.90 
(0.86-0.94) 
0.88  
(0.84-0.92) 0.581 0.571 0.001* <0.001* 
PPV 
3 0.82 (0.75-0.88) 
0.86 
(0.79-0.92) 
0.81 
(0.74-0.87) 
0.81  
(0.73-0.87) 0.310 0.977 0.842 0.201 
4 0.90 (0.84-0.95) 
0.91 
(0.85-0.96) 
0.85 
(0.78-0.90) 
0.81  
(0.73-0.87) 0.813 0.355 0.141 0.016 
NPV 
3 0.66 (0.60-0.71) 
0.65 
(0.60-0.70) 
0.67 
(0.62-0.72) 
0.65  
(0.60-0.71) 0.883 0.883 0.656 0.952 
4 0.67 (0.61-0.72) 
0.64 (0.59-
0.69) 
0.67 
(0.62-0.73) 
0.65  
(0.59-0.70) 0.551 0.474 0.800 0.912 
AUC  0.72 (0.68-0.76) 
0.70 
(0.66-0.74) 
0.73 
(0.69-0.77) 
0.71 
(0.67-0.75) 0.547 0.318 0.265 0.675 
* Denotes the comparison remains significantly different following Bonferroni correction for multiple comparisons. 
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The ROC for reader 1 are displayed in Figure 5-17, and for reader 2 in Figure 5-18. For protocols A 
and C the cDWI AUC was higher than sDWI, but the difference was not significant (DeLong’s test) . 
The only significant difference (p = <0.001) was the significant increase in AUC for reader 1’s sDWI 
analysis when T2WI was added to the assessment in (Table 5-5 and Table 5-6). 
 
Figure 5-17. Receiver operating characteristic curve of sectoral diagnostic performance of reader 1. 
 
Figure 5-18. Receiver operating characteristic curve of sectoral diagnostic performance of reader 2.  
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Sectoral reliability 
Interobserver agreement of reader 1 and 2 of the sectoral analysis as denoted by the weighted 
kappa (!) with 95% CI is demonstrated in Table 5-7. The weighted kappa was not significantly 
different between cDWI and sDWI with and without T2WI (two proportion Z-test). The 
interobserver reliability was not significantly different between the peripheral and transitional 
zones within each sequence. Agreement dropped after the addition of the T2WI sequence, but 
the difference was not significant. The interobserver agreement was substantial for cDWI 
sequence and moderate for the remainder of the sequences [200]. 
Table 5-7. Interobserver reliability, as demonstrated by weighted kappa tests, between reader 1 and 2 for 
all sectors, and the peripheral zone and transitional zone sectors. 
Sectors cDWI (A) sDWI (C) A vs C (p-value) 
cDWI + T2WI 
(B) 
sDWI + T2WI 
(D) 
B vs D 
(p-value) 
All 0.62 (0.55–0.69) 
0.59 
(0.51–0.67) 0.58 
0.54 
(0.47–0.62) 
0.52 
(0.43–0.60) 0.74 
Peripheral zone 0.62 (0.51–0.72) 
0.59 
(0.47–0.70) 0.72 
0.56 
(0.45–0.67) 
0.50 
(0.38–0.62) 0.48 
Transitional zone 0.62 (0.52–0.71) 
0.58 
(0.48–0.70) 0.58 
0.52 
(0.42–0.63) 
0.52 
(0.41–0.63) 0.99 
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Diagnostic performance of DWI sequences: lesion-based analysis 
83 lesions were identified on histopathological analysis of the 40 patients’ radical prostatectomy 
specimens. Two lesions were excluded from the sDWI MRI reads (Protocols C and D) as the apex 
and lesions were not included on the images.  
In the comparable sequences both reader 1 and 2 identified more index lesions on cDWI than 
sDWI, with and without T2WI, as demonstrated in Table 5-8. The best tumour detection rate was 
87.5%, which was in reader 1’s clinical assessment of the cDWI sequence without T2WI. 
Table 5-8. Index lesion identification of reader 1 and 2 with all imaging protocol following a stringent and 
clinical assessment of readers' results. 
 
Protocol Stringent Clinical 
Seen   % Seen % 
Reader 1 
 
cDWI (A) 33 82.5 35 87.5 
sDWI (C) 30 75 33 82.5 
cDWI + T2WI (B) 33 82.5 34 85 
sDWI + T2WI (D) 31 77.5 33 82.5 
Reader 2 cDWI (A) 31 77.5 34 85 
sDWI (C) 30 75 31 77.5 
cDWI + T2WI (B) 33 82.5 34 85 
sDWI + T2WI (D) 32 80 32 80 
 
The positive predictive value of reader 1’s lesion assessment was consistently higher with sDWI 
than cDWI with and without T2WI, and following both ‘stringent’ and ‘clinical’ evaluation, which 
was due to the reduced number of false positive lesions (Table 5-9). The sensitivity was better 
with cDWI than sDWI without T2WI, but similar with T2WI. 
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Table 5-9. Reader 1 lesion accuracy. 
Reader 1 Protocol True 
Positives 
False 
Positives 
False 
Negatives 
Sensitivity PPV 
Stringent cDWI (A) 47 13 36 0.57 
(0.45–0.67) 
0.78 
(0.83–0.99) 
sDWI (C) 42 4 39 0.52 
(0.40–0.63) 
0.91 
(0.79–0.98) 
cDWI + T2WI (B) 47 8 36 0.57 
(0.45–0.67) 
0.86 
(0.71–0.95) 
sDWI + T2WI (D) 46 4 35 0.57 
(0.45–0.68) 
0.92 
(0.81–0.98) 
Clinical cDWI (A) 53 13 30 0.64 
(0.53–0.74) 
0.80 
(0.69–0.89) 
sDWI (C) 46 4 35 0.57 
(0.45–0.68) 
0.92 
(0.81–0.98) 
cDWI + T2WI (B) 50 8 33 0.60 
(0.49–0.71) 
0.86 
(0.75–0.94) 
sDWI + T2WI (D) 50 4 31 0.62 
(0.50–0.72) 
0.93 
(0.82–0.98) 
 
Similar findings were observed in reader 2’s lesion accuracy assessment (Table 5-10). cDWI was 
more sensitive than sDWI with and without T2WI, but the reverse was seen with positive 
predictive value and a reduced number of false positives. A maximum sensitivity of 59% is 
observed with cDWI and a maximum positive predictive value of 98% was demonstrated with 
sDWI and T2WI combined. 
  
  Results 
 
166 
Table 5-10. Reader 2 lesion accuracy. 
Reader 2 
 
Protocol True 
Positive 
False 
Positives 
False 
Negatives 
Sensitivity PPV 
Stringent cDWI 43 5 40 0.52 
(0.41–0.63) 
0.90 
(0.77–0.97) 
sDWI 40 2 41 0.49 
(0.38–0.61) 
0.95 
(0.84–0.99) 
cDWI + T2WI 46 7 43 0.55 
(0.44–0.66) 
0.87 
(0.75–0.95) 
sDWI + T2WI 41 2 42 0.49 
(0.39–0.61) 
0.95 
(0.84–0.99) 
Clinical cDWI 49 5 34 0.59 
(0.48–0.70) 
0.91 
(0.80–0.97) 
sDWI 43 2 39 0.53 
(0.42–0.64) 
0.96 
(0.85–0.99) 
cDWI + T2WI 49 7 34 0.59 
(0.48–0.70) 
0.88 
(0.76–0.95) 
sDWI + T2WI 43 1 38 0.53 
(0.42–0.64) 
0.98 
(0.88–1.00) 
Effects of haemorrhage and tumour grade on lesion-based accuracy 
An assessment of the percentage of lesions seen which were affected and not affected by 
haemorrhage was performed (Figure 5-19 – 5-22). Lesions outwith an area of haemorrhage were 
detected more frequently by both radiologists, with both DWI sequences and with or without 
T2WI. 
Tumours were more likely to be seen if they were of higher grade regardless of imaging protocol 
(Figure 5-23 - 5-26).
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Figure 5-19. Influence of peri-lesional haemorrhage on Radiologist 1's ability to detect and localise 
tumour with cDWI and T2WI. 
 
 
Figure 5-20. Influence of peri-lesional haemorrhage on Radiologist 1's ability to detect and localise 
tumour with sDWI and T2WI. 
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Figure 5-21. Influence of peri-lesional haemorrhage on Radiologist 2's ability to detect and localise 
tumour with cDWI and T2WI. 
 
 
Figure 5-22. Influence of peri-lesional haemorrhage on Radiologist 2's ability to detect and localise 
tumour with sDWI and T2WI. 
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Figure 5-23. Comparison of detection rate of tumours of different Gleason Grade Group with cDWI by 
Radiologist 1. 
 
 
Figure 5-24. Comparison of detection rate of tumours of different Gleason Grade Group with sDWI by 
Radiologist 1. 
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Figure 5-25. Comparison of detection rate of tumours of different Gleason Grade Group with cDWI by 
Radiologist 1 
 
 
Figure 5-26. Comparison of detection rate of tumours of different Gleason Grade Group with sDWI by 
Radiologist 2. 
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Quantitative analysis of lesions 
Signal intensity of tumour and non-tumour tissue 
The signal intensity (SI) of tumour was lower than non-tumour (normal) tissue on the ADC maps of 
both DWI sequences and higher than non-tumour tissue on the b1000 and b1500 images (Table 
5-11 and Table 5-12). The signal intensity between tumour and non-tumour tissue was 
significantly different on all sequences except on the b1000 images of the cDWI sequence. The 
signal intensity measured on ADC maps is also a measure of the ADC. 
Table 5-11. Table of signal intensities of normal and tumour tissues in cDWI sequences. 
cDWI Tissue Median signal intensity (IQR) Tumour vs normal† 
(p-value) 
Mean ADC  
(x10-6 mm2/sec) 
Normal 1526 ± 250* 
<0.001 
Tumour  960 (8371068) 
Minimum ADC 
(x10-6 mm2/sec)  
Tumour  784 ± 208*  
Mean b1000 SI Normal  147 (125189) 
0.935 
Tumour  147 (128174) 
Mean b1500 SI Normal  83.4 (68100) 
<0.001 
Tumour  109 ± 32* 
* Mean ± Standard Deviation, † Wilcoxon signed rank test 
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Table 5-12. Table of signal intensities of normal and tumour tissues in sDWI sequences. 
sDWI Tissue Median signal intensity (IQR) Tumour vs normal* 
(p-value) 
Mean ADC Normal 1258 (10741387) 
<0.001 
Tumour  766 (672887) 
Minimum ADC Tumour  514 (374698)  
Mean b1000 SI Normal  156 (138179) 
<0.001 
Tumour  174 (154206) 
Mean b1500 SI Normal  139 (125 160) 
<0.001 
Tumour  120 (102 122) 
* Wilcoxon signed rank test 
 
A selection of histograms of signal intensities from tumour and non-tumour tissue of different 
cDWI and sDWI sequences are demonstrated in Figure 5-27 A-D. Most distributions were non-
parametric, but the signal intensity of tumour on b1500 images, the minimum tumour ADC, and 
the mean ADC value of non-tumour tissue on the cDWI sequence demonstrated a normal 
distribution. 
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Figure 5-27. Histograms of selected signal intensities demonstrating parametric and non-parametric 
distributions and their Shapiro-Wilk test p-value. A - Mean ADC value of tumour, B - Minimum ADC value 
of tumour, C - b1000 and D – b1500 signal intensity of normal tissue.  
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Noise measurement 
The measure of noise was the standard deviation of the SI of a ROI drawn over obturator internus. 
This was performed for the ADC map, b1000 and b1500 sequences of both cDWI and sDWI, and 
for which the results are demonstrated in Table 5-13 with example histograms demonstrated in 
Figure 5-28 A and B. There was more noise in the ADC maps of both sequences with lower noise 
levels at b1500 compared to b1000 images. There was significantly higher noise in the cDWI ADC 
maps compared to sDWI, but the opposite was observed in the b1000 and b1500 images (all 
comparisons p = <0.001, Wilcoxon Signed Rank test) 
Table 5-13. Median noise measurements of sDWI and cDWI sequences. 
 Sequence Median noise level (IQR) 
sDWI ADC map 93.4 (81.8103.5) 
b1000  9.2 (8.59.9) 
b1500 8.0 (7.48.4) 
cDWI ADC map 127.2 (112.3165.6) 
b1000  5.7 (4.96.0) 
b1500 4.2 (3.35.3) 
 
 
Figure 5-28. Histogram of noise level of A - sDWI ADC map and B – cDWI ADC maps. The p-value 
represents the Shapiro-Wilk test indicating a non-parametric distribution. 
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Tumour quantitative characteristics 
The signal-to-noise ratio (SNR), contrast-to-noise (CNR), and contrast ratio (CR) of lesions on the 
ADC map, b1000 and b1500 sequences of both sDWI and cDWI are demonstrated in Table 5-14. 
There were 83 lesions included in the cDWI group and 81 lesions in the sDWI for reasons 
described on page 164. Most of the tumour quantitative parameters were not normally 
distributed as suggested by the p-value of the Shapiro-Wilk test. A selection of histograms are 
demonstrated in Figure 5-29A-F illustrating examples of normal and not normal distribution. 
Table 5-14. Tumour SNR, CNR and CR on cDWI and sDWI sequences and comparison between DWI 
sequences. 
Sequence  cDWI sDWI Comparison of cDWI & sDWI 
Wilcoxon Signed Rank Test 
p-value Median (IQR) Median (IQR) 
ADC map SNR 7.4  
(5.8–8.9) 
8.8 ± 2.5* <0.001 
CNR -4.1  
(-5.6–2.6) 
-4.65 ± 2.82* 0.770 
CR -0.22 ± 0.11* -0.21 ± 0.13* 0.339† 
b1000 SNR 25.7  
(21.5–35.4) 
18.9  
(16.8–22.8) 
<0.001 
CNR -0.57  
(-4.12–6.14) 
2.22  
(-0.21–3.81) 
0.054 
CR 0.003 ± 0.15* 0.06 
(0.01–0.10) 
0.001 
b1500 SNR 23.2 
(18.0–31.8) 
17.3 
(15.3–19.8) 
<0.001 
CNR 4.30  
(-0.08–10.74) 
3.08 
(1.35–4.86) 
0.190 
CR 0.12 ± 0.24* 0.11 ± 0.08* 
 
0.151† 
*mean ± standard deviation, †paired samples t-test 
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Figure 5-29. Histogram of selected tumour quantitative results of different sequences with Shapiro-Wilk 
test p-values demonstrated. A - cDWI ADC SNR, B - sDWI ADC SNR, C - cDWI b1000 CR, D - sDWI b1000 CR, 
E - cDWI b1500 CNR, F - sDWI b1500 CNR. 
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Comparison of quantitative results of sDWI and cDWI sequences 
The cDWI and sDWI results were compared using the Willcoxon-Signed Rank or paired t-tests. The 
SNR of the ADC map lesions was significantly higher on sDWI than cDWI, but the opposite was 
observed on the b1000 and b1500 images. The CR was significantly higher at b1000 with sDWI, 
but this difference was not observed at b1500. There was no significant difference between the 
CNR results between sDWI and cDWI on any sequence (Table 5-14).  
The median mean ADC value of tumour was 766 x10-6 mm2/sec on sDWI ADC maps and 960 x10-6 
mm2/sec on cDWI maps which was a significant difference (p = <0.001, Wilcoxon Signed Rank test) 
(Table 5-11 and Table 5-12, Figure 5-30). There was also a significant difference between the 
minimum ADC values of tumour between the two DWI sequences (p = <0.001, Wilcoxon Signed 
Rank test) (Figure 5-31). 
 
Figure 5-30. Boxplot of mean tumour ADC values of sDWI and cDWI ADC maps. 
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Figure 5-31. Boxplot of minimum tumour ADC values of sDWI and cDWI ADC maps. 
 
Comparison of tumour quantitative results of b1000 and b1500 images 
The SNR of lesions on b1000 images was significantly higher than on b1500 for both cDWI and 
sDWI (Figure 5-32 A and B, p = <0.001 – Wilcoxon signed rank). There was a significant 
improvement in tumour CNR (Figure 5-33 A and B) and CR (Figure 5-34 A and B) on b1500 images 
compared to b1000 for both cDWI and sDWI sequences (p = <0.001). The comparison of CR on 
cDWI images was performed using a paired samples t-test and the other comparisons of CNR and 
CR with a Wilcoxon Signed Rank test.  
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Figure 5-32. Comparison of SNR of tumour on b1000 and b1500 images using a Wilcoxon Signed Rank 
test. A - cDWI, B – sDWI. 
 
 
Figure 5-33. Comparison of CNR of tumour on b1000 and b1500 images using a Wilcoxon Signed Rank 
test. A - cDWI, B – sDWI. 
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Figure 5-34. Comparison of CR of tumour on b1000 and b1500 images. A - cDWI (paired samples t-test), B 
- sDWI (Wilcoxon Signed Rank test). 
 
Receiver Operating Characteristic curves of mean ADC values. 
The ROC curves of the mean ADC value of cDWI and sDWI ADC map are demonstrated in Figure 
5-35 and Figure 5-36, respectively. The area under the ROC curve (AUC) for the cDWI sequence 
was 0.96 (95% CI, 0.93–0.99) and for the sDWI sequence was 0.90 (0.84–0.96) which was not 
significantly different (p = 0.07, De Long’s test for two correlated ROC curves). For the cDWI ADC 
map an ADC cut-off for tumour of less than 1153 x10-6 mm2/sec results in a sensitivity of 0.86 and 
specificity of 0.98. For the sDWI ADC map an ADC cut-off of for tumour of less than 898 x10-6 
mm2/sec results in a sensitivity of 0.77 and a specificity of 0.93. 
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Figure 5-35. Receiver operating characteristic curve of mean ADC values of the cDWI sequence. 
 
 
Figure 5-36. Receiver operating characteristic curve of mean ADC values of the sDWI sequence. 
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Quantitative results of tumour index lesions 
The mean and minimum ADC values of index tumours were significantly different from non-index 
lesions, as was the SNR on ADC maps of both cDWI and sDWI (Table 5-15 and Table 5-16). The 
CNR of index lesions on sDWI ADC maps and CR of index lesions on cDWI ADC maps were 
significantly lower than non-index lesions. Signal intensity, SNR, CNR and CR of index lesions and 
non-index lesions were not significantly different on b1000 and b1500 images.  
Table 5-15. Comparison quantitative imaging characteristics of index and non-index tumours on cDWI 
sequence. 
cDWI   Index lesion 
Median (IQR) 
Non-index lesion 
Median (IQR) 
Difference 
p-value 
ADC map ADC mean  
(x10-6 mm2/sec) 
852 (795–960) 1028 (946–1124) <0.001† 
ADC min  
(x10-6 mm2/sec) 
646 (546–772) 889 ± 176* <0.001† 
SNR 6.6 (4.9–7.8) 8.4 (6.7–9.6) 0.003† 
CNR -4.91 ± 2.94* -3.85 ± 2.49* 0.080‡ 
CR -0.26 ± 0.11* -0.21 ± 0.09* 0.002‡ 
b1000 SI 162 ± 46* 144 (126–157) 0.189† 
SNR 26.6 (20.9–37.7) 27.0 ± 8.2* 0.444† 
CNR 2.36 ± 9.00* -0.70 ± 7.25* 0.103‡ 
CR 0.03 ± 0.16* -0.01 (-0.10–0.04) 0.282† 
b1500 SI 114 ± 36* 99 (83–116) 0.111† 
SNR 23.1 (19.6–30.6) 24.6 ± 10.0* 0.535† 
CNR 6.80 ± 7.94* 3.22 ± 8.72* 0.194‡ 
CR 0.14 ± 0.28* 0.10 ± 0.16* 0.191‡ 
* Mean ± Standard deviation, † Mann-Whitney U test, ‡ Independent samples t-test  
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Table 5-16. Comparison quantitative imaging characteristics of index and non-index tumours on sDWI 
sequence. 
sDWI   Index lesion 
Median (IQR) 
Non-index lesion 
Median (IQR) 
Difference 
p-value 
ADC map ADC mean 
(x10-6 mm2/sec) 
724 ± 141* 885 ± 199* <0.001‡ 
ADC min  
(x10-6 mm2/sec) 
426 (340–517) 623 ± 238* <0.001† 
SNR 7.9 ± 2.3* 9.6 ± 2.5* 0.003‡ 
CNR -5.21 ± 2.73* -4.11 ± 2.84* 0.014‡ 
CR -0.24 ± 0.11* -0.18 ± 0.13* 0.080‡ 
b1000 SI 185 ± 43* 171 (154–206) 0.487† 
SNR 20.1 ± 5.0* 18.9 (16.9–22.2) 0.613† 
CNR 2.78 ± 3.70* 1.49 (-.60–3.09) 0.236† 
CR 0.07 ± 0.09* 0.04 (0.01–0.11) 0.218† 
b1500 SI 145 ± 32* 138 ± 31* 0.386‡ 
SNR 17.8 (16.0–20.2) 17.1 ± 4.6* 0.375† 
CNR 3.78 (1.38–5.87) 3.06 ± 3.01* 0.183† 
CR 0.11 (0.06–0.18) 0.08 (0.08) 0.142† 
* Mean ± Standard deviation, † Mann-Whitney U test, ‡ Independent samples t-test  
 
The AUC of the sDWI sequence was 0.96 (95%CI, 0.91–1.00) and for cDWI was 0.97 (95%CI, 0.94–
1.00) which was not significantly different (p=0.56). For index tumours, an ADC cut-off of 789 x10-6 
mm2/sec gives a sensitivity of 0.75 and a specificity of 0.97 for sDWI, and a cut-off of 1122 x10-6 
mm2/sec gives a sensitivity and specificity of 0.90 and 0.97 for cDWI, respectively (Figure 5-37). 
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Figure 5-37. ROC curve of mean ADC value of index lesions on each ADC map. 
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Influence of haemorrhage on tumours 
The mean tumour ADC was significantly higher in lesions within haemorrhage when compared to 
those outwith, and this significance is observed in both cDWI and sDWI ADC maps (Table 5-17 and 
Table 5-18). This significant difference is also demonstrated in the minimum ADC value of tumours 
on cDWI. Significantly increased contrast (both CNR and CR) was observed in lesions not affected 
by haemorrhage on the sDWI ADC map, when compared to tumours affected by haemorrhage. 
There was no significant effect of haemorrhage on lesions on the b1000 or b1500 images on cDWI 
or sDWI. Wilcoxon signed rank test comparing sDWI and cDWI mean and minimum tumour ADC 
values in tumours without evidence of haemorrhage was statistically significant (p=<0.001).  
Table 5-17. Quantitative imaging parameters and comparison of tumours situated within and outwith 
haemorrhage on cDWI sequence. 
cDWI   No haemorrhage 
Median (IQR) 
Haemorrhage present 
Median (IQR) 
Difference 
p-value 
ADC map ADC mean 
(x10-6 mm2/sec) 918 (816–1037) 1012 (959–1137) 0.011† 
ADC min 
(x10-6 mm2/sec) 750 ± 195* 886 ± 216* 0.009‡ 
SNR 7.2 (5.7–8.9) 8.2 (6.3–9.4) 0.209† 
CNR -4.42 (-5.58–-2.69) -3.89 ± 3.26* 0.414† 
CR -0.23 ± 0.10* -0.19 ± 0.13* 0.132‡ 
b1000 SI 155 ± 47* 148 (134–183) 0.660† 
SNR 28.5 ± 11.1* 25.05 (22.5–35.2) 0.834† 
CNR -0.41 (-4.066.32) -0.63 ± 7.30* 0.444† 
CR -0.01 ± 0.16* -0.01 ± 0.12* 0.579‡ 
b1500 SI 109 ± 34* 106 ± 24* 0.814‡ 
SNR 23.2 (18.0–33.0) 25.0 ± 10.2* 0.900† 
CNR 5.96 ± 7.89* 4.87 ± 6.37* 0.568‡ 
CR 0.12 ± 0.15* 0.12 ± 0.17* 0.992‡ 
* Mean ± Standard deviation, † Mann-Whitney U test, ‡ Independent samples t-test 
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Table 5-18. Quantitative imaging parameters and comparison of tumours situated within and outwith 
areas of haemorrhage on sDWI sequence. 
sDWI   No haemorrhage 
Median (IQR) 
Haemorrhage present 
Median (IQR) 
Difference 
p-value 
ADC map ADC mean 
(x10-6 mm2/sec) 741 (649–871) 909 ± 197* 0.005† 
ADC min 
(x10-6 mm2/sec) 498  (371–637) 621 ± 245* 0.071† 
SNR 8.6 ± 2.6* 9.3 ± 2.2* 0.285‡ 
CNR -5.14 ± 2.54* -3.16 ± 3.16* 0.002‡ 
CR -0.23 ± 0.11* -0.13 ± 0.14* 0.006‡ 
b1000 SI 176 (155–206) 177 ± 41* 0.718† 
SNR 19.1 (16.8–22.2) 19.5 ± 4.92* 0.793† 
CNR 2.50 (-0.48–4.27) 2.17 ± 3.44* 0.801† 
CR 0.06 ± 0.11* 0.05 ± 0.10* 0.882‡ 
b1500 SI 139 (125–161) 139 ± 28* 1.000† 
SNR 17.29 (15.8–19.8) 17.14 ± 4.12* 0.870† 
CNR 3.09 (1.27–4.86) 3.41 ± 2.55* 0.987† 
CR 0.11 ± 0.09* 0.09 (0.07–0.14) 0.784† 
* Mean ± Standard deviation, † Mann-Whitney U test, ‡ Independent samples t-test 
 
The ROC curve demonstrated an AUC of 0.92 (95%CI, 0.87–0.98) and 0.97 (95% CI, 0.95–1.00) for 
lesions not affected by haemorrhage for sDWI and cDWI sequences respectively (Figure 5-38). An 
ADC cut-off on the sDWI sequence of less than 894 x10-6 mm2/sec for tumour and non-tumour 
tissue results in a sensitivity of 0.83 and specificity of 0.93. For cDWI, an ADC cut-off of less than 
1153 x10-6 mm2/sec gives a sensitivity of 0.89 and specificity of 0.98. 
 
  Results 
 
187 
 
Figure 5-38. ROC curve of mean ADC value of sDWI and cDWI sequences including only tumours not 
affected by haemorrhage. 
  
  Results 
 
188 
Correlation of tumour ADC value and tumour aggressiveness 
There is a trend towards reducing mean and minimum ADC values as the tumour grade rises 
(Table 5-19, Figure 5-39 - Figure 5-42), but no Spearman correlation coefficient reached statistical 
significance. The strongest correlation was a ρ of -0.210 (p = 0.057) when the minimum ADC value 
of tumours on the cDWI sequence were correlated with Gleason Grade group (Figure 5-39B). The 
correlation coefficient did not improve when the Gleason Grade Groups were split into Group 2 
lesions and those more aggressive.  
Table 5-19. Mean and minimum ADC values of tumours of different Gleason Grade Group and for 
tumours of Gleason Grade 3+4 and those above. 
  cDWI sDWI 
Number 
of 
tumours 
Mean ADC 
Mean ± SD 
(x10-6 mm2/sec) 
Minimum ADC 
Mean ± SD 
(x10-6 mm2/sec) 
Mean ADC 
Mean ± SD 
(x10-6 mm2/sec) 
Minimum ADC 
Mean ± SD 
(x10-6 mm2/sec) 
Normal tissue  1526 ± 250  1258 
(1074–1387)* 
 
Grade Group       
2 57 979(837–1088)* 805 ± 214 824 ±197 567 ± 250 
3 18 929 ± 187 740 ± 202 777 ± 180 506 ± 198 
4 4 961 (864–965)* 720 ± 156 695 ± 148 407 ± 224 
5 2 885 ± 119 571 ± 16 776 ± 72 428 ± 10 
Gleason Score      
3 + 4 57 979 (837–1088)* 805 ± 214 824 ± 256 567 ± 333 
> 3 + 4 26 891 (823–970)* 722 ± 189 763 ± 209 483 ± 218 
SD – Standard deviation * Median (IQR) as data is non-parametric. 
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Figure 5-39. Boxplot and Spearman Rank correlation coefficient of ADC of different tumour grades on 
cDWI. A - Mean tumour ADC, B - Minimum tumour ADC. 
 
 
Figure 5-40. Boxplot and Spearman Rank correlation coefficient of ADC of different tumour grades on 
sDWI. A - Mean tumour ADC, B - Minimum tumour ADC. 
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Figure 5-41. Boxplot and Spearman Rank correlation coefficient of tumour ADC of Gleason Score 3+4=7 
lesions and those greater than Gleason Score 3+4=7 on cDWI. A - Mean tumour ADC, B - Minimum 
tumour ADC. 
 
 
Figure 5-42. Boxplot and Spearman Rank correlation coefficient of tumour ADC of Gleason Score 3+4=7 
lesions and those greater than Gleason Score 3+4=7 on sDWI. A - Mean tumour ADC, B - Minimum 
tumour ADC. 
  Discussion 
 
191 
Chapter 6 Discussion 
Accuracy of the DWI sequences 
Lesion-based accuracy 
Regardless of reader, addition of T2WI sequence, or whether a ‘stringent’ or ‘clinical’ lesion 
accuracy assessment was conducted, more index lesions were identified by conventional DWI 
than small FOV DWI. The differences between the comparable DWI sequence (ie the same reader, 
with or without T2WI) were often small. For example, 31 index lesions were seen by reader 2 with 
cDWI and 30 with sDWI when subject to a ‘stringent’ analysis. However, when a ‘clinical’ 
assessment was performed the difference was 3 tumours (34 versus 31 index lesions, 
respectively). In a clinical setting the difference between missing three index lesions for every 40 
patients using small FOV DWI compared to conventional DWI could be considered significant, 
particularly as these are the tumours which are largest, most advanced or most aggressive. 
Regardless of which DWI sequence was used, about one-fifth of index lesions were not correctly 
identified and localised within the prostate, with more identified, but perhaps not accurately 
localised, within the hemi-gland. The addition of the T2WI sequence facilitated the identification 
of more index lesions for both DWI sequences and this result was observed in both readers.  
There results of the diagnostic performance of both readers were similar when all lesions were 
assessed. They both found conventional DWI to be more sensitive; small FOV DWI to have a 
greater positive predictive value; and the ‘clinical’ assessment of the MRI reads was better than 
the ‘stringent’. In general, the addition of the T2WI sequence improved sensitivity and PPV, with 
the exception that reader 1’s cDWI ‘clinical’ and ‘stringent’ sensitivity assessment, and reader 2’s 
sensitivity and PPV results changed very little. There was no significant difference between the 
results of the comparable cDWI and sDWI lesion accuracy analyses. The strongest evidence (p-
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value 0.05–0.10) of a difference between DWI sequences was the higher PPV of reader 1’s 
comparison of DWI sequences without T2WI, and reader 2’s comparison of DWI sequences with 
T2WI in which small FOV out-performed the conventional DWI. 
 
Figure 6-1. Multifocal prostate cancer. A - cDWI b1500, B - cDWI ADC map, C - sDWI b1500, D - sDWI 
ADCmap, E - Pathology template report, F - Image of pathology slide. 
Figure 6-1 demonstrates a multifocal prostate cancer with 3 separate tumours in the mid-gland. 
The index lesion was the larger and identified by both readers on both DWI sequences, where as 
the 2nd lesion (T2 on Figure 6.1F) was a Gleason 3+4 tumour and seen by neither radiologist on 
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both DWI sequences. The third lesion (T3) was seen by both radiologists, but only on the 
conventional DWI sequence. This difference in tumour identification between DWI sequences ois 
potentially because of the apparent low ADC signal in the right peripheral zone on cDWI with no 
conspicuous lesion on sDWI. Visually, the ADC map has been described as being more accurate 
than the trace DWI images [81] and therefore the more conspicuous lesion on cDWI ADC maps 
perhaps has resulted in the improved lesion detection and sensitivity. 
The greatest hindrance to determining whether the differences in sensitivity and PPV between 
the DWI sequences was significant was the small number of lesions, which is evident in the wide 
confidence intervals in the results. Attempts to maximise the number of included lesions was 
made initially by instructing the histopathologists to assess for multifocality, rather than just the 
index lesion, and having a size cut-off for inclusion of at least 5mm in the maximum axial 
diameter. This is in comparison to some other studies which also have a volume cut-off of 0.5cm3 
[202] and therefore excluded smaller tumours. Some studies which assess for index lesions alone 
and not for multiple lesions calculate and cite the PPV [81,134]. In the FODIP study, the PPV for 
index lesion detection was not calculated as the readers were instructed at outset to assess the 
prostate for multiple lesions rather than the single index tumour. This would allow the overcalling 
(false positive) of more than one lesion. Whereas if specifically assessing just for a single index 
lesion an incorrectly located lesion becomes both a false positive and false negative. 
Overall, despite the small number of lesions included, the similarity of the results between 
readers, regardless of presence of T2WI, adds to the confidence of the findings indicating the 
conventional DWI sequence is better at lesion detection, but has a greater likelihood of 
overcalling tumours.  
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Likert scoring system 
Both readers were more definite in scoring the presence or absence of tumour, with more Likert 1 
and 5 scores assigned to sectors, compared to Likert 2 and 4 lesions. The addition of the T2WI 
sequence did not alter the distribution of scores of reader 1, but had more of an effect on reader 
2 with a reduction in Likert 1 lesions and an increase in Likert 5 lesions when T2WI was added. The 
lack of change is potentially due to the immediate reads of Protocols B and D following the read of 
Protocol A and C, respectively, for each case and will be addressed later in the discussion.  
One clinically useful finding is the reduction in Likert 3 lesions when the T2WI sequence was 
added. Likert 3 lesions are indeterminate and are a diagnostic dilemma if tumour has not already 
been proven histologically. If a targeted prostate biopsy follows the report of an indeterminate 
lesion and returns negative for tumour, the urologist and patient have a difficult decision to make 
regarding re-biopsing the prostate, which is invasive and not without risk, or monitoring the 
patient with other tools such as serum PSA levels and PSA density. 
The interplay between different Likert score cut-offs on the values of the 2 x 2 table for both 
readers behaved as expected. When a Likert 3 cut-off was used, with scores of 3 and above 
deemed tumour and less than 3 negative for tumour, this resulted in a greater number of true 
positive and false positive lesions, and greater sensitivity and smaller specificity. When the cut-off 
is changed to 4 the number of true and false positives fall, but false and true negatives rise, 
resulting in a fall in sensitivity and a rise in specificity when compared with a cut-off score of 3.  
The interplay of Likert score cut-offs is important because in some instances it may be of more 
use to have a more specific or sensitive test. For example, in prostate cancer management if the 
MRI of the prostate was performed to stage biopsy proven prostate cancer it may be of more use 
to have a more sensitive test with fewer false negatives and a greater ability to identify, localise 
and accurately stage the known cancer. Conversely, in a pre-biopsy setting a more specific test 
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may be more beneficial where the ability to rule out clinically significant cancer is important to 
reassure the patient and avoid a biopsy. Likert scoring systems can be tailored to each patient 
dependant on their wishes. In the management of prostate cancer a Likert scoring system is 
regularly used when following the guidelines outlined in PI-RADS version 2 [67]. A grey area is 
frequently the management of Likert 3 lesions and much of the current research is focused on 
these patients and lesions. As the results demonstrate higher specificity than sensitivity, 
regardless of protocol or reader, it was decided for the lesion-based assessment a Likert 3 lesion 
and above would be considered positive for tumour to improve sensitivity.  
There is variation in the use of Likert score cut-offs and the reporting of them amongst diagnostic 
test accuracy studies in prostate cancer. A review of most of the scoring systems used in the T2WI 
and DWI meta-analysis (Chapter 3, page 82) has shown that most used the same scoring system 
used in FODIP study, but some studies displayed the diagnostic performance of the tested 
sequences but did not state the cut-off used [83,104,187]. Only one study stated diagnostic 
performance of different cut-offs [180], some used a cut-off of 4 and above for tumour [85,177] 
and most used a cut-off of 3 [86,138,140]. 
Sector-based accuracy 
The results of the FODIP study demonstrated an improvement in sensitivity using the 
conventional DWI sequence when compared to the small FOV DWI, which reached statistical 
significance with reader 1 (example demonstrated in Figure 6-1, Page 192). Conversely, specificity 
was higher with sDWI than cDWI and again reached statistical significance with reader 1. 
Although, there was higher PPV with small FOV DWI and NPV with conventional DWI, these 
differences did not reach statistical significance regardless of reader or presence of T2WI. There 
was a significant improvement in sensitivity with conventional DWI and reduction in specificity 
with sDWI for reader 2. Reader 1 found a significant improvement in sensitivity with the addition 
of T2WI to sDWI. Many of these significant differences persisted when Bonferroni correction for 
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multiple comparisons was applied to the McNemar tests. The AUC of the ROC curve analysis 
indicated the cDWI and sDWI sequences were fair diagnostic tests [153] with trends suggesting 
cDWI is a better diagnostic test than sDWI, but this did not reach statistical significance. Reader 1 
found the AUC to significantly increase with the addition of T2WI to sDWI. 
The results of the sectoral diagnostic performance indicate that conventional DWI is better at 
tumour detection, despite no significant difference between DWI in the quantitative tumour, 
except a higher sDWI contrast ratio on the b1000 images. The conventional DWI sequence 
demonstrated significantly higher tumour SNR on the DWI images, but lower SNR on the ADC 
maps. This is likely related to the higher levels of noise found in the ADC map of the conventional 
DWI sequence, but lower noise in the b1000 and b1500 sequences when compared to the sDWI 
sequence. There have been few studies directly comparing the qualitative diagnostic performance 
of the DWI images compared to the ADC maps [81,82]. In Rosenkrantz’s diagnostic test accuracy 
study of high b-value DWI compared to high b-value ADC maps found that sensitivity improved 
with the b2000 image set compared to the ADC map, and there were less false positive lesions on 
the DWI maps [81]. In an earlier study by Rosenkrantz et al. [82] tumour contrast ratios were 
higher on ADC maps than on the b500 and b1000 sequences. If indeed high b-value images are 
the most sensitive then perhaps the significantly greater SNR of the conventional b1000 and 
b1500 images has led to the improved detection of tumours.  
A further possible explanation for the difference in diagnostic performance of small FOV and 
conventional DWI is the use of high b-values which is associated with lower signal. As the b-value 
rises the signal in normal tissue falls more than the signal in cancerous tissue. However, for 
smaller fields-of-view the lower signal at higher b-values is compounded by an increase in the 
image noise. It is possible that at high b-values the signal is sufficiently low with a small FOV that it 
compromises the detection of tumour. This is further supported by the improved CNR of lesions 
with cDWI at b1500, but with sDWI at b1000. This could be further evaluated by repeating the 
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qualitative and quantitative accuracy study with ADC maps derived from the b100 and b1000 
images for both small and large fields of view. 
Challenges of the radiologic-histopathologic correlation 
The precision of the sectoral and lesion-based accuracy results is dependent on the accuracy of 
the histopathological assessment and thereafter the correlation of the radiology and pathology 
findings. The validity of the Gleason Grades of each tumour and the size of the lesion is improved 
by the review by histopathologists, however, there were other points in the process in which 
error could have been introduced.  
Firstly, the thickness of the prostates slices ranged between 4.5 and 7mm, and between these 
slices tumours may be sited and have been missed. In comparison, the slice thickness of the DWI 
and T2WI sequences was 3.6mm with no gaps. Therefore, MRI samples all the gland and 
histopathology risks missing lesions due to sampling of a small volume of the prostate with thicker 
slice. This could result in some of the lesions called false positive sectors incorrectly and were in 
fact true positives. 
 The variation in slice thickness is due to the technique of cutting the prostate which involves the 
free-hand slicing of the prostate in the axial plane after the apex has been cut-off. The freehand 
cutting technique has a greater chance of producing axial slices which are not perpendicular to 
the cranio-caudal axis of the prostate and do not quite correlate to the axial slices of the MRI. This 
could also lead to a mis-registration of the exact location of the tumour. 
Determination of the location within the gland with respect to height and placement within the 
base, mid-gland and apex is a challenge for both MRI and histopathology assessment. There are 
no reliable anatomical landmarks at either assessment that differentiate between them. For both 
radiologists and histopathologists this was done by assessing how many slices the prostate has 
been divided into and then splitting the slices into the three groups. Although, histopathologists 
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traditionally consider the apex the slice which is separated and cut longitudinally. The potential 
for misplacement of lesions into different locations in the gland has implications for the accuracy 
of the assessment. 
The correlation of the histopathology and radiology templates was also a challenge. In particular, 
the lesion analysis was difficult when there was more than one tumour in the same region of 
gland. The correlation was performed by KG and after the assessment of a few cases it lead to the 
creation of some rules to increase the consistency of the correlation process. For example, if two 
tumours were in the same sector at histopathology for both to be seen at radiology there would 
have to be two tumours drawn. Also, if a tumour is described as two separate lesions by a 
radiologist, but one by a pathologist then the correlation was described as a true positive with no 
additional false positive. Finally, if a tumour was considered as one tumour by radiology, but two 
by histopathology then if both lesions called by the radiologist were in the same area the 
histopathologist lesion was drawn, this was considered a single true positive and no false positive. 
Any discrepancies were put to the histopathology team and resolved in consensus (KG and HP2). 
For example, in one case a tumour was seen by both radiologists in the apex of the gland and 
reported as a Likert 5 lesions in all 4 protocols, but no tumour was reported in this region by 
histopathology. A request was then made to histopathology to re-evaluate the apex and a 
Gleason 4+3 lesion was seen on the re-assessment, which was the index tumour. Figure 6-2 
demonstrates the left peripheral zone apical tumour which was missed by pathology. It shows 
high signal on DWI signal with correlating low signal on the ADC map and was recorded as a Likert 
5 lesion (highly suspicious for tumour) by both raidologists. 
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Figure 6-2. Example of a tumour missed on initial assessment by the histopathologists. A - cDWI b1500, B 
- cDWI ADC map, C - sDWI b1500, D - sDWI ADC map. 
On another instance, a lesion was seen in the left hemi-gland by both radiologists, on all 
sequences, and the histopathology map showed bilateral tumours, but the right sided 
histopathology tumour was identical in shape and location to the radiologists’ left sided tumour, 
but just mirrored to the other side of the gland. During the cutting of the prostate each quadrant 
of the outside of the gland is painted with a different colour so when the axial slices are reviewed 
later the pathologists know what anterior and posterior, and left and right are. On review of the 
TRUS biopsy in this case a Gleason Grade 4+3 lesion was found on the left and a 3+4 tumour 
found on the right, which was the opposite from the histopathology findings. In this instance, the 
pathology team believed there could have been error in the documentation of which colour paint 
corresponded to which side of the gland leading to sides being mixed. These are two examples of 
potential errors which were avoided, but there may be others which were not detected. 
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Further error could have been introduced whilst drawing ROIs of lesions which were not visible on 
DWI or T2WI images. This was done by KG, a radiology registrar with sufficient experience to 
report prostate MRI independently but less experienced than the readers. It was performed whilst 
assessing all MRI images, pictures of the histopathology slides, and the histopathologist reports. 
Due to the mismatch of number of pathology slides compared to MRI slices through the prostate, 
there is potential for incorrectly localising the tumour and ROI, particularly if the tumour is small 
and in a region of post-biopsy haemorrhage. This could have led to tumour ROI’s containing some 
or no tumour tissue, leading to inaccurate results. Some studies limit the assessment to index 
lesions which increase the likelihood of correctly localising the tumour [98,203] and some studies 
only drew ROI’s on tumours which are visible [82,157]. Given the multifocality of prostate cancer 
it was decided by the researchers to perform a quantitative and qualitative assessment of all 
tumours. 
Correlating histopathology and radiology findings is technically challenging. Isebaert et al. [141] 
tried to formalise the registration of MRI and pathology slides. The diagram in Figure 6-3 
demonstrates their methodology. This approach formalises the process the radiologists and 
histopathologists attempted to follow in this study. Other approaches to improve correlation and 
ROI placement include using an additional radiologist, separate from the readers and radiologist 
who draws the ROI, to decide the lesion location in the histopathology report and based on 
images of the slides [142,204]. Another possible way to improve the process is for the correlation 
for all lesions to be performed in consensus between the reporting histopathologist and a 
separate radiologist [81,168,178]. The use of a separate radiologist is to minimise bias as this 
radiologist should be blinded to the MRI reports of the reporting radiologist in the study.  
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Figure 6-3. Diagram based on the methodology by Isebaert et al. (2012) [141] demonstrating the 
correlation of the different segments of the prostate on histopathology and radiology. 
If this current study was performed again further steps could be introduced to improve the lesion-
based accuracy assessment, and the correlation of prostate MRI and pathology. Firstly, the 
correlation could be performed in the presence of a histopathologist. Secondly, the lesion-based 
accuracy assessment could be validated by repeating the correlation assessment of lesions by the 
radiologist and histopathologist. Thirdly, prior to the initial reads of the prostate scans by the 
radiologists, a separate radiologist could have reviewed the scans and decided which slices 
correlated with the different height sectors of the gland. Finally, instead of hand cutting the 
prostate specimens, histopathologists can use a device which cuts the prostate at a consistent 
angle and at set intervals, which could be matched to the MRI slice thickness [127]. 
Reliability of DWI sequences and comparison to current literature 
As well as being accurate a diagnostic test should be consistent and the precision of a test 
depends in part on levels of agreement between assessors. A weighted Cohen’s kappa test was 
performed on the sectoral accuracy analysis of all 4 protocols. There were overlapping confidence 
intervals and high p-values between the comparable sequences indicating the differences were 
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not significant. However, the trend was for the cDWI sequence to be more reliable than sDWI 
regardless of the presence of T2WI. The most reliable test was with the cDWI sequence where the 
weighted kappa was 0.62 indicating substantial agreement [200]. When T2WI was added into the 
assessment of either DWI sequence the kappa value fell by 0.08 for cDWI and 0.07 for sDWI.  
The sectoral based reliability was advantageous over the reliability based on lesion assessment as 
the numbers of sectors were greater than the number of lesions. Lesion reliability can be assessed 
by determining how many lesions are seen by both radiologists, and can be measured as 
percentage agreement. However, without true negatives the kappa coefficient cannot be 
calculated and as a result only sector-based reliability was performed. As the readers often 
started their assessment by identifying lesions and then drawing the lesion in the tumour map, a 
process they do in normal clinical practice, the information on the lesion-based reliability should 
be incorporated into the data and results of the sectoral approach. As with the correlation of 
pathology and radiology, a potential source of error in the sectoral reliability assessment is 
differences in interpretation between readers as to which slices represent the apex, mid-gland 
and base of the prostate. This is an important decision to make in clinical practice as prostate MRI 
is increasingly being used to guide biopsy and focal therapies rather than stage cancer. 
Reader experience is important in the assessment of MRI prostate examinations [205]. In this 
study, we assessed the reliability and accuracy of two experienced readers. Both are uro-
radiologists, have completed fellowships in the field, and much of their reporting work each week 
is reporting prostate MRI. It would have been useful to assess the effect of an inexperienced 
reader on the reliability. A third reader adds to the confidence the reliability results are 
generalisable, and the addition of an inexperienced reader could study whether prostate MRI is 
an examination more radiologists could report. Currently at NNUH amongst 32 radiologists, only 3 
radiologists report prostate MRI regularly, in comparison to other MRI examinations such as MRI 
heads and lumbar spines which almost all the radiologists in the department report. The 
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specialised nature of prostate MRI examinations was the reason for performing the diagnostic 
accuracy study with two experienced readers, rather than an experienced and inexperienced 
reader. 
There is a wide variation in the interobserver reliability between and within prostate DWI 
diagnostic accuracy studies. For example, Ohgiya et al. [85] found reliability to increase with 
increasing b-value with a kappa of 0.35 for T2WI and b500, a kappa of 0.55 for T2WI and b1000, 
and a kappa of 0.75 for b2000. However, Koo et al. [91] found reliability to increase from a kappa 
of 0.22 using a b300 ADC map, to 0.27 for a b2000 ADC map. The moderate and substantial level 
of agreement of sDWI and cDWI, respectively, is similar to many other diagnostic accuracy studies 
[83,141,180,184,204], but comparing them directly is not reliable given the different experience 
of readers, and technical parameters and combination of sequences used.  
One difference between the published reliability of prostate DWI accuracy studies and the FODIP 
interobserver reliability is the improvement in reliability with the addition of anatomical 
sequences, typically T2WI alone compared to T2WI and DWI [83,178,180,184,204]. For example, 
Doo et al. [204] found reliability to rise from a kappa of 0.61 to 0.69 with the addition of ADC to 
T2WI. This study found reliability to fall with the addition of T2WI to DWI, a result which occurred 
with both DWI sequences. Only Morgan et al. [169] found a drop in reliability with the addition of 
DWI to T2WI (kappa of 0.51 with T2WI alone, and kappa of 0.33 with T2WI and DWI). A possible 
explanation for this is the manner in which T2WI was assessed. The T2WI sequence was used in 
protocols B and D and for each patient protocols B and D were read immediately after reading 
DWI alone in protocols A and C, respectively. This is in comparison to the time gap in reporting 
imposed between cDWI and sDWI reads to reduce recall bias. The decision to read the T2WI 
sequence for every case immediately after was intended to reduce the total time of the reads, but 
potentially introduced bias to the reports. The initial read of the DWI sequence could have had 
varying influence between readers when it came to reporting the T2WI and DWI sequences 
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immediately after. It would be beneficial to repeat the reads of the DWI, and T2WI and DWI 
sequences with a time period introduced in order to more reliably determine whether the 
reduction in interobserver reliability was indeed due to the immediate read with the T2WI 
sequence after the DWI before moving on to the next case. 
Small-field of view results compared to current literature 
Currently the only study which has assessed the qualitative diagnostic accuracy of a small field of 
view DWI technique at detecting prostate cancer is by Brendle et al. [119]. In addition, to finding 
an improvement in lesion conspicuity and reduced distortion they found a sensitivity of 0.66, 
specificity of 0.99 and an AUC of 0.82. These diagnostic findings were not significantly different 
from the conventional imaging they used. The readers, who were blinded to clinical data, read the 
MRI in consensus and had T2WI and T1WI sequences available. The study was of 15 patients using 
a 12 sector reporting template and had prostatectomy specimens as a reference standard. It is 
unclear if they assessed just for index lesions or allowed for multifocality and whether they used a 
Likert scale or had a binary cut-off. The sensitivity is higher than found in the FODIP study (0.44–
0.52 depending on Likert cut-off and reader), as is the specificity (0.88–0.95) and AUC (0.79 and 
0.71). The reason for the difference is perhaps due to the imbalance of sectors with tumour to 
those without (29 with vs 151 without) in Brendle’s study suggesting they assessed only for the 
index lesion. Furthermore, the assessment of the studies in consensus by two experienced 
readers could account for the differences.  
The group also used b values of 50 and 800 sec/mm2 for their ADC maps which was different from 
this study. This factor’s influence is also supported by the higher mean and minimum tumour ADC 
values when compared to the FODIP study (ADCmean of 1000 x10-6 vs. ADCmean of 766 x10 -6 
mm2/sec; ADCmin of 700 x10-6 mm2/sec vs. ADCmin of 500 x10-6 mm2/sec). This difference is striking, 
particularly if they did only assess index lesions which tend to be of higher grade and lower ADC 
value. Feng et al. [115] used the same small FOV DWI sequence as the FODIP study (FOCUS), but 
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used b-values of 0 and 800 sec/mm2, had a pre-biopsy scan, used TRUS biopsy as a reference 
standard, and qualitatively assessed image quality parameters and quantitatively assessed the 
ADC values of index lesions. Like Brendle et al. [119] they found qualitative improvements in 
image quality using the small FOV DWI sequence, and the ADC value of tumours was higher with 
the small FOV technique in comparison to the large FOV sequence with comparable qualitative 
image quality results between studies.  
It is believed that by reducing the field of view there is a reduction in partial voluming leading to a 
more accurate assessment of the ADC value. The large discrepancy in tumour ADC between the 
FODIP study and others in the literature is potentially due to the technical parameters chosen. It is 
also likely that the difference in tumour ADC between small FOV and conventional DWI sequences 
in the FODIP study and the other small FOV DWI studies is related to other factors beyond FOV, 
such as choice and number of b-values used to create the ADC map and the SNR. The reduction in 
the FOV leads to lower SNR [206]. The use of small FOV techniques at 3T is to counteract many of 
the susceptibility effects at the higher field strength, but when combined with higher b-values, 
which also lowers the signal, the benefit of greater signal at 3T may not be enough to prevent the 
loss of signal from reducing the FOV and increasing the b-value. The result of a reduction in SNR 
can be an underestimation of tumour ADC [207,208], which could account for the lower ADC 
values of tumours in this study.  
Accuracy results of DWI sequences compared to the meta-analyses and current 
literature 
The results of the sectoral diagnostic performance of DWI alone compared to the qualitative 
accuracy analysis in chapter 2 (4 studies [90,91,141,142]) has shown this study to have a reduced 
AUC (0.76 for cDWI and 0.72 for sDWI vs 0.95 for high b-value meta-analysis), a similar sensitivity 
compared to the pooled sensitivity (0.62 for cDWI and 0.45 for sDWI vs 0.58), and a worse 
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specificity (0.85 for cDWI and 0.92 for sDWI vs 0.93). The reduced sensitivity of the small FOV DWI 
sequence compared to the pooled results is large and suggests that as a sequence it missed a 
significant number of tumours which may outweigh the benefit of its high specificity. The 
difference in AUC between this study and the meta-analysis is large, but needs to be interpreted 
with caution given this study AUC is derived from a ROC curve created from the Likert scores and 
the meta-analysis from a summary ROC curve, which is a different process that is prone to errors, 
for example, from sampling variability between studies and bias in the weightings in included 
studies. 
Comparing the results of this study to the meta-analysis is challenging given the heterogeneity 
between the included studies. For example, even between the four studies there was a difference 
in the number of sectors used (between 10 and 24), field strength, b-value, use of binary or Likert 
score, and which combination of DWI and ADC images were used. The closest comparison study is 
that of Koo et al. [91] which was matched for field strength and visual assessment of DWI and ADC 
together, but used 10 sectors and was comparing b1000 and b2000 images. Like the pooled 
results in the meta-analysis their sensitivity was much higher (0.85 at b1000 and 0.74 at b2000) 
and their specificity comparable (0.94 at b1000 and 0.96 at b2000). One difference between the 
FODIP study and the four in the visual assessment subgroup is the higher percentage of sectors 
containing tumour (almost half) in the FODIP study. For example, in the studies by Koo et al. [91] 
and Kim et al. [90] only approximately 25% of sectors contained tumour. However, Isebaert et al. 
[141] described 55% of sectors being positive and their results were similar to this study 
(Sensitivity 0.37, Specificity 0.94). The eligibility criteria for the presence of tumours in these four 
studies appears similar to the FODIP study and they all tested for multifocal tumours. Potentially, 
if the difference between the number of tumour positive sectors is due to an omission of smaller 
lesions this could account for the worse sensitivity experienced in this study. 
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There is greater heterogeneity between the studies of the T2WI and DWI meta-analysis (chapter 
3, page 82). There was no included study which matched the FODIP study for high b-value 
(b≥1000), use of DWI and ADC map, 12 sector assessment of the whole gland, 3T field strength, 
and with radical prostatectomy specimens as reference standard. There were many which 
contained most of the same study characteristics.  
For reader 1 with a Likert cut-off of 3 and above considered positive for tumour; the sensitivity, 
specificity and AUC results for conventional DWI alone were similar to the results of the results of 
DWI and T2WI combined meta-analysis, but there was a significant improvement of reader 1’s 
sensitivity and AUC when T2WI was added to the small FOV DWI sequence assessment. In 
general, the pooled sensitivity of the T2WI and DWI meta-analysis are more like the results of the 
FODIP study than to the high b-value DWI meta-analysis. The T2WI and DWI meta-analysis pooled 
sensitivity was 0.68 (reader 1 cDWI and T2WI - 0.60, sDWI and T2WI - 0.50), pooled specificity was 
0.84 (reader 1 cDWI and T2WI - 0.85, sDWI and T2WI - 0.93) and AUC was 0.84 (reader 1 cDWI 
and T2WI - 0.79, and sDWI and T2WI - 0.79). When compared to matching subgroups such as 3T, 
radical prostatectomy and visual assessment of both DWI and ADC maps, the difference between 
the lower sensitivity found in FODIP study and those subgroups increases, but specificity remains 
similar.  
Most of the sectoral-based accuracy studies in the T2WI and DWI meta-analysis had a smaller 
proportion of tumour positive sectors compared to this study. There were a few which had 
greater than 40% of tumour involved sectors [83,168,169,177,180,209]. Ueno’s two studies of 
high b-value DWI and computed DWI images alone against a radical prostatectomy specimens 
using 8 sectors per patient at 3T [83,168] found sensitivities ranging from 0.76 to 0.84 depending 
on b-values (b1000 and b2000), but their specificities were substantially lower (0.62 to 0.70). This 
perhaps was due to the different number of sectors used in their study, as by using 8 sectors and 
dividing the entire transitional zone into 2 sectors, rather than the 6 in the FODIP study, more 
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weight is given to the peripheral zone assessment in the results. Transitional zone tumours are 
harder to identify than peripheral zone tumours with increased false positives because of the 
overlap in appearance with hyperplastic nodules, typically located in the transitional zone, with 
tumour [81]. 
Another limitation of comparing the FODIP study’s results with the available literature and a 
possible explanation in the discrepancy between results is publication bias. It is an important form 
of bias when studies with favourable results are more likely to be published than those without 
[210]. In addition, they are published earlier and within journals with higher impact factors. 
Studies with significant differences are more likely to be published than ones without significant 
findings. Often diagnostic test accuracy studies do not require ethical review leading them to be 
harder to trace results and follow up [211]. Funnel plots have been demonstrated to be 
misleading for diagnostic studies with low power [191] and therefore, was not performed in the 
meta-analyses. Nevertheless, it should be considered as a potential cause for the difference 
between results. 
The number of published studies which have assessed the diagnostic performance of DWI at 
detecting prostate tumours by following a lesion-based approach is much smaller than the 
sectoral-based approach. The use of the radiologist reporting templates and prostate map 
requires the reader to draw a lesion in a specific area of the prostate and also detail other 
characteristics of the individual lesions in the adjacent table. This facilitated the simultaneous 
assessment of lesion and sectoral accuracy. The reporting instructions for the radiologists 
(Appendix 2) was designed to mimic normal clinical practice as much as possible as a reporting 
radiologists will probably assess the MRI firstly for the presence of lesions, then draw the lesion in 
the prostate map, and finally consider the remaining sectors to determine the likelihood of 
tumour absence. This last step is furthest from a radiologists normal practice, and therefore, the 
lesion-based approach could be considered the closest to daily clinical practice of radiologists. But 
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the sectoral-based approach is popular in the published literature as it provides a complete 2x2 
contingency table and facilitates the creation of ROC curves. 
There is variability among the published lesion-based accuracy study methodology with some 
studies assessing for index lesions [81,135,136] and some for all lesions [99,212,213]. There is also 
variability among the choice and combination of sequences assessed, choice of b-values, and 
blinding of radiologists to histopathology results. Localising tumours to specific areas of the 
prostate is important as the recent introduction of focal treatments, such as brachytherapy, high-
intensity focused ultrasound and cryotherapy, has necessitated the need for diagnostic imaging to 
extend beyond staging tumours and provide more detailed information regarding size and 
location of lesions. In comparison to Rosenkrantz’s [136] assessment of lesion-based accuracy of 
high b-value DWI sequences, including both acquired and computed images, the b1500 DWI 
subset had a lesion detection rate of 77% for index lesions with Gleason Score ≥ 3+4. In 
comparison to the results of the both DWI protocols in the FODIP study, reader 1 identified 82.5% 
of index lesions with the conventional DWI sequence and 75% with the small FOV DWI sequence. 
This perhaps highlights the advantage of having the ADC map as well as the b-value images when 
assessing for index lesions. 
In the FODIP study, although, the inclusion of false positive results in the accuracy assessment for 
index lesions due to the readers’ requirement for assessment for multiple lesions at the outset 
the evaluation for index lesions has merit. The consensus in the current literature places 
increased importance on the index lesion, rather than all tumour foci, and urologists are now 
using the information about the index lesion to provide prognostic information and drive 
management decisions [36,214,215]. The high detection rate of index lesions by conventional and 
small FOV DWI is promising and supports the use of higher b-values. These results in combination, 
with the high PPV for both these sequences, in the assessment of all lesions, adds weight to the 
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potential for treating patients’ prostate cancer on the basis of a suspicious finding without biopsy, 
as a high PPV is necessary to avoid focally treating benign tissue whilst missing the index lesion. 
In summary, the FODIP study sectoral analysis results of the small FOV and conventional DWI 
sequences are difficult to compare directly to the published literature and the performed meta-
analyses given the lack of studies with matching study protocols. In general, the results 
demonstrate that the sensitivity results of both sequences are below that of the published 
literature, and substantially for the small FOV DWI sequence. However, the specificity results are 
comparable, with the small FOV DWI sequence perhaps slightly better. The difference in the 
number of positive tumour sectors between the FODIP study and the majority of other 
comparable diagnostic accuracy studies is a potential cause for the discrepancy. 
Comparison of b1000 and b1500 results 
When quantitative tumour characteristics were compared at b1000 and b1500 there was a 
significant increase in SNR of b1000 over b1500 for both DWI sequences. Conversely, the tumour 
contrast was significantly improved with b1500 for both DWI sequences. As the b-value increases 
the rate of reduction of signal within non-cancerous tissue decreases more quickly than the signal 
loss within cancerous tissue; this leads to the improved contrast. However, when the b-value 
becomes too high the benefit of the added contrast between cancer and non-cancerous tumour is 
lost due to the lack of signal within the image. Multiple studies have shown SNR to be significantly 
lower at b2000 compared to b1000 [87,88,195], but only a few studies have compared SNR of 
b1500 and b1000. Similar to the FODIP study, Metens et al. [87] found higher SNR with b1000, 
however, Wang et al. [88] found the opposite. The SNR values found in those two studies were 
similar to the values found in small FOV DWI sequence (between 16 and 20), but the SNR of the 
conventional DWI sequence was 25.7 and 23.16 for the b1000 and b1500 sequence, respectively. 
The cause of the high SNR of the conventional DWI sequence is unclear as most of the imaging 
parameters that influence signal was comparable with Wang et al., such as FOV and TE. It is 
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possible that the number of excitations were higher for the conventional DWI sequence, but this 
was not published by this group. The most likely explanation for the higher SNR in the 
conventional DWI sequence is the larger FOV which results in a decrease in signal noise. The 
improved contrast parameters at b1500 over b1000 for both sequences is consistent with other 
studies comparing these values [87,216] and justifies the choice of using b1500 as the highest b-
value when optimising both DWI sequences prior to the commencement of recruitment. 
ADC value of tumours 
As in most studies, the ADC value of tumour was significantly lower than normal prostate tissue. 
Using 3 b-values the ADC values of tumour using a small FOV sequence were significantly lower 
than the large FOV conventional sequence. Despite the reduction in ADC value of tumour on sDWI 
there was a significantly greater AUC with cDWI when a ROC curve of mean ADC values was 
performed. The AUC for cDWI and sDWI were 0.96 and 0.90, respectively, which indicates ADC 
value measurement has excellent accuracy at distinguishing tumour from non-tumour tissue. 
With cDWI an ADC cut-off of 1153 mm2/sec gave a sensitivity and specificity of 0.86 and 0.98, 
respectively, whereas with sDWI an ADC cut-off of 898 mm2/sec gave a sensitivity of 0.77 and 
specificity of 0.93. However, there should be some caution when interpreting these results given 
the possible mis-registration of the ROIs drawn on lesions to measure tumour ADC values, 
particularly as lesions were less visible and sensitivity lower for the small FOV DWI sequence.  
The results of the quantitative ADC AUC results are substantially higher than the comparable 
subgroup in the high b-value meta-analysis (Chapter 2, page 74). This was potentially because 
ROIs were drawn with access to the histopathology reports (non-blinded) and with a optimised 
ADC value determined, as opposed to blindly with a pre-determined ADC cut-off. Furthermore, 
the ROIs were drawn around the margins of the tumour as seen on imaging rather than on the 
histopathology maps which were often larger and could have falsely lowered the ADC of tumour.  
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The ability to distinguish tumour from non-tumour using ADC values is useful, particularly given 
the higher AUC from the quantitative ROC curve compared to the qualitative ROC curve. But, the 
ADC values of tumours vary significantly in the literature. The choice and number of b-values have 
an influence on ADC value of tumours with ADC values falling with rising b-values [89,91,107]. 
However, this finding is not reliable as Kim et al. [90] found tumour to have a significantly higher 
mean ADC value with a b2000 ADC map compared to a b1000 ADC map (1580 x 10-6 vs 1190 x 10-6 
mm2/sec, respectively). Even when studies with relatively matched DWI technical parameters the 
ADC values of tumour can vary such as between Kumar et al. [149], who used 5 b-values and a 
maximum b-value of 1000 sec/mm2 , and deSouza et al. [217], who used 4 b-values and a 
maximum of b-value of 800 sec/mm2, the former study found tumour ADC to be much lower than 
the latter (980 x 10-6 vs 1300 x 10-6 mm2/sec). The variation in ADC values of tumour and non-
tumour tissue between different DWI sequences and studies is the major reason why the 
quantitative measurement of lesions and regions of the prostate is not used in routine clinical 
practice. However, in individual institutions it may be useful to use ‘ideal’ ADC cut-offs between 
tumour and non-tumour tissue. These results indicate the possible reduction in ADC value of 
tumour when using smaller FOV DWI sequences with high b-values. 
Correlation of Gleason Score and tumour ADC value 
The mean and minimum ADC value of tumours had an inverse correlation with rising Gleason 
Score, which is in keeping with most other studies [104–106,218–220]. Only the minimum ADC 
value of the conventional DWI sequence had an almost significant inverse correlation with 
increasing Gleason Grade Group, but the Spearman Rank correlation coefficient was only -0.210, 
which is considered a weak correlation. The mean ADC value of tumours on cDWI and sDWI and 
the minimum ADC value on sDWI were not significant and the correlation very weak. Due to the 
small numbers of higher grade tumours, when splitting tumours into a Gleason Score 3+4 group 
and those more aggressive, the correlations were no more strong or significant. 
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This is in comparison to most other studies in which the correlation ranges from weak (ρ = -0.32) 
to fair (ρ = -0.50). The reason for the weaker correlation is not clear. Firstly, there were no 
Gleason 3+3 tumours included in the study which is unusual given that other studies, some with 
similar size eligibility criteria of 0.5cm in maximum axial diameter, have at least one Gleason Score 
3+3 tumour and in general range from 2-35% of tumours in radical prostatectomy analyses 
[81,88,98,140,141,152,164,180,221]. The theory of decreasing ADC value and increasing 
restricted diffusion of tumours with increasing grade is based on the architecture of higher grade 
prostate tumours, which have a higher level of cellularity and therefore more restriction of water 
movement and lower ADC values. Some Gleason Score 6 lesions may have facilitated a stronger 
correlation as having Gleason Score 6 tumours with low levels of cellularity could have provided 
further data-points for which to add strength to the correlation. This, however, does not negate 
the evidence of the overlap of mean and minimum ADC values of tumours with different Gleason 
Scores in the FODIP study.  
Another potential reason for the weak correlation found in this study compared to the wider 
literature is the method and reproducibility of drawing of the ROI. Care was made to avoid 
adjacent non-tumour tissue, but if the ROIs had overlapped this could lead to increased and more 
variable ADC values with more overlap and weaker correlation with the degree of cellularity of 
the tumour. By repeating the ROI drawings and validating this method of sampling with intraclass 
correlation coefficients a better understanding of the repeatability and accuracy of the ROI 
measurements would be possible.  
Furthermore, many studies of ADC correlation with Gleason Grade were non-blinded and use 
index lesions. The index lesion of the tumour tends to be the largest, the highest grade and the 
most likely to have spread beyond the prostate. There are many studies which demonstrate a 
stronger correlation between ADC and Gleason score at radical prostatectomy than this study 
[104,106,157,183,218–220], but the following used just the index tumour [106,157,220], which 
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naturally selects the tumours which are largest, easiest to delineate and potential to get the most 
accurate ADC value from. Whilst, in this study ROIs were drawn on all tumours which met the 
eligibility criteria, some were not visible on imaging even with photographs of the tumour slides 
and the histopathology reporting template for guidance. In addition, the pathology slides were 
cut with a free hand and not necessarily on the same axial plane as the MRI therefore adding to 
the risk of misplacement of the tumour ROI. 
The lack of Gleason 3+3 tumours is unfortunate as it is important clinically to be able to 
discriminate between low grade disease and intermediate and higher grades and to be able to do 
this non-invasively with imaging would be beneficial. Another important clinical distinction is 
between Gleason Score 3+4=7 and Gleason 4+3=7 as patients in the lower grade group often are 
offered active surveillance as opposed to more radical treatment for the higher-grade group. For 
this reason, ADC value was correlated with Gleason Grade Group rather than total Gleason Score 
which has been done frequently before. Gleason grade group 2 tumours equate to Gleason Score 
3+4 and Gleason Score 4+3 are grade group 3. There are currently no MRI diagnostic accuracy 
studies in the literature which describe prostate tumours in terms of Gleason Grade Group, nor 
do any correlate grade group with ADC. As in all tumours and grade groups there was no 
significant difference in mean tumour ADC and the Gleason grade and nor was there between 
Gleason grade 3+4 tumours and those more aggressive. Part of the reason for sampling all 
tumours more aggressive than 3+4 was to increase numbers and to determine whether there was 
a significant difference between the two groups which is useful clinically. However, the significant 
overlap of ADC values and low level of correlation is in keeping with Rosenkrantz et al. (2015) 
[218]. In comparison, Vargas et al. [104], Nagarajan et al. [106] and Hambrock et al. [80] all 
demonstrated a significant difference in ADC values between these groups.  
In addition to validating the method of drawing the tumour ROIs, investigating why there was a 
lack of Gleason Score 6 tumours, and assessing just the index lesions, there are other ADC value 
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related factors which can be employed to correlate with Gleason score. The variation in ADC 
values due to technical factor such as number and choice of b-values used to make the ADC map, 
can be minimised using ADC ratio. This involves dividing the ADC value of tumour by a constant 
within the field of imaging. Some groups have attempted to normalise the ADC ratio by dividing 
the ADC value of tumour with the ADC of urine within the bladder [177] and muscle [222], which 
can be highly variable and low signal respectively. Barrett et al. [203] used an ADC ratio of tumour 
to normal prostate tissue and demonstrated a stronger correlation with tumour grade than 
absolute tumour ADC and also a more consistent correlation with tumour grade using ADC maps 
created with different b-values.  
Influence of post-biopsy haemorrhage on results 
Post-biopsy haemorrhage, as denoted by high signal on T1 weighted images, was present in many 
of the prostate MRI studies and was seen in over one quarter of the lesions included in the 
analysis. 81% of prostates have haemorrhage up to 3 weeks after biopsy, just under half of 
prostates have haemorrhage after 3 weeks, and the haemorrhage can be detected up to 4 months 
after biopsy [70]. Haemorrhage within the tumour itself occurs in approximately 5% of cases [73], 
but the number of lesions containing haemorrhage at histopathology was not assessed in the 
FODIP study. Haemorrhage is believed to resolve more quickly in tumour tissue than in normal 
prostate tissue which gives rise to the Haemorrhage Exclusion Sign. This imaging sign occurs when 
low signal tumour is outlined by high signal haemorrhage on T1WI [69] and can often aid the 
radiologist in detecting tumour in the presence of haemorrhage. It occurs in 20% of patients with 
post-biopsy haemorrhage, and has a positive predictive value of just over 50%. In this study, the 
radiologists were not asked to comment on its presence, but their access to T1WI on all the 
imaging protocols may have resulted in the detection of tumour and influenced the accuracy of 
the imaging results.  
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The results of the qualitative assessment of accuracy indicated that both radiologists’ ability to 
detect tumour improved when assessing for tumours with no peri-lesional haemorrhage 
compared to those with. This finding was consistent regardless of radiologist, diffusion sequence, 
or presence of T2WI sequence. An example of tumour seen outwith haemorrhage and missed 
within an area of haemorrhage is demonstrated in the figure below. 
 
Figure 6-4. Example of peripheral zone tumours. The left PZ tumour was detected. The right PZ tumour in 
an area of haemorrhage was not seen. A) cDWI ADC map, B) cDWI b1500, C) sDWI ADC map, D) cDWI 
b1500, E) T1WI , F) Correlate pathology slide. 
The quantitative assessment of haemorrhage in tumours resulted in a significantly higher mean 
and minimum tumour ADC with the conventional DWI sequence and mean ADC with the small 
FOV DWI sequence. A rise in the ADC value of tumour tissue compared to the adjacent prostate 
tissue, which is of higher signal, can reduce the tumour to normal tissue contrast potentially 
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reducing the ability of the reader to detect the tumour. The tumour CR and CNR was significantly 
greater in lesions with no haemorrhage with the sDWI ADC map which would suggest the rise in 
the ADC of haemorrhagic tissue is possibly a cause for the decreased lesion detection. However, 
the alteration in contrast was not seen in the conventional DWI ADC map, nor in either DWI 
sequence b1000 or b1500 imaging set, suggesting other causes for decreased accuracy. The AUC 
for non-haemorrhagic lesions using ADC was greater in lesions without haemorrhage compared to 
all lesions with sDWI and cDWI again indicating a potential benefit of not having haemorrhage in 
the prostate when assessing with MRI. 
The current practice at NNUH is to wait 4 weeks following biopsy for MRI. This delay accounts for 
a considerable amount of time in the National referral to decision-to-treat cancer target. For a 
period early in the recruitment window (September 2015-November 2015) the 4 week delay 
ceased with some patients being scanned within 1 week of biopsy. Although, this goes against 
guidelines for delaying imaging after biopsy, which suggest a delay between 3 and 10 weeks 
[68,223], the effects of post-biopsy haemorrhage using multi-parametric sequences, such as DWI, 
is believed to be much less than T2WI and not significant [72,73,224]. Rosenkrantz et al. (2010) 
demonstrated that there was still a significant difference in ADC of tumour tissue compared to 
haemorrhagic and non-haemorrhagic peripheral zone tissue [73]. The qualitative assessment of 
sectoral accuracy by the same group demonstrated that none of the diagnostic parameters were 
affected by haemorrhage using DWI and DCE, but T2WI demonstrated significantly decreased 
sensitivity when haemorrhage was present in the sector [72].  
A cut-off delay of 3 weeks from biopsy to MRI was decided for the FODIP study. A decision to 
lower the delay from the local 4 week guideline was made as the study’s primary objective was to 
assess DWI sequences, which are less affected by haemorrhage. In addition, Park et al. [225] 
demonstrated accuracy of mpMRI was not significantly different in MRI performed before and 
after 21 days. Our results, however, do suggest post-biopsy haemorrhage can influence accuracy 
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and therefore, justifies a cut-off delay being implemented. There is an inverse correlation with the 
visual measurement of post-biopsy haemorrhage and time following biopsy [72,225] and 21 days 
is cited by multiple studies as a key time where the haemorrhagic effects are reduced sufficiently 
to reliably use MRI and therefore this was the justification for choosing this delay [70,226].  
The results demonstrate an effect of haemorrhage on qualitative and quantitative accuracy of the 
ADC maps of both DWI sequences. These results should be treated cautiously as the lesions which 
were deemed to have peri-lesional haemorrhage may also be more likely to be of lower Gleason 
Grade or smaller, both of which affect accuracy. A multivariate logistic regression analysis might 
have been a useful way to determine the combined effects of each of these factors on accuracy 
and could have provided information on the importance of each. 
Current trends in prostate cancer investigation is moving towards imaging patients before biopsy. 
Following the PROMIS trial results indicating the strength of mpMRI and weakness of TRUS biopsy 
at detecting significant cancer when assessing the presence of tumour on a whole gland basis 
(unlike sectoral and lesion based accuracy assessment in the FODIP study) [58], the shift to a pre-
biopsy MRI is being implemented in more centres in the UK. This has changed the focus to 
detecting clinically significant cancer rather than all cancers, guiding biopsy rather than staging 
disease, and with the main benefit being reduced number of TRUS biopsies. This approach also 
has the benefit of reducing the effects of post-biopsy haemorrhage on assessment of tumour and 
is an argument for assessing the potential diagnostic accuracy of lesions and sectors which are 
free from the effects of haemorrhage. 
Further limitations 
To reduce recall bias there was a 2 week gap between reads of the cDWI and sDWI sequences. 
However, the T1WI and T2WI sequences were present in both the reads, which may increase the 
chances of recalling the case. The order the cases were assessed in was randomised using an 
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online number randomiser [194] to reduce the impact of recall bias. Although, 40 cases in total 
were assessed this was done in two blocks of 20. Initially cases 1-20 of cDWI were assessed, 
followed by cases 1-20 of sDWI, then 21-40 of cDWI, and finally 21-40 of sDWI. This was due to a 
slowing of the recruitment process in September 2016 where it became apparent that cases 36-
40 would take another 4 weeks to acquire as the radical prostatectomy procedures were not 
scheduled until then. Therefore, in consensus, the research team decided to commence the 
blinded radiology assessment on the first 20 cases and by halving the groups this minimised the 
impact of the increased risk of recall. 
The study was a prospectively planned and ethically approved observational study. The 
observational nature of the FODIP study did subject it to potential selection and verification bias. 
There was careful planning of the study before the recruitment window opened. Meticulous 
consideration of the technical parameters of the DWI sequence was made in discussion with an 
application specialist from General Electric, the manufacturer of the 3T scanner. These sequences 
were tested and implemented before recruitment opened in September 2015. In addition, the 
inclusion and exclusion criteria was set prior to commencement, and a detailed plan was made to 
identify potential patients eligible for the study. To gain ethical approval without the need for 
informed written consent from patients it was important to emphasise that at no point was this 
study going to impact in any patient’s clinical management pathway and therefore a significant 
amount of prospective planning occurred. This greatly reduced the need to alter any aspects of 
the methodology other than the above mentioned splitting of the case load in half and the 
insertion of a minimum of 21 days post-biopsy to the eligibility criteria, the limitations for which 
have been discussed. However, the patients were not prospectively recruited as the study 
proceeded, with identification of potential eligible subjects after prostatectomy had been 
performed. Therefore, during the routine NHS clinical care of the included patients the results of 
the assessment of the patient’s MRI, and also the histopathologists interpretation of biopsy 
specimens, and surgeons and anaesthetists assessment of appropriateness for surgery, all 
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influenced whether the patient proceeded to radical prostatectomy and therefore introduced 
verification bias into the study. 
Finally, the use of radical prostatectomy specimens as the reference standard inserts a significant 
selection bias to the study. This choice of reference standard is thought to be gold standard as it 
allows a more accurate and reliable assessment of the entire gland and correlation with axial 
slices of MRI sequences. However, a specific group of patients are selected for the procedure. 
They tend to have tumours of higher grade (Gleason Grade Group 2 and above), but of a locally 
confined stage such as T2a, T2b, T2c and early T3a disease, with no significant nodal spread. In 
addition, they are younger and fitter patients as the surgery does have a significant morbidity. 
When it comes to the interpretation of the MRI in this group, prostate cancer is present, as 
urologists would not proceed with the surgery without histological proof, and the lesions are 
more likely to be visible as they are of higher grade. The diagnostic accuracy of MRI in a broader 
clinical setting is possibly going to be worse as many more low-grade and non-visible tumours will 
be present in this population group. However, in routine clinical work the radiologist typically has 
access to PSA, digital rectal examination, and if in the post-biopsy population, the results of this 
investigation, compared with the readers in this study who were blinded to this information.  
The other potential reference standard which allows sampling of the whole gland is template 
prostate mapping biopsies as in the PROMIS trial [58], which carried out template biopsies of the 
entire gland at 5mm intervals. However, PROMIS assessed the likelihood of tumour presence on a 
whole-gland basis, but did not aim to localise tumours within the gland nor did they assess for the 
tumour stage. The use of this technique would allow the assessment of MRI earlier in the 
diagnostic pathway, including some men who do not have cancer, however, its use is limited to 
large trials, with significant financial support, large multi-disciplinary infrastructure, and written 
consent from patients. Furthermore, its ability to correlate with MRI in the localisation of tumour 
within the gland has not been tested.  
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There are advantages to using a technique and a methodology which has been used by most the 
published literature. The repeated use of radical prostatectomy specimens and the relative ease 
of correlation with MRI has been tested, optimised and to some extent validated. In addition, by 
following set methodology it allows a more confident comparison of this study’s results with the 
published literature and the meta-analyses performed. 
Wider implication of results and potential future research 
This is the first study which has assessed the diagnostic performance of small FOV DWI using 
radical prostatectomy specimens as the reference standard. Additionally, it’s comparison with the 
conventional large FOV has not been performed in this population. Finally, no study has combined 
the small FOV technique with higher b-values.  
The strength of the study is the combined sectoral and lesion-based accuracy assessment with a 
statistical comparison of results, the reliability analysis, and the quantitative tumour 
characteristics. Its weaknesses are the known difficulties in correlating MRI with radical 
prostatectomy specimens, which could have been improved by the process being performed by a 
3rd experienced radiologist in consensus with a histopathologist. Additionally, the potential 
influence of haemorrhage on the interpretation of the results is unknown, but could have been 
significant.  
From the results, the small FOV DWI sequence is significantly poorer in the detection of prostate 
cancer than the conventional large FOV sequence, but conversely, its strength is in its ability to 
rule out prostate cancer by minimising the overcalling of lesions. The small FOV DWI sequence is 
moderately reliable, but the cDWI is substantially reliable. The results of both sequences are 
worse than the published literature and the meta-analyses performed in Chapters 2 and 3. The 
reasons for this are unknown, but may have been influenced by post-biopsy haemorrhage, or 
radiologist and histopathologist inexperience with the research methodology. Publication bias is 
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another potential cause for this discrepancy. The ADC values of tumours on the small FOV DWI 
sequence were significantly lower than the conventional DWI sequence, which is out of keeping 
with other studies using small FOV at lower b-values suggesting the combination of small FOV and 
high b-value are the cause of this, potentially due to the loss of signal combining these 
techniques. Finally, the correlation of tumour ADC value with Gleason grade was weaker with the 
small FOV sequence, but both sequences demonstrated a weaker correlation compared to other 
studies. 
With these results it is unlikely, with the technical parameters used, that the sDWI sequence 
would replace the cDWI sequence locally given its poor lesion detection rate. It is debateable 
whether it would be used alongside the conventional DWI sequence as it takes approximately 
eight minutes to complete the sequence which is considerable in a busy radiology department. 
Shortening the imaging protocol has the potential to increase capacity. As well as the improved 
diagnostic performance, the larger FOV also provides diagnostic information about the entire 
pelvis which allows the reader to assess for bony metastases, localise lymph nodes, and 
potentially identify other pathology not seen on the small FOV. The small FOV DWI sequence used 
is commercially available, but software and sequence upgrades can be considerable in cost, and if 
the potential benefits are minimal then it may not be worth considering acquiring. However, the 
small FOV DWI sequence can be used on other body parts, on which this sequence should be 
validated. 
There is potential for further work to be done on the images obtained and data collected as part 
of the FODIP study. A logistic regression analysis of the accuracy data with haemorrhage, tumour 
size and gleason score as independent variables would be a useful analysis. It is important to 
better understand the reasons for potentially spotting and missing lesions, as this could lead to 
retraining of radiologists to assess for variables which have a large effect on accuracy thus leading 
to improved diagnostic performance.
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Although, the diagnostic performance of sDWI was poorer than cDWI, anecdotally amongst the 
prostate radiologists at the NNUH there is a preference for the small FOV imaging. There are 
potential reasons for this which could lead to further research. Performing image quality analysis: 
qualitatively with subjective assessment of distortion and artefact, and quantitatively doing 
tumour texture analysis and using software to measure distortion could allow a better 
understanding of small FOV DWI’s benefits and limitations.  
Further research should be performed on the sequence as the medical physics theories 
underpinning the use of small FOV DWI sequences on the prostate are sound. A potential 
limitation has perhaps been the combination with high b-values due to the loss of signal. 
Therefore, it would be useful to assess the accuracy and reliability of the sequence at lower b-
values. Additionally, ADC maps can be created using different combinations of b-values allowing 
qualitative diagnostic performance, quantitative analysis, and correlation of ADC value and 
tumour grade to be performed resulting in better optimisation of the sequences used. 
The creation of ADC maps with b-values greater than 1000 sec/mm2 is controversial and a 
potential way to gain the diagnostic benefits of higher b-value, but without the loss of signal is to 
use a computerised b-value. This allows the creation of a synthetic high b-value image by 
extrapolating the data acquired in the lower b-values, for example 100 and 1000 sec/mm2. This 
provides a high b-value image without the associated loss of signal and provides an ADC map 
derived from recommended b-values. Finally, extending the study to include more patients would 
increase the confidence in the findings and potentially reveal more significant differences 
between large and small FOV DWI sequences.  
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Chapter 7 Summary of FODIP study 
The diagnosis and management of prostate cancer is a challenge. The spectrum of severity of 
disease, the non-specific nature of the PSA blood test, and the high false negative rate of the most 
common biopsy technique contribute to this. MRI is continually developing with improvements in 
diagnostic performance. In particular, there have been notable recent advances in DWI imaging 
with the use of high b-values, which is now established practice, and the reduction in the field-of-
view. 
A diagnostic test accuracy meta-analysis of high b-value DWI alone for detecting prostate cancer 
included 10 studies and on which the quality of studies was considered good. The results 
demonstrated that a visual assessment of high b-value DWI images was significantly more 
accurate than quantitative accuracy using ADC measurement for tumour.  
The major limitation of the high b-value meta-analysis was the small number of included studies, 
particularly those in which the primary aim was to assess high b-value DWI. Most diagnostic 
accuracy studies of DWI use T2WI as well, with the latter sequence seen as a standard presence 
and the technical parameters rarely discussed. The meta-analysis of diagnostic test accuracy of 
visual assessment of T2WI and DWI for the detection of prostate cancer included 22 studies and 
found this technique to be a good diagnostic tool and the best diagnostic performance was with 
b-values greater than 1000 sec/mm2 and assessment of the ADC maps. 
Most DWI techniques scan the entire pelvis with the prostate occupying a small proportion of the 
scanned area. By reducing the FOV there is a reduction in distortion and an increase in in-plane 
resolution. The study described in this thesis is the first study which has assessed the diagnostic 
accuracy of a small FOV DWI technique with radical prostatectomy as a reference standard and 
the first which combined the technique with b-values greater than 1000 sec/mm2.  
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A prospective observation study comparing a small FOV technique against a more conventional 
large FOV sequence matched for b-values (b100, b1000 and b1500) and slice thickness was 
performed. Two radiologists blindly assessed 40 anonymised cases using DWI alone and with 
T2WI. Each DWI sequence assessed with a 2-week gap and in a random order to reduce recall 
bias. Readers recorded their findings on a reporting template which was identical to the 
histopathology reporting template to improve correlation. 
The results concluded that the conventional DWI sequence was more sensitive, reliable and 
accurate, and the small FOV sequence more specific, with some of the differences reaching 
statistical significance. ADC of tumour was less than normal tissue for both sequences, but was 
significantly lower in small FOV than conventional DWI.  
The diagnostic performance of both sequences was not as good as much of the published 
literature and the meta-analyses presented in this thesis, particularly the sensitivity. This is 
explained by the possible inclusion of much smaller tumours in the FODIP study, and potentially 
publication bias. Additionally, the assessment for tumour multifocality within the prostate 
resulted in the inclusion of all tumours rather than the index tumour, which is usually larger 
and/or more aggressive than the other tumours within the gland and therefore easier to detect 
and locate. 
The quantitative results demonstrated a weak correlation in tumour ADC value and negative 
correlation with both DWI sequences. This may have been influenced by the large number of 
tumours which were situated in an area of post-biopsy haemorrhage. However, the weak 
correlation and significant overlap of values of ADC values in tumours of different grade means 
that the use of either sequence as a reliable non-invasive means of predicting tumour 
aggressiveness is not advised. 
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It is unlikely the small FOV technique will replace conventional DWI, but the use of high b-values 
will persist. The improved overall diagnostic performance of conventional imaging is not the only 
benefit of this sequence, the greater coverage of the pelvis allows assessment for pelvic 
lymphadenopathy and bony disease, as well as the reduced scan time, are further indications for 
the continued use of this sequence. The strength of the small FOV technique is its high specificity 
and thus its ability to correctly rule out significant prostate cancer. As the recent PROMIS trial has 
suggested there is a benefit in performing MRI before rather than after biopsy and this practice is 
being implemented at most hospitals in England. Thus a specific test, like small FOV DWI, in this 
scenario would non-invasively allow the more appropriate selection of men who do not have 
clinically significant prostate cancer and therefore do not require biopsy, which has benefit to the 
patient and reduces cost.  
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Definitions 
ADC Apparent Diffusion Coefficient PZ Peripheral Zone 
AFMS Anterior fibromuscular stroma ROC Receiver Operating Characteristic Curve 
cDWI Conventional DWI sequence ROI Region of Interest 
CI Confidence Interval sDWI Small FOV DWI sequence 
CZ Central Zone SD Standard Deviation 
DCE Dynamic Contrast Enhancement SI Signal Intensity 
DRE Digital Rectal Examination sROC Summary ROC Curve 
DWI Diffusion-weighted Imaging T1WI T1 Weighted Imaging 
EPI Echo Planar Imaging T2WI T2 Weighted Imaging 
FOV Field-of-View TE Echo Time 
FOCUS 
Field-of-view Optimized and 
Constrained Undistorted Single-
Shot sequence 
TNM Tumour Node Metastasis staging system 
IQR Interquartile Range TP Transperineal biopsy 
mpMRI Multiparametric MRI TRUS Trans-rectal Ultrasound biopsy 
MRI Magnetic Resonance Imaging TURP Trans-urethral resection of prostate 
NNUH Norfolk and Norwich University Hospital TZ Transition Zone 
PACS Picture Archiving and Communication System   
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Appendix 1 
Published material and presentations 
Godley KC, Syer TJ, Toms AP, Smith TO, Johnson G, Cameron D, Malcolm PN. Accuracy of high b-
value diffusion-weighted MRI for prostate cancer detection: A meta-analysis. Acta Radiol. 
2017;doi: 10.1177/0284185117702181 
 
  Appendix 1 
 
253 
 
  Appendix 1 
 
254 
 
  Appendix 1 
 
255 
 
  Appendix 1 
 
256 
 
  Appendix 1 
 
257 
 
  Appendix 1 
 
258 
 
  Appendix 1 
 
259 
 
  Appendix 1 
 
260 
 
Godley KC, Syer T, Smith TO, Toms AT, Malcolm PN. Accuracy of high b-value diffusion-weighted 
MRI for prostate cancer detection: a meta-analysis. Oral presentation at Royal College of 
Radiologists Annual Scientific Meeting. London. September 2016 
Syer TJ, Godley KC, Smith TO, Malcolm PN. Diagnostic accuracy meta-analysis of diffusion and T2 
weighted imaging for prostate cancer detection: which b-value is most accurate. Oral 
presentation at European Congress of radiology. Vienna. March 2017. 
 
List of formal teaching and courses attended 
List of courses and conferences attended 
European Congress of Radiology, Vienna, March 1-5th 2017 
Royal College of Radiologists Annual Scientific Meeting, London, September 12-14th 2016 
East Anglian Radiological Society, Norwich, 26th May 2016. 
GCP Course. Good Clinical Practice (secondary care), Online, May 2015. 
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PPD sessions UEA 
Improving your use of Word 2015/16 
Practical Use of SPSS 2015/16 
Having an Impact at a Conference 2015/16 
Improving your use of Excel 2016/17 
Preparing for your Viva 2016/17 
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Appendix 2 
Radiologist reporting instructions 
Instructions for Radiologists 
Overview 
- Four reporting sessions – cases split into batches of 20 cases. 
- At least two weeks between each session 
- 20 cases 
- 2 reads in each session. 
 
 
Case identifiers 
- All patients’ Hospital number will be FODIP. 
- Accession numbers will give you access to the different cases. 
- In session 1 – Accession numbers will be 1A and 1B etc. 
- In session 2 – Accession numbers will be 1C and 1D etc 
- 1A and 1B will be the same patient etc. 
- 1A and 1B will not be the same case as 1C and 1D– they will be changed to a random order. 
- Please report in chronological order – 1 to 20 and 21 to 40. 
 
 
Augmentation of images 
Each reader can change windows centre and level to their own preference.  
Template 
- A reporting template will be provided for every read.  
- By the end of the study each case will have 4 completed templates by each reader. 
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Session 1 (conventional DWI – cDWI) 
- All cases will have a T1 sequence. 
- The ‘A’ cases will contain T1 and cDWI (b100, b1000, b1500) and it’s corresponding ADC map. 
- The ‘B’ cases will contain T1, cDWI (b100, b1000, b1500) and it’s corresponding ADC map, as well 
as a Hi-Res Axial T2 sequence 
- For each case you will read A followed by B and then move onto the next case 
- For example - 12A then 12B then 13A then 13B. 
 
 
Session 2 (small field-of-view DWI – sDWI) 
- All cases will have a T1 sequence 
- The ‘C’ cases will contain T1 and sDWI (b100, b1000, b1500) and it’s corresponding ADC map. 
- The ‘D’ cases will contain T1, sDWI (b100, b1000, b1500) and it’s corresponding ADC map, as well 
as a Hi-Res Axial T2 sequence 
- For each case you will read C followed by D and then move onto the next case 
- For example,  
12C then 12D then 13C then 13D. 
Completing the template 
Patient identification 
 
Insert the Case number and reader into the specified box. 
  
  Appendix 2 
 
264 
Prostate map 
 
The prostate map is displayed here. The prostate is divided into 
12 sectors.  
- Base, Mid, Apex 
- Peripheral zone (light grey) and transitional zone (dark   
grey) 
- Right and left 
 
Each reader decides the boundaries of the base, mid and apical 
gland after taking into account the size of the prostate. 
The seminal vesicles are visualised also. 
The outer line defining the prostate equates to the prostate 
capsule. 
 
Haemorrhage, lesion location and shape, and Likert score for each sector should be documented 
on the map. 
Prostate width – B and D cases 
 
On T2 measure the maximum width of the prostate in mm and note the slice number. 
 
 
Maximum prostate width on T2(mm) & slice:  
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Haemorrhage – A and C cases 
 
Review the T1 image and decide if haemorrhage is present and delete the below field as 
appropriate. 
The locations of the haemorrhage should be documented on the Prostate Map and a ‘H’ placed in 
the circle. 
Assessment for tumour 
There are two components to this 
- Lesion analysis – all lesions suspected of being tumour should be drawn on the Prostate 
Map and characteristics drawn in the Lesion Table. 
- Sector analysis – the likelihood of tumour in each sector of the prostate should be 
documented on the Prostate Map. 
 
A Likert score will be documented for each lesion and sector. 
The Likert score is as follows 
1: Clinically significant disease is highly unlikely to be present  
2: Clinically significant cancer is unlikely to be present 
3: Clinically significant cancer is equivocal 
4: Clinically significant cancer is likely to be present  
5: Clinically significant cancer is highly likely to be present.  
 
 
 
Haemorrhage: Y / N 
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1. Sector analysis 
 
For all 12 sectors of the prostate a Likert score should be written on the Prostate map. This can be 
seen in the example below. 
2. Lesion analysis 
 
Firstly, each lesion should be drawn on the Prostate Map and numbered. The drawing of the 
tumour should as closely as possible resemble the perceived shape of the tumour. If a lesion 
extends from one sector to another, such as mid-gland to apex, the lesion should be drawn in 
each sector it resides. If the lesion extends beyond the capsule or into the seminal vesicles this 
should also be drawn.  
In the Lesion Table in the corresponding Lesion number row the following should be documented. 
- Location  
o Base/Mid/Apex – if in multiple sectors document this and underline the 
predominant place it resides. 
o Right/Left – if in multiple sectors document this and underline the predominant 
place it resides. 
o PZ/TZ– if in multiple sectors document this and underline the predominant place 
it resides. 
- Maximum axial diameter 
- Series and slice number – on which the maximum axial diameter was measured.  
o For cases in A and C this should be the ADC map.  
o For cases B and D this should be both the ADC map or T2 sequence. 
- Width – perpendicular to the maximum axial diameter on the same slice. 
- Height – The most craniad and caudal slice the tumour is visible on. 
- Likert score– 1–5 
- ECE – Extra-capsular extension -  Yes or No – Also document the distance of extra-
capsular extension. 
- SVI - Seminal vesicle invasion – Yes or No. 
 
 
  Appendix 2 
 
267 
 
  Appendix 2 
 
268 
Histopathology reporting instructions 
FODIP 
Histopathology reporting instructions 
Notification of cases to histopathologists 
KG will send a list of patients to RB.  
Patient ID and corresponding study ID will be provided. 
RB and trainee to independently review prostatectomy samples. Samples cannot be anonymised 
to histopathologists (ethical approval for this). 
Histopathologists blinded to clinical information and MRI results. 
 
Tumours to include 
Tumours ≥5mm in maximum axial diameter. 
Prostate information 
Document maximum axial diameter of prostate. 
Estimated slice thickness 
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Lesion information 
Location 
• Base/middle/apex 
• Right/left 
• Peripheral zone/ transitional zone. 
• If a lesion is in more than one sector then document all sectors involved but underline the 
predominant sector. 
• eg 
 
Dimensions of lesion 
• Maximum axial diameter (length) (mm). 
• Width – perpendicular to length (mm). 
• Height – (number of slices + 1) x slice thickness 
 
Extra-capsular extension 
• Y/N 
• mm of extension 
 
Seminal vesicle invasion 
• Y/N 
 
Gleason and Grade Group Score. 
• Of every lesion. 
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Sector information 
Tumour presence in each of the 12 sectors of the prostate - Y/N 
eg 
 
 
Following review of cases by histopathologists 
• RB and trainee to provide a consensus histopathology assessment on the reporting 
template. 
• Tumours to be outlined on each slide and a midline sagittal line drawn on the slide. 
• Colour photocopies of the slides will be taken and anonymised. 
• Cases reviewed with histopathologists and KG together in order to draw Regions Of 
Interest on the scan which as accurately as possible correspond to the exact locations of 
tumours. 
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Appendix 3 
Favourable opinion of proportionate review at Research and Ethics Committee 
subject to conditions – 18th January 2016 
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Favourable opinion of proportionate review at Research and Ethics Committee 
– 22nd January 2016 
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Non-substantial amendment approval – 15th August 2016 
 
